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ABSTRACT 
 
The human gastrointestinal tract harbours a rich microbial community made up of an 
estimated 500 different bacterial species. This complex community plays an integral role in 
intestinal development and maintenance and functions as a protective barrier against invading 
pathogens. HIV/AIDS is a global epidemic, severely affecting the health systems of many 
countries, especially South Africa. Progression of the HIV disease is characterised by a 
massive depletion of CD4
+
 T cells and it has been shown that patients living with a more 
advanced HIV infection have a higher risk of developing diarrhoea due to the disruption of the 
gastrointestinal microbiota caused by either the HIV-infection or the use of antibiotics and 
drugs such as highly active antiretroviral therapy (HAART). An imbalance in the microbial 
composition, attributable to a disturbed mucosal barrier, as well as increased permeability and 
inflammation caused by HIV, can influence the metabolic (carbohydrate fermentation) and 
protective functions provided by the microbiota. The effect of HIV on the intestinal microbiota 
has not been widely examined and those studies that have focused on HIV and the 
gastrointestinal tract, have investigated it mainly from a virological perspective. Consequently, 
the aim of the study was to ascertain whether the diversity and/or abundance of the 
endogenous intestinal microbiota of South African HIV-positive patients was disrupted on 
account of HIV within the gastrointestinal tract. An additional aim was to determine whether 
the administration of HAART affected the microbiota during a 6 month longitudinal study.  
 
The diversity of the intestinal microbial composition was characterised with respect to the total 
bacteria, Bifidobacterium and Lactobacillus species using PCR-DGGE. qPCR was used to 
determine the abundance of total bacteria, Bifidobacterium, Lactobacillus, Escherichia coli, 
the Bacteroides/Prevotella, Clostridium coccoides and Clostridium leptum groups. The study 
cohort for DGGE studies consisted of 12 South African HIV-negative and 12 HIV-positive 
donors (females n = 8 and males n = 4). During HAART, in a 6 month longitudinal study the 
cohort was reduced to 8 subjects in each group. In addition, three potential intestinal pathogens 
(Clostridium difficile, Campylobacter jejuni and Salmonella enterica) were monitored by 
qPCR during this period, to determine their prevalence in the HIV-positive patients. The 
recruited HIV-positive donor group comprised mostly Black African females between the ages 
of 20 and 45, all of whom had blood CD4
+
 T cell counts of less than 200 cells/mm
3
. PCR-
DGGE analyses revealed host specific banding profiles for all the donors.  
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Before the initiation of HAART, the microbial diversity of the total bacteria, as determined by 
PCR-DGGE and using the Shannon-Wiener diversity index (  ), showed that it was 
significantly lower in the HIV-positive donors (  = 1.80) when compared to the HIV-negative 
donor group (  = 2.27) (p = 0.009). Although the diversity of Bifidobacterium spp. appeared 
higher in the faecal samples of the HIV-positive donors (   = 0.65), relative to the HIV-
negative group (  = 0.37), this was not statistically significant (p = 0.10). No significant 
difference was seen in the Lactobacillus group. The Bifidobacterium and Lactobacillus 
populations were both monitored over a 6 month longitudinal period and showed general 
temporal stability. However, the most noticeable change in the dynamics of these groups was 
seen when multiple antibiotics were administered, which drastically affected the diversity of 
the species present.   
 
The results generated using quantitative real-time PCR (qPCR) provided additional insight 
into the effect that HIV infection has on the abundance of other intestinal bacterial groups. 
Comparative analysis of selected groups within the gastrointestinal tract of HIV-positive 
patients and HIV-negative donors, showed a significant reduction in the abundance of the C. 
leptum group (p = 0.02) in the HIV-positive donors prior to the initiation of HAART. The 
Bacteroides group was also reduced in the HIV-positive patients, but this did not attain 
statistical significance (p = 0.08). There was no significant difference between the two donor 
groups with respect to any of the other groups tested. After 6 months of HAART, significant 
differences in the abundance of the C. leptum (p = 0.05) and Bacteroides (p = 0.004) groups as 
well as the total bacteria (p = 0.03) were seen relative to the HIV-negative donors. No 
detectable levels of Enterococcus spp. were found in either the HIV-positive or HIV-negative 
donor groups, while S. enterica and Clostridium cluster XI species were detected in both donor 
groups.  
 
The Bifidobacterium and Lactobacillus populations were not majorly affected by the 
persistence of HIV within the gastrointestinal tract, and as a result of this, prescribing these 
bacteria as probiotics may not necessarily aid HIV recovery. Conversely, the significant 
reduction in the abundance of the C. leptum and Bacteroides groups, in the HIV-positive 
cohort after 6 months of HAART, suggests that probiotic supplementation with specific 
bacteria from within these groups may assist in normalising the gut microbiota. Species 
belonging to these dominant bacterial groups could be considered as possible probiotic 
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candidates, as increasing the abundance of these groups within the intestinal tract, may 
counteract and reduce the disruption and inflammation caused by the replication of HIV. 
 
This pilot study is the first to report on the differences in the diversity and abundance of 
bacterial species within the gastrointestinal tracts of South African HIV-positive patients. The 
findings of this study have shed some light on the impact that HIV has on the intestinal 
microbiota, but also emphasise the need for more in-depth analysis that will expand further on 
the data generated in this thesis. Finally, successful monitoring of the status of the 
gastrointestinal microbiota of HIV-positive patients, along with the identification of potential 
probiotic candidates may open the way to more efficient and targeted probiotic 
supplementation in these patients as a supportive care during HAART.  
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ABBREVIATIONS 
 
AIDS : acquired immunodeficiency syndrome 
ARV : antiretroviral  
bp : base pairs 
BSA : bovine serum albumin 
CFU : colony forming units 
DGGE : denaturing gradient gel electrophoresis 
DNA : deoxyribonucleic acid  
dNTP : deoxynucleotide triphosphate 
EDTA : ethylenediaminetetra-acetic acid  
FISH : fluorescent in situ hybridisation 
g : gram(s)  
gDNA : genomic DNA 
GALT : gut associated lymphoid tissue 
GC : guanine and cytosine 
   : shannon wiener diversity index  
HAART : highly active antiretroviral therapy  
HIV : human immunodeficiency virus  
L  litre 
LAB : lactic acid bacteria 
log : logarithmic  
M : molar  
mg : milligram  
ml : millilitre  
mM : millimolar  
min : minute(s)  
n : number of samples 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
5 
 
ng : nanogram 
nm : nanometre 
p : p-value, indicating significance  
PCR : polymerase chain reaction  
qPCR : quantitative real time PCR 
QR : quartile ranges 
RNA : ribonucleic acid  
rRNA : ribosomal ribonucleic acid  
sec  : second(s)  
spp. : species 
STI : sexually transmitted infections 
TAE : tris-acetate-EDTA electrophoresis buffer 
TB : tuberculosis 
Tris : tris(hydroxymethyl)aminomethane 
µl : microlitre  
µg : microgram  
µM : micromolar 
UV : ultraviolet 
V : volts  
v/v : volume per volume  
w/v : weight per volume  
α : alpha 
% : percent  
o
C : degree(s) Celsius  
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1.1  THE HUMAN GASTROINTESTINAL MICROBIOTA   
The human gastrointestinal tract (GIT), which includes the stomach, small and large intestines, 
is densely populated by a highly complex community of obligate and facultative anaerobic 
microbial species (Nielsen et al., 2003, Tannock, 2001; Zoetendal et al., 2002). The 
gastrointestinal microbiota of humans can be divided into two distinct groups namely, transient 
and endogenous (Gerritsen et al., 2011; Isolauri et al., 2004). The latter comprises bacterial 
species that originate and are established within the gastrointestinal tract, while the former refers 
to microorganisms that are not members of the endogenous intestinal microbiota, but have been 
introduced from the environment, for example, through the intake of food. Transient bacterial 
species may also become endogenous if they become established within the gastrointestinal tract 
(Alvarez-Olmos and Oberhelman, 2001; Alderberth, 2000).           
 
 
 
 
 
 
 
 
 
 
The diversity and composition of the endogenous intestinal microbiota varies considerably along 
the gastrointestinal tract (Figure 1.1). The upper gastrointestinal tract, namely the stomach and 
small intestine, is characterised by short transit times of contents, relatively low pH, and a range 
of digestive enzymes from the stomach, liver and pancreas, all of which contribute to a small 
microbial population size (10
1–104 CFU/ml) (Booijink et al., 2007; Dethlefsen et al., 2006). 
However, within the lower section of the gastrointestinal tract, the flow of contents becomes 
slower. Fewer inhibitory and antimicrobial compounds as well as more anaerobic conditions are 
present, consequently favouring the establishment of a more complex and dynamic microbiota 
(Isolauri et al., 2004; Rastall, 2004; Holzapfel et al., 1998). The large intestine harbours a rich 
Figure 1.1: Distribution of the microbiota commonly found in the gastrointestinal tract of a 
healthy, human adult (Ouwehand and Vesterlund, 2003). 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
9 
 
microbial community with typical numbers of about 10
10
-10
12
 CFU/ml (Booijink et al., 2007; 
Dethlefsen et al., 2006).  
 
Both culture-dependent and culture-independent studies have demonstrated that the vast 
majority of the gastrointestinal microbiota, found in healthy individuals, belongs to two major 
phyla, namely the Gram-positive Firmicutes and the Gram-negative Bacteroidetes (Flint, 2011; 
Mariat et al., 2009; Eckburg et al., 2005). These two dominant phyla together account for 
approximately 90% of the total bacteria based on 16S rRNA molecular analyses (Flint, 2011). 
The Bacteroidetes phylum consists of three classes, of which the genera Bacteroides and 
Prevotella are the most well studied. The Firmicutes is the largest phylum, containing over 200 
genera, with majority of the Firmicutes detected in the gastrointestinal tract falling into two 
main groups, namely, the Clostridium coccoides group (also known as Clostridium cluster 
XIVa) and the Clostridium leptum group (referred to as Clostridium cluster IV) (Mariat et al., 
2009). Some of the predominant Firmicutes identified include: Faecalibacterium prausnitzii, 
Eubacterium rectale/Roseburia spp. and Eubacterium hallii (Walker et al., 2011; Louis and 
Flint, 2009).  
 
In addition to the Bacteroidetes and Firmicutes phyla, species belonging to other phyla such as 
Proteobacteria, Actinobacteria, Fusobacteria and Spirochaetes have also been detected within 
the gastrointestinal tract (Walker et al., 2011; Tap et al., 2009; Zoetendal et al., 2008; Rajilić-
Stojanović et al., 2007). Culture-independent analysis of the fungal diversity within the 
gastrointestinal tract revealed that the majority of fungal species belong to the fungal phyla 
Ascomycota (Candida and Saccharomyces) and Basidiomycota (Ott et al., 2008).   
 
1.1.1 Functions of the gastrointestinal microbiota  
The ultimate role of the endogenous intestinal microbiota is to positively benefit the host, by 
carrying out various metabolic, nutritional, physiological and immunological processes in the 
human body (Gerritsen et al., 2011; Wang et al., 2005). Examples of some of these key 
functions include specific metabolic activities, regulation and maintenance of the intestinal 
epithelium and immune system, and protection against opportunistic pathogens (Guarner and 
Malagelada, 2003).  
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Metabolic functions    
One of the major metabolic functions carried out by the endogenous microbiota is the 
fermentation of otherwise indigestible dietary polysaccharides such as, resistant starch and 
dietary fibres, to produce short chain fatty acids (SCFA) including butyrate, acetate and 
propionate and various gases (e.g. carbon dioxide and hydrogen) (Gerritsen et al., 2011; Laparra 
and Sanz, 2010). These short chain fatty acids regulate epithelial cell growth and differentiation 
in the small and large intestine (Canny and McCormick, 2008; Frankel et al., 1994), play an 
important role in the maintenance of the mucosal layer and in providing the colonic cells with 
additional energy, as well as stimulating the proliferation of the epithelium (Turroni et al., 2008; 
Marchesi and Shanahan, 2007; Anuradha and Rajeshwari, 2005; Eckburg et al., 2005; Isolauri et 
al., 2004; Guarner and Malagelada, 2003; Brouns et al., 2002; Salminen et al., 1998).  
 
This diverse microbial community within the colon is estimated to have 100 times more total 
genes than the human host, which means that a variety of enzymes and biochemical pathways, 
distinct from the host’s own enzymes, are available and can be used to the host’s advantage 
(Keeney and Finlay, 2011; Guarner and Malagelada, 2003). Genomic and physiological studies 
have demonstrated that the gut microbiota provides enzymes specialised in the utilisation of 
non-digestible carbohydrates and host-derived glycoconjugates (mucin) (Laparra and Sanz, 
2010). Gut bacterial enzymes are also involved in the metabolism of cholesterol and bile acids. 
The endogenous microbiota is capable of reducing cholesterol to coprostanol, which is then 
secreted and removed in the faeces (Laparra and Sanz, 2010). Bacteroides intestinalis, 
Bacteroides fragilis and Escherichia coli have all been described, in the literature, as potentially 
being involved in the generation of secondary bile acids in the colon (Fukiya et al., 2009). 
Primary bile acids, cholic acid and chenodeoxycholic acid, which are both synthesised from 
cholesterol in the liver, are readily converted into secondary bile acids (deoxycholic acid and 
lithocholic acid) by the intestinal bacteria. The conversion of these primary bile acids into 
secondary bile acids assists in limiting the solubilisation and absorption of dietary lipids 
throughout the intestine (Ridlon et al., 2006).      
 
Other important metabolic contributions of the intestinal microbiota include biosynthesis of 
essential vitamins, such as vitamin B and K (Salminen et al., 1998), production of amino acids 
required by humans (Laparra and Sanz, 2010; Hamer et al., 2008; Wong et al., 2006), and the 
absorption of calcium, magnesium and iron (Younes et al., 2001).  
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Immune functions 
Another important function carried out by the intestinal microbiota is the establishment of 
communication between the host and the microbiota at the mucosal barrier, thereby allowing the 
development and regulation of the host’s immune system (Sanz and De Palma, 2009; Canny and 
McCormick, 2008). The intestinal epithelium constitutes a physical barrier that regulates the 
transit of exogenous substances and prevents the entry of luminal antigens. This barrier is 
further strengthened by the presence of the mucus layer (comprising mucins) and the synthesis 
of antimicrobial peptides and other secretions such as bile acids and enzymes (Laparra and Sanz, 
2010). The endogenous microbiota form part of the primary line of defence and are capable of 
regulating the expression of mucin genes found within the goblet cells, as well as the secretion 
of specific antimicrobial peptides (e.g. α-defensins) by the paneth cells (Laparra and Sanz, 
2010). Furthermore, the intestinal microbiota plays an integral role in the postnatal development 
of the host’s immune system by influencing the number of T cells found within the lamina 
propria, the number of immunoglobulin A producing B cells, as well as intraepithelial T cells 
(Laparra and Sanz, 2010; Tlaskalovà-Hogenovà et al., 2004). There is a strong indication that 
microbial colonisation of the gastrointestinal tract also functions in regulating the gut associated 
lymphoid tissue (Macdonald and Monteleone, 2005). 
 
Protective functions 
A further important function of the intestinal microbiota is to protect the host from invading 
pathogens and prevent damage to the epithelial cells by serving as a protective barrier (Keeney 
and Finlay, 2011; Guarner and Malagelada, 2003; Rolfe, 2000). Several different mechanisms 
whereby the endogenous microbiota exerts a protective effect against potential pathogens have 
been proposed. For example, many species of the endogenous microbiota are capable of 
producing antimicrobial compounds that inhibit the growth of both Gram-positive and negative 
bacteria. These inhibitory substances include hydrogen peroxide, organic acids and microbial 
proteins such as bacteriocins (Louis and O’Byrne, 2010; Rastall et al., 2005; Rolfe, 2000). A 
second possible mechanism involves the intestinal microbiota binding to the intestinal epithelial 
surfaces and competitively inhibiting the attachment or toxin binding sites of pathogenic 
bacteria such as Salmonella and Clostridium species (Rastall et al., 2005; Rolfe, 2000). Lastly, 
direct competition for nutrient availability is another strategic mechanism employed, whereby a 
number of species of the intestinal microbiota actively utilise nutrients required by the pathogen 
(Keeney and Finlay, 2011).    
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1.1.2 Factors influencing the composition of the gastrointestinal microbiota  
Even though the endogenous microbiota of the intestinal tract is generally temporally stable, 
factors such as the age of an individual, diet and nutrition, and antibiotic treatments are all 
capable of influencing the composition and diversity of this community.  
 
1.1.2.1 Age of an individual    
The age of an individual has been shown to influence and affect the composition of the intestinal 
microbiota. During adult life, the intestinal microbial community is relatively stable (Costello et 
al., 2009), unlike the intestinal tract of infants which appears to be in a continuous state of 
change, with an extremely low microbial diversity (Roger et al., 2010; Blaut et al., 2002). The 
microbial diversity of the gastrointestinal tract of infants is influenced by several factors such as 
mode of delivery (natural birth or caesarean section), gestational age, infant hospitalisation and 
antibiotic use (Penders et al., 2006). Colonisation of the gastrointestinal tract commences 
immediately after birth and, by the time a child turns 2 years old, an adult-like microbiota has 
become well established with a strong predominance of Bacteroides and Clostridium spp. 
(Tiihonen et al., 2010; Frank and Pace, 2008; Isolauri et al., 2004; Alvarez-Olmos and 
Oberhelman, 2001).   
 
On the other hand, a significant shift and modification of the intestinal microbiota has also been 
shown to occur within the elderly (usually defined as people over the age of 65). In the elderly, 
there are marked physiological changes that occur, all of which have an impact on the 
composition and functionality of the intestinal microbiota (Tiihonen et al., 2010; Woodmansey 
et al., 2007). Many elderly humans suffer from decreased intestinal motility, which can result in 
prolonged intestinal transit times and faecal retention. In addition, age-related deterioration of 
the immune system, as well increased use of laxatives, antibiotics and other medication have 
also been shown to be associated with a change in the microbiota composition (Gerritsen et al., 
2011; Schiffrin et al., 2010). The gastrointestinal microbiota of the elderly is characterised by 
low Bifidobacterium, Lactobacillus and Bacteroides numbers, along with a significant increase 
in Clostridium and Enterobacteriaceae species (E. coli) compared to healthy, younger controls 
(Gerritsen et al., 2011; Zwielehner et al., 2009; Marchesi and Shanahan, 2007; Woodmansey, 
2007; Bartosch et al., 2004). 
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1.1.2.2 Diet and Nutrition    
Modulation of the intestinal microbiota of humans can also occur as a result of diet (Barnett et 
al., 2012), and the influence of diet and lifestyle habits on the structure and dynamics of the 
endogenous microbiota has been widely investigated. The diet of an individual serves as the 
main source of energy for the intestinal microbiota, and, therefore, plays an integral role in 
determining which bacterial species will persist within the large intestine (Louis and Flint, 
2009).  
 
During the first few months of development, a particularly high number of Bifidobacterium spp., 
up to 90% of the total faecal bacteria, have been detected in breast-fed infants while, after only 6 
months, increasing levels of species belonging to the Bacteroides and C. coccoides groups were 
identified (Laparra and Sanz, 2010; Hopkins et al., 2005). This significant change in microbial 
diversity has been directly linked to weaning, on account of the introduction of alternative 
carbohydrate-based substrates (Scott et al., 2011). However, it is important to note that the 
Bacteroides to Firmicutes ratio is still significantly lower than that present in adults (Mariat et 
al., 2009). In contrast, infants receiving a formula-based diet tended to exhibit a more mixed 
microbiota, consisting of larger numbers of Lactobacillus, Bacteroides, Clostridium, 
Ruminococcus and Streptococcus species and relatively few Bifidobacterium species (Laparra 
and Sanz, 2010; Alvarez-Olmos and Oberhelman, 2001; Salminen et al., 1998).  
 
In a study conducted by Ley et al., (2006), the effect of diet on the gastrointestinal microbiota 
was evaluated, using culture-independent techniques. The results of this study showed that the 
microbial communities of 12 obese individuals were significantly enriched in Firmicute species 
and depleted in Bacteroides species, relative to a non-obese control group. Moreover, 
consumption of a low-calorie diet by the obese study group led to a shift in their intestinal 
microbial community back towards a healthy, lean state (Ley et al., 2006). However, since the 
publication of the findings by Ley et al., (2006), the majority of other investigations have been 
unable to confirm these results, with all showing varying results with respect to the diversity and 
composition of the intestinal microbiota of obese people (Zhang et al., 2009; Duncan et al., 
2008).    
 
Plant cell wall polysaccharides such as cellulose and pectins, and storage polysaccharides such 
as inulin and resistant starch are all important for the growth of endogenous intestinal 
microbiota. Diets rich in nondigestible carbohydrates often lead to high levels of bacterial 
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fermentation in the large intestine. Dietary components, such as resistant starch have been 
shown to increase the production of butyrate in the large intestine (Louis and Flint, 2009; Louis 
et al., 2007). In a recent study conducted by Walker et al., (2011), rapid (within 3 days) and 
reversible changes in the abundance of specific dominant bacterial groups were observed 
following specific dietary changes. The most noticeable response was the significant increase in 
the abundance of Ruminococcus bromii and Eubacterium rectale in the volunteers who had been 
receiving a diet consisting of resistant starch (Walker et al., 2011). In a different study, Duncan 
et al., (2007) reported that decreasing the carbohydrate intake in a diet resulted in a significant 
decrease in detectable numbers of the E. rectale/Roseburia group, as well as butyrate 
production. This distinct relationship between the numbers of the E. rectale/Roseburia group, 
butyrate production and carbohydrate intake has been shown in other human studies (Abell et 
al., 2008).    
 
1.1.2.3 Antibiotic treatments   
The administration of antibiotics results in the disturbance of the intestinal microbiota and 
increases the risk of opportunistic pathogenic species becoming established and colonising the 
intestinal tract (Tiihonen et al., 2010). Broad-spectrum antibiotics are routinely administered, in 
an attempt to counteract the spread and colonisation of invading pathogenic microorganisms. 
However, the use of antibiotics is not always desirable in that, not only are the targeted 
pathogens affected, but so too are members belonging to the endogenous microbiota, 
significantly altering the structure and diversity of the microbial community (Gerritsen et al., 
2011; Donskey et al., 2003). In spite of this, normalisation of the microbiota to a stable, 
regulated state has been shown to occur following the cessation of the antibiotic treatment 
(Dethlefsen and Relman, 2010). An additional problem associated with the widespread use of 
antibiotics is the increased prevalence of antibiotic resistance resulting from the transfer of 
resistances between microorganisms (Jernberg et al., 2010).      
 
1.1.3 Physiology of the gastrointestinal mucosal barrier   
The gastrointestinal mucosal barrier is the complex mucous layer coating the stomach, small 
intestine and large intestine and is the main barrier separating the host’s epithelial cells and 
underlying tissues from the microbiota present in the lumen (Johansson et al., 2011; McGuckin 
et al., 2011). Thickness of the mucosal layer varies throughout the gastrointestinal tract, ranging 
from 700 µm in the stomach, where it provides protection against the strong acidic conditions, 
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to 150-300 µm and 800 µm in the small and large intestines respectively (Atuma et al., 2001). 
On the whole, the structure of the mucosal barrier consists of a single layer of columnar 
epithelial cells covered with a layer of mucous that is composed of two separate layers, namely, 
a thin internal layer and a thicker outermost layer (Figure 1.2A). The innermost layer remains 
firmly attached to the epithelium, whilst the outermost mucus layer is continuously removed on 
the lumen side and replenished by secretion from the underlying epithelium (Derrien et al., 
2010; Linden and McGuckin, 2010). Goblet cells are largely responsible for the production of 
mucins, as well as several other proteins. Mucins are high molecular weight glycoproteins and 
are the major structural components of the mucous layer, responsible for giving it its viscous 
nature. A total of 15 human mucins have been identified so far (McGuckin et al., 2011; Derrien 
et al., 2010; Linden and McGuckin, 2010). The main mucin constituent, identified in both of the 
mucus layers within the large intestine, was MUC2 while MUC5AC and MUC6 are present in 
the stomach (McGuckin et al., 2011; Derrien et al., 2010). Paneth cells, however, produce non-
specific antimicrobial compounds such as α-defensins, lysozymes, lactoferrin, Trefoil factors 
and specific immunoglobulins that are secreted and retained within the mucous matrix (Figure 
1.2B) (McGuckin et al., 2011).  
 
The gastrointestinal mucosal barrier has several functions. These include facilitating the transit 
of food along the gastrointestinal tract by acting as a lubricant, and providing a nutrient source 
for the growth of certain bacterial species. Mucin glycans are an excellent energy source for the 
endogenous microbiota that are capable of utilising glycan-degrading enzymes to digest the 
glycans, resulting in the releas  of monosaccharides. Bacteria then use these monosaccharides to 
produce SCFA (Johansson et al., 2011). Commensal microbiota utilise the outermost mucosal 
layer for attachment (Derrien et al., 2010). The mucosal barrier also functions as a mechanical 
barrier, separating the commensal microbiota present in the lumen from the epithelium (Leser 
and Mølbak, 2009) and protecting the commensal microbiota present in the lumen of the 
gastrointestinal tract (acts as first line of defence) as well as providing the starting point for host-
microbe interactions (Derrien et al., 2010).  
 
Mucosa associated bacteria are less susceptible to elimination, have access to a wider range of 
nutrient sources provided by the mucous and are in close proximity to the epithelial cells, thus 
potentially influencing these cells (Derrien et al., 2010). The number of bacterial species 
associated with the mucosal layer is lower in number than those present within the lumen 
(Zoetendal et al., 2008). Maintenance of the integrity of the mucosal layer is essential to  
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Figure 1.2: Basic structure of the gastrointestinal mucosal barrier. (A) Schematic 
representation of the gastrointestinal mucosal barrier (McGuckin et al., 2011). (B) 
Illustration of the mucosa in a healthy gastrointestinal tract (Canny and McCormick, 
2008). Abbreviations: [sIgA] – Immunoglobulin A; [M cell] – epithelial microfold cell; 
[Nod 2] – nucleotide oligomerisation domain 2; [BPI] – bactericidal increasing protein; 
[LL 37] – cathelicidin and [PMN] – polymorphonuclear leukocyte migration.   
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ensure that the underlying epithelial cells are protected. A disruption to the integrity of the 
mucosal barrier can be an indication of the development of a disease condition, for example 
Crohn’s disease or ulcerative colitis (Derrien et al., 2010).  
1.2  THE GASTROINTESTINAL TRACT AND HIV 
1.2.1 HIV infection and the gastrointestinal tract   
The mucosal surfaces of the human gastrointestinal tract play a vital role in the overall 
pathogenesis of HIV (Smith et al., 1997). The progression of HIV is characterised by a massive 
depletion of CD4
+
 T cells, which occurs during all the stages of HIV infection. The intestine 
has been shown to be the earliest site of CD4
+
 T cell depletion in HIV-positive patients, with 
approximately 70-95% depletion of these cells occurring within the first few weeks after 
exposure to HIV (Gori et al., 2008; Veazey and Lackner, 2004; Veazey et al., 1998). T helper 
cells are a type of white blood cell that plays an integral role in the human immune system. 
Mature T helper cells express the surface protein CD4 and are then classified as CD4
+
 T cells. 
CD4
+
 T cells play a central role in immune protection through their capacity to help B cells 
make antibodies, the induction of macrophages, the production of cytokines and the 
recruitment of neutrophils, eosinophils, and basophils to sites of infection and inflammation 
(Zhu and Paul, 2008). The CCR5 protein belongs to the beta chemokine receptor family of 
integral membrane proteins, and is predominantly expressed on the surface of T cells, 
macrophages and dendritic cells (Samson et al., 1996). 
   
The mucosal immune system is directly involved in the generation of innate and adaptive 
immune responses in order to protect the host from external factors such as invading 
opportunistic pathogens (Paiardini et al., 2008). The largest component of this immune system 
is the gut associated lymphoid tissue (GALT), present throughout the gastrointestinal tract and 
containing approximately more than 10
6
 lymphocytes/g of tissue (Paiardini et al., 2008; Hein, 
1999; Salminen et al., 1998). Lymphocytes populating the gastrointestinal tract can be divided 
into two categories, namely those present in the epithelium and those in the underlying inductive 
(Peyer’s patches, lymphoid follicles) and effector (diffuse lamina propria) gut-associated 
lymphoid tissues (Figure 1.3) (Shacklett and Anton, 2010). The lamina propria is rich in plasma 
cells, granulocytes and mast cells, while both the inductive and effector sites possess 
macrophages and dendritic cells (Shacklett and Anton, 2010; Hein, 1999; Salminen et al., 1998).  
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Figure 1.3: HIV infection and the gastrointestinal tract. (A) Intestinal inductive and effector 
sites in HIV-infection (Shacklett and Anton, 2010). Numbers indicate how HIV 
and/or infected cells may cross the epithelium: (1) transcytosis across epithelial or M 
cells; (2) adhering to dendrites of mucosal dendritic cells; (3) direct passage through 
epithelial breaches. (B) HIV-negative individual shows large aggregates of lymphoid 
tissue and large numbers of CD4
+
 T cells, while a newly infected HIV-positive 
individual shows a complete lack of this tissue and significant CD4
+
 T cell depletion 
in the gastrointestinal tract (Brenchley et al., 2004). Arrows indicate CD4
+
 T cells.  
HIV- HIV+
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The preferred targets of HIV are the mucosal memory CD4
+
 T cells, expressing the CCR5 HIV 
co-receptor. As many as 70% of the CD4
+
 T cells found within the gastrointestinal tract possess 
the CCR5 HIV co-receptor (Douek, 2007; Brenchley et al., 2004; Veazey and Lackner, 2004). 
In contrast, only 20% of the peripheral blood lymphocytes are found to express the CCR5 co-
receptor (Anton et al., 2000). Inductive lymphoid tissue sites are characterised by the presence 
of resting CD4
+ 
and CD8
+ 
T cells, which are capable of migrating to effector lymphoid tissue 
sites upon exposure to a variety of antigens (Veazey and Lackner, 2004).  
 
Immediately after exposure, HIV is capable of penetrating and initiating infection within the 
intestinal epithelial lining through a number of different routes. HIV can access the lamina 
propia directly, either through small mucosal breaks within the epithelium or by simply adhering 
to the mucosal dendritic cells or specialised transport cells, known as M cells (Figure 1.3A), 
which transfer the virus to susceptible CD4
+
 T cells present in the underlying inductive sites 
(Shacklett and Anton, 2010). Once inside the intestinal lamina propria, viral replication is 
initiated, resulting in a rapid depletion of CD4
+
 CCR5
+
 T cells in as little as 21 days from 
infection (Figure 1.3B) (Lackner et al., 2009; Veazey and Lackner, 2004). Following replication 
newly infected cells move towards the lymph draining nodes, where they are then disseminated 
throughout the body to infect new target cells (Lackner et al., 2009).The rapid depletion of CD4
+
 
T cells from the gut associated lymphoid tissues, results in an increase in gut mucosa 
permeability, significant impairment of the mucosal immune system, translocation of microbial 
products such as lipopolysaccharides and, increased activity of opportunistic and pathogenic 
intestinal microorganisms (Paiardini et al., 2008; Veazey and Lackner, 2004). 
 
1.2.2 Highly Active Antiretroviral Therapy (HAART)  
The elucidation of virus-specific processes during the virus replication cycle (viral binding, 
entry into host cells, reverse transcription and viral DNA and RNA synthesis), provides a 
number of suitable targets for antiviral drugs, ultimately resulting in a reduction in viral 
replication without any detrimental effects to the host (De Clercq, 2001). The introduction of 
highly active antiretroviral therapy (HAART) into local hospitals has resulted in a considerable 
improvement in the quality of life for the patient and a decrease in the morbidity and mortality 
rates (Call et al., 2000). HAART is the term used to describe the combination of at least three 
different antiretroviral (ARV) drugs used in the treatment of HIV. These combinations are 
generally made up of two nucleoside/nucleotide analogue reverse transcriptase inhibitors 
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(NRTIs) and, either a non-nucleoside reverse transcriptase inhibitor (NNRTIs) or a protease 
inhibitor (PI) (Warnke et al., 2007; Tramarin et al., 2004). To date, a total of 30 ARV drugs 
have been approved for use in HIV-positive patients, and are grouped into six different drug 
classes, based on their mechanism of action (Table 1.1) (Kim and Read, 2010; Chen et al., 
2007; Warnke et al., 2007). For the purpose of this thesis, the three most important drug classes 
used in first-line ARV regimes will be discussed further.   
 
Table 1.1  ARV drugs currently administered to HIV-positive patients      
ARV class Selected Examples  ARV class Selected Examples  
Nucleoside/nucleotide 
analogue reverse 
transcriptase inhibitors 
(NRTIs) 
Didanosine (ddi) 
Stavudine (d4T) 
Lamivudine (3TC)  
Tenofovir (TDF)  
Zidovudine (ZDV/AZT) 
Fusion Inhibitors Enfurvitide (T-20) 
Non-nucleoside reverse 
transcriptase inhibitors 
(NNRTIs) 
Nevirapine (NVP) 
Efavirenz (EFV) 
Delavirdine (DLV) 
CCR5 Inhibitors 
Maraviroc (MVC) 
Viciviroc (VCV) 
Protease Inhibitors 
Ritonavir (RTV) 
Lopinavir (LPV) 
Aluvia (INNs) 
Integrase Inhibitors  
Raltegravir (RAL) 
Elvitegravir 
 
Nucleoside/Nucleotide Analog Reverse Transcriptase Inhibitors:  
Nucleoside/Nucleotide Analog Reverse Transcriptase Inhibitors (NRTIs) are an important 
component of the ARV regimen and are used in the majority of first-line treatments. NRTIs are 
incorporated into the viral DNA and the mechanism of action involves inhibiting viral DNA 
synthesis by preventing reverse transcription (Figure 1.4). As a result of this, viral replication is 
prematurely terminated and the infection of new CD4
+
 T cell targets is subsequently reduced. 
However, in order to carry out the abovementioned antiviral activity, NRTIs require intracellular 
phosphorylation by cellular kinases (Warnke et al., 2007). Currently, there are eight different 
NRTIs available, with Zidovudine (AZT) and Lamivudine (3TC) being two of the most 
frequently used NRTIs (Warnke et al., 2007). Interestingly, Lamivudine (3TC) has been shown 
to be effective against both HIV and a Hepatitis B co-infection (Chen et al., 2007).    
 
Non-Nucleoside Reverse Transcriptase Inhibitors:  
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) function at the same point of the 
HIV replication cycle as the NRTIs (Figure 1.4), but are capable of binding directly to the 
reverse transcriptase of HIV (Grob et al., 1992; Merluzzi et al., 1990). In contrast to the NRTIs, 
NNRTIs do not require intracellular phosphorylation and are not incorporated into the viral 
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DNA (Chen et al., 2007; Warnke et al., 2007). Nevirapine (NVP), Efavirenz (EFV) and 
Delavirdine (DLV) are examples of three specific NNRTIs currently used in the treatment of 
HIV. Nevirapine and Efavirenz are also both inducers of the hepatic cytochrome CYP450 3A4 
isoenzymes (Chen et al., 2007).   
 
Protease Inhibitors: 
HIV-1 protease is a multifaceted enzyme responsible for the cleavage of large viral precursor 
polypeptide chains into smaller, functional proteins needed in the formation of new virions. This 
particular process takes place at the end of the HIV replication cycle (Figure 1.4) (Chen et al., 
2007; Warnke et al., 2007). Inhibiting HIV-1 protease results in the release of disorganised, 
non-infectious virions (Pillay et al., 1995). Drug interactions are an important consideration with 
the use of Protease inhibitors. Protease inhibitors that are most commonly administered to HIV-
positive patients include Ritonavir (RTV) and Lopinavir (LPV).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: HIV replication cycle and ARV drug targets. (Chen et al., 2007). 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
22 
 
The current trend in the treatment of HIV in South African Public Health Facilities is to delay 
the initiation of HAART until HIV-positive patients exhibit characteristic symptoms of AIDS-
related infections or have significantly low CD4
+
 T cell levels in the blood (< 200 CD4
+
 T 
cells/µl). Before initiating any first-line HAART regime, factors such as the efficacy of the 
prescribed combination, possible drug interactions between ARV’s, Hepatitis A and B co-
infections, pregnancy and any adverse side effects, need to be considered. Moreover, lack of 
adherence to the HAART regime is a serious limitation encountered during the treatment and 
management of HIV, possibly resulting in heightening the risk of increased drug resistance, as 
well as reduced ARV activity and/or efficacy.   
 
1.2.3 HIV-related diarrhoea   
Diarrhoea is a recurrent gastrointestinal manifestation associated with HIV/AIDS, having a 
negative impact on the quality of life for the patient. Clinical symptoms of diarrhoea in HIV-
positive patients can occur in either an acute or chronic form. Acute diarrhoea is characterised 
by irregular abdominal cramps and is generally short-lived, lasting only 2 to 3 weeks, while 
chronic diarrhoea, although being less painful, lasts for several months (Sestak, 2005; Tramarin 
et al., 2004). At present, the etiology of diarrhoea in HIV-positive patients can be separated into 
two categories, specifically, opportunistic infections and non-infectious causes.   
 
The introduction of HAART has seen a subsequent improvement in the immune status of HIV-
positive patients and, as a result, a significant reduction in the incidence of diarrhoea caused by 
opportunistic pathogens (Wilcox and Saag, 2008; Nannini and Okhuysen, 2002). However, prior 
to the use of HAART in the treatment of HIV, the most common opportunistic pathogens known 
to cause diarrhoea in HIV-positive patients included: Cryptosporidium and Cyclospora species, 
Cytomegalovirus, Microsporidium, Mycobacterium avium and Giardia lamblia (Sestak, 2005). 
Furthermore, pathogenic bacteria such as Salmonella, Shigella, Escherichia, Campylobacter and 
Clostridium species, have also been shown to be capable of colonising the compromised 
intestinal tract of HIV-positive individuals, resulting in the development of secondary infections 
that often require treatment with an antibiotic (Schroder et al., 2006; Sestak, 2005). In particular, 
C. difficile is fast becoming a commonly identified causative agent of antibiotic induced chronic 
diarrhoea in HIV-positive patients (Sanchez et al., 2005).    
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However, despite the significant reduction in the number of opportunistic pathogens causing 
diarrhoea in HIV-positive patients, the number of reported diarrhoea cases has not decreased 
significantly and this is thought to be as a result of drug-associated diarrhoea. Drug-induced 
diarrhoea is a common side-effect, seen particularly in patients receiving protease inhibitors, 
such as amprenavir, ritonavir and idinavir, as part of their HAART programme. Studies have 
shown that the incidence of diarrhoea associated with protease inhibitors, occurs in 33-50% of 
patients receiving nelfinavir and in up to 20% of those prescribed lopinavir/ritonavir and 
fosamprenavir/ritonavir (Guest et al., 2004). Given the relatively high prevalence of drug-
induced diarrhoea in HIV-positive patients, prescribing a protease based HAART regime is not 
done regularly, as there remains a major concern that patients will discontinue the prescribed 
HAART regime. Consequently, an ARV regime, comprising two nucleoside/nucleotide 
analogue reverse transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor, 
serves as a valuable alternative to protease inhibitors, as it is often associated with lower 
incidents of diarrhoea (Nannini and Okhuysen, 2002).  
 
In light of the fact that diarrhoea continues to remain a frequent gastrointestinal complication in 
HIV-positive patients, targeted complementary therapy (in addition to HAART) that limits the 
incidence of diarrhoea and supports re-colonisation of the gastrointestinal tract in these patients 
is needed, and the use of probiotic agents provides an attractive solution that is worth exploring 
further. 
 
1.3 PROBIOTIC AGENTS IN HUMANS 
1.3.1 Probiotics and Prebiotics   
Probiotics can be defined as viable, non-pathogenic microorganisms that, when ingested, 
beneficially influence the host, by exerting a positive effect on the health of the host and 
improving intestinal barrier function (Harish and Varghese, 2006). Probiotic formulations are 
usually composed of large numbers of one or more strains of a single species, or a mixture of 
several species, all of which are common components of the gastrointestinal microbiota 
(Chapman et al., 2011; Timmerman et al., 2004). Several studies have reported the successful 
incorporation of specific probiotic strains into food products such as yoghurt (Dols et al., 2011; 
Anukam et al., 2008; Hekmat and Koba, 2006), fermented milk products (Farnworth et al., 
2007) and even ice cream (Akin et al., 2007). In spite of numerous improvements in treatments 
such as antibiotics and immunosuppressive therapies, gastrointestinal complications, together 
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with changes in the composition of the gut microbiota, continue to pose a major clinical problem 
(Rolfe, 2000). Probiotics are routinely used in the treatment of intestinal disorders, where the 
normal endogenous microbiota of the GI tract has been disrupted, making the host susceptible to 
disease and colonization by pathogens. These include antibiotic-associated diarrhoea (AAD), 
irritable bowel syndrome (IBS), Crohn’s disease, colon cancer, obesity and small bowel 
bacterial overgrowth (Gerritsen et al., 2011; Gareau et al., 2010; Iannitti and Palmieri, 2010). 
The desired outcome of administering probiotics is to increase the number and activity of the 
health-promoting microorganisms, until such time that a healthy microbiota composition is re-
established (Gerritsen et al., 2011). Research has shown that the numerous beneficial health 
effects attributed to probiotic strains can be classified into three distinct categories. Firstly, all 
probiotic species are capable of directly interacting with the gastrointestinal tract, for example 
by interacting with the endogenous intestinal microbiota or through enzymatic activities 
(Gerritsen et al., 2011; Rijkers et al., 2010). Secondly, probiotic species can interact directly 
with the intestinal mucus layer and epithelium, and thirdly they can be responsible for 
stimulating a range of specific and non-specific host immune responses (Gerritsen et al., 2011; 
Rijkers et al., 2010). These may include enhancing phagocytic and natural killer (NK) cell 
activity (Rastall et al., 2005).  
 
Currently, the best-studied probiotics are species that belong to the Lactobacillus and 
Bifidobacterium genera, both of which are integral components of the gastrointestinal 
microbiota (Kleerebezem and Vaughan, 2009; Felis and Dellaglio, 2007; Rolfe, 2000). In 
addition to these genera, other commercially available probiotics contain species from other 
genera such as Streptococcus, Enterococcus, Bacillus and Propionibacterium. Interestingly, 
some Gram-negative bacteria for example E. coli and yeast (Saccharomyces) are also being used 
as probiotic microorganisms (Gareau et al., 2010; Iannitti and Palmieri, 2010).  
 
The use of prebiotics has been proposed as an alternative or simultaneous treatment strategy in 
improving the composition of gastrointestinal microbiota. Prebiotics can be defined as a non-
digestible food component, which beneficially affects the host, by stimulating the growth and/or 
activity of one or more of the normal intestinal microbiota that confer positive health benefits to 
the host (Roberfroid et al., 2010). Prebiotics are carbohydrate substrates which are not 
hydrolysed or absorbed in the small intestine, and become available to serve as a substrate for 
the endogenous microbiota of the large intestine (Laparra and Sanz, 2010). Prebiotics, 
commonly used in human nutrition, can range from small disaccharides to large 
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oligosaccharides, examples of which are lactulose, galacto-oligosaccharides (GOS), fructo-
oligosaccharides (FOS), xylo-oligosaccharides (XOS), lactosucrose and inulin-derivatives 
(Laparra and Sanz, 2010; Harish and Varghese, 2006). The main end product of carbohydrate 
metabolism is the production of short chain fatty acids, which then are made available to the 
host as an additional energy source (Laparra and Sanz, 2010; Harish and Varghese, 2006; 
Isolauri et al., 2004). Studies have shown that the use of prebiotics, such as galacto-
oligosaccharides and inulin, are capable of increasing the Bifidobacterium and Faecalibacterium 
prausnitzii concentration within the large intestine (Laparra and Sanz, 2010, Ramirez-Farias et 
al., 2009), and enhancing resistance to colonization of the intestine by C. difficile (Katz, 2006). 
Specific prebiotics can be administered simultaneously with probiotic species, to form a 
“synbiotic” (Gerritsen et al., 2011). A synbiotic functions through a distinct synergistic action 
where the probiotic will enhance the composition of the endogenous intestinal microbiota by 
colonising the epithelial lining, whilst the prebiotic serves as a substrate that the probiotic can 
utilise once established, thus beneficially affecting the host (Rolfe, 2000).  
 
1.3.2 Probiotics in HIV therapy    
HIV infection has a negative, disruptive effect on the gastrointestinal mucosal barrier and the 
mucosal immune system, resulting in the deterioration of gut homeostasis, an altered digestive 
function and increased permeability. Subsequent bacterial translocation may further stimulate 
the immune system, promoting HIV replication (Gori et al., 2011; Sestak, 2005; Veazey and 
Lackner, 2004). Probiotic supplementation, when administered in an appropriate dose in HIV-
positive patients, may assist in restoring GALT homeostasis. Proposed mechanisms through 
which this could occur include: the stimulation of natural killer (NK) cell activity (Gill et al., 
2001), re-establishment of essential functions performed by the mucosal barrier (Hummelen et 
al., 2010) and a substantial reduction in systemic inflammation (Kekkonen et al., 2008). A 
limited number of studies have evaluated and monitored the viability of probiotic 
supplementation in HIV-positive patients and some of these findings will be discussed briefly.   
 
In a randomised controlled clinical (RCT) study based in Tanzania, 145 HIV-positive women, 
all receiving HAART, were supplied for 29 days with either plain yoghurt or specially 
formulated yoghurt supplemented with L. rhamnosus GR-1 (Dols et al., 2011). Although gut 
health was not the primary focus of this investigation, researchers did record an improvement in 
the vaginal microbiota of the women, a better appetite and an increase in energy. Dols et al., 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
26 
 
(2011) concluded that the results of this RCT study showed that yoghurt was a nutritious food 
component and a suitable probiotic delivery method that could be safely administered daily to 
HIV-positive patients on HAART. In a second clinical trial, conducted by Anukam et al., 
(2008), a similar finding was recorded, when yoghurt containing L. rhamnosus GR-1 and L. 
reuteri RC-14 was administered to 24 HIV-positive patients and resulted in a significant 
decrease in diarrhoea as well as diarrhoea-related conditions, along with a small increase in the 
CD4
+
 T cell count. More recently, Hummelen et al., (2011) assessed whether long-term 
probiotic supplementation in HIV-positive patients would lead to a maintained and consistent 
immune function. Immune compromised HIV-positive patients (> 200 CD4
+
 T cells/µl) were 
given oral capsules comprising 2 x 10
9
 CFU/capsule of L. rhamnosus GR-1 and L. reuteri RC-
14 for 25 weeks. For the duration of the longitudinal study, CD4
+
 T cell counts were recorded 
prior to probiotic supplementation and at 10 and 25 weeks after starting probiotics. After 10 
weeks of probiotic use, CD4
+
 T cell counts increased on average 50 cells/µl while, after 25 
weeks of probiotic administration, the CD4
+
 T cell count showed an increase of 46 cells/µl. 
Hummelen et al., (2011) concluded that L. rhamnosus GR-1 and L. reuteri RC-14 could both be 
safely administered at a concentration of 2 x 10
9
 CFU/day, but that these probiotic species did 
not appear to have a significant impact on the immune function.  
 
Other treatment strategies have involved supplementing the diet with components such as 
soluble fibers, calcium supplements and L-Glutamine, but this has resulted in only small 
improvements in gastrointestinal symptoms associated with HIV-infection (Huffman and 
Walgren, 2003). In a study carried out by Gori et al., (2011), 57 HIV-positive, HAART naïve 
patients supplemented their diet for 12 weeks with a unique oligosaccharide mixture, made up of 
galacto-oligosaccharides, fructo-oligosaccharides and pectin hydrosylate-derived 
oligosaccharides. The results of this study showed changes in the microbial composition upon 
prebiotic supplementation specifically, an increase in Bifidobacterium species and a decrease in 
the Clostridium coccoides/Eubacterium rectale and Clostridium lituseburense/Clostridium 
histolyticum groups. Another significant finding of this study was the increased natural killer 
cell activity seen in the treatment group when compared to the control group. Therefore, 
administration of a prebiotic mixture to HIV-positive patients resulted in an improvement in the 
composition of the intestinal microbiota and possible re-establishment of homeostasis within the 
gastrointestinal tract (Gori et al., 2011).  
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Finally, a concern associated with probiotics in HIV therapy, is the risk of bacteraemia, bacterial 
translocation and sepsis. Thus far, only 5 cases of lactobacillemia have been reported in severely 
immune compromised HIV-positive patients. Moreover, all of these patients had extremely low 
CD4
+
 T cell counts (< 55 cells/µl) and were suffering from a secondary infection (Rogasi et al., 
1998; Abgrall et al., 1997; Horwitch et al., 1995). Nevertheless, no specific safety concerns 
have been raised preventing probiotic use in HIV-positive patients, but close monitoring and 
establishing what the most advantageous point during the HIV infection might be for probiotic 
intervention to provide the best results, is strongly recommended.  
1.4  PROFILING OF COMPLEX MICROBIAL POPULATIONS 
In light of the importance of the gut microbiota in human health, it is important to be able to 
monitor its composition and abundance in assessing the roles of its various members in disease. 
A variety of analytical techniques have been employed in the study of the gastrointestinal 
microbiota of humans. The availability and use of these techniques has provided researchers 
with considerable insight into the composition, function and dynamics of the endogenous 
intestinal microbiota. Several methods currently used in the profiling and analysis of large, 
complex microbial communities, will be reviewed in detail below. 
 
1.4.1 Culture-dependent analysis of the intestinal microbiota  
The composition of the intestinal microbiota of humans has been extensively studied and 
examined using mostly traditional culture-based methods. These methods have many advantages 
including a reduced cost, enumeration and isolation of various bacterial species and further 
biochemical and phenotypical investigations. Unfortunately, these techniques are also limited in 
that they are time consuming, labour intensive, require complex selective and differential media 
as well as specific anaerobic growth conditions, and have a poor discriminatory index (Mohania 
et al., 2008; Turroni et al., 2008; Tannock, 2002; Heilig et al., 2002; Tannock, 2001). 
Previously published reports have estimated that approximately 60 to 80% of the endogenous 
intestinal bacterial population could not be successfully cultured within the laboratory, 
highlighting the importance of alternative detection methods (Gerritsen et al., 2011; Eckburg et 
al., 2005; Nielsen et al., 2003; Tannock, 2002). However, results generated in a recent study by 
Walker et al., (2011), indicated that this particular conclusion may no longer be valid. Walker et 
al., (2011) showed that the percentage of phylotypes having > 98% sequence identity to a 
cultured bacterial species, increased proportionally with phylotype abundance. The four most 
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abundant phylotypes detected were E. rectale, F. prausnitzii, Clostridium aerofaciens and 
Bacteroides vulgates. All four of these species corresponded with the most abundant species 
detected by anaerobic culture, in an investigation performed by Moore and Moore, (1995). 
These findings tend to suggest that the inability to culture gastrointestinal bacterial species may 
be due to insufficient anaerobic isolation work rather than inherent non-culturability (Walker et 
al., 2011).  
 
1.4.2 Culture-independent analysis of the intestinal microbiota    
In order to overcome the limitations associated with culture work, novel culture-independent or 
molecular-based methods have been developed and applied in investigations targeting the 
diversity of the intestinal microbiota. A variety of different molecular-based techniques have 
been used to study the intestinal microbial community and have led to both a more detailed 
insight into the intestinal microbiota and the identification of a large number of new bacterial 
species. Culture-independent techniques that have been developed and utilised in analysing 
complex microbial communities such as the intestinal microbiota, include: PCR together with 
denaturing gradient gel electrophoresis (PCR-DGGE), Fluorescent in situ hybridization (FISH), 
%GC profiling, quantitative real time PCR (qPCR), the human intestinal tract chip (The 
HITChip) and metagenomics (Turroni et al., 2008).  
 
1.4.2.1 16S rRNA Sequencing    
The 16S ribosomal RNA (rRNA) gene has been the most frequently used genetic marker in 
studying bacterial phylogeny and diversity (Janda and Abbott, 2007; Pernthaler and Amann, 
2005; Amann et al., 1990). The reasons for this include its universal presence in almost all 
bacteria, the fact that the function of the 16S rRNA gene has not changed significantly over 
time, and that the 16S rRNA gene readily allows group and species specific primers to be 
designed (Patel, 2001). Since the development and implementation of automated DNA 
sequencing and subsequent work on 16S rRNA sequencing of bacteria, a vast amount of 
sequence information has been accumulated (Woo et al., 2008). Comparisons of these sequences 
have indicated that the 16S rRNA gene is conserved within organisms belonging to the same 
genus and species, but differ between organisms of other genera and species. The use of 16S 
rRNA sequencing has resulted in numerous bacterial genera and species being re-classified or 
re-named, novel bacterial species have been discovered and classified, and intricate 
phylogenetic relationships determined (Woo et al., 2008).   
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1.4.2.2 PCR amplification and Denaturing gradient gel electrophoresis   
PCR-DGGE is an example of a DNA fingerprinting tool that essentially generates a DNA 
profile of the microbial community present in each sample and allows comparison between 
different samples, based on any differences evident between the two fingerprints (Sekirov et al., 
2010). The fundamental principle of PCR-DGGE involves the electrophoresis of PCR amplified 
16S rRNA gene fragments through a polyacrylamide gel composed of a linear, chemical (urea 
and formamide) denaturing gradient (Mohania et al., 2008; Tannock, 2002; Muyzer et al., 
1993). Bacterial DNA is extracted from the faecal sample before undergoing PCR amplification 
with species-specific primers, one of which contains a 5’ GC-clamp (Nielsen et al., 2003). The 
double-stranded DNA fragments migrate through the polyacrylamide gel according to their G+C 
content (the most stable DNA will migrate further) until the sample is partially denatured, 
resulting in the formation of a distinctive banding pattern (Sekirov et al., 2010). Complete 
denaturation of the PCR fragment does not occur on account of the GC clamp and overall 
migration of the product is also significantly slowed (Tannock, 2002; Muyzer et al., 1993). The 
banding pattern generated is representative of the microbial diversity present within the samples 
screened (Sekirov et al., 2010). PCR-DGGE makes it possible for samples to be evaluated over 
time (temporal variation) or different treatments (antibiotics/probiotics) (Ben Amor et al., 2007). 
PCR-DGGE is, in general, efficient in terms of time, labour and reproducibility and can be 
considered a semi-quantitative method, due to the fact that the differences in the relative 
intensities of the bands produced, reflect the relative number of amplicons present (Heilig et al., 
2002; Muyzer et al., 1993). Additional benefits associated with PCR-DGGE, include the 
excision of specific DGGE bands that can be re-amplified using PCR and sequenced directly, 
eliminating the need for a cloning step (Muyzer et al., 1993). Unfortunately, PCR-based 
analytical techniques are limited as different types of bias, such as inefficient cell lysis during 
DNA extraction, and preferential amplification during PCR are introduced, which might lead to 
an inaccurate representation of the microbial diversity present within the tested sample (Wang et 
al., 2005).              
 
1.4.2.3 Fluorescent in situ hybridisation   
Fluorescent in situ hybridisation (FISH) is a relatively new technique that has been widely used 
for the quantitative analysis of intestinal microbiota. FISH makes use of fluorescently labelled 
oligonucleotide probes that have been designed to a specific region within the 16S rRNA gene 
of the targeted bacterial group. Probes can be designed in such a way that relatively large groups 
of bacteria can be detected. Alternatively, more specific predominant bacterial groups can be 
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targeted (Sekirov et al., 2010). Cells are first permeabilised either with paraformaldehyde or 
ethanol, allowing the probes to reach their target and causing the cell to fluoresce (Blaut et al., 
2002). Individual cells are then counted, using fluorescence microscopy or flow cytometry 
(Amann et al., 1990). A major advantage of FISH is being able to detect specific targeted 
bacterial species within a complex sample mixture and not requiring the use of culture work 
(Blaut et al., 2002). FISH has an added advantage of being able to utilise multiple fluorescent 
probes within the same sample, to differentiate between different bacterial targets (Bartlett, 
2003). However, FISH is associated with certain limitations, such as low sensitivity (Rinttilä et 
al., 2004; Schwiertz et al., 2000), low probe permeability, especially through the gram-positive 
cell wall (Cleusix et al., 2010; Rinttilä et al., 2004; Franks et al., 1998), possible nonspecific 
detection (Schwiertz et al., 2000; Franks et al., 1998) and is time-consuming when used in 
conjunction with fluorescence microscopy (Cleusix et al., 2010). The latter limitation has been 
improved since combining FISH with flow cytometry (Rigottier-Gois et al., 2003).   
 
1.4.2.4 Percent Guanine Cytosine (% GC) profiling   
Percent GC profiling is a tool which, when used in conjunction with other molecular profiling 
techniques is able to improve the microbial diversity detected by enriching for bacterial groups 
of a known GC composition. The foundation of G+C profiling is based on the fact that all 
bacterial species present within an unknown sample, contain a unique percent G+C content in 
their chromosomal DNA, which will affect its density. In other words, bacterial species having a 
high G+C content will migrate differently during density gradient centrifugation, compared to 
species with low percent G+C content. To enrich the microbial diversity obtained, total bacterial 
genomic DNA is extracted from the microbial rich community and, thereafter, samples are 
fractionated using density gradient centrifugation (Kassinen et al., 2007). Following 
ultracentrifugation, all of the DNA-containing fractions are quantified, using UV absorbance 
(280 nm) (Dicksved et al., 2008; Apajalahti et al., 1998). A unique advantage of percent G+C 
profiling is its ability to examine a large DNA pool acquired from a complex unknown 
microbial community and is not influenced by external biases, such as primer inefficiency or 
PCR inhibitors (Dicksved et al., 2008). It also allows bacterial species that are not present in 
high numbers to be amplified during later downstream processing (Kassinen et al., 2007; 
Holben and Harris, 1995). It should be noted however, that G+C profiling is not extensively 
used, due to its limited application (Mühling et al., 2008) and because researchers tend to favour 
a more sequencing-based approach when investigating complex microbial communities.     
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1.4.2.5 Quantitative real-time PCR  
Quantitative real-time PCR (qPCR) is another molecular-based technique that monitors the 
amplification of a DNA target through changes in the fluorescence signal and can be used to 
target specific bacterial groups. qPCR is generally used either in conjunction with FISH, to 
confirm the results recorded, or as an alternative detection method to FISH (Cleusix et al., 2010; 
Sekirov et al., 2010). During qPCR, a fluorescence signal reflecting the amount of PCR product 
present is generated during the initial cycles of amplification. The fluorescent signal is weak and 
cannot be differentiated from the background but, as amplification continues, the amount of 
product generated begins to accumulate, and the fluorescent signal being produced increases 
exponentially before levelling off (Mohania et al., 2008; Kubista et al., 2006; Malinen et al., 
2003). Currently, there are numerous options available to measure fluorescence during qPCR 
and include hydrolysis probes, molecular beacons and double-stranded DNA intercalating dyes 
(D’haene et al., 2010).  
 
Real time qPCR has several advantages over conventional PCR, in that it focuses on product 
accumulation within the exponential phase of the amplification cycle rather than end point 
analysis, thereby achieving more accurate and non-biased results. The elimination of post-PCR 
manipulation ensures a reduction in crossover contamination and fast turnaround time of results 
(D’haene et al., 2010; Mohania et al., 2008; Kubista et al., 2006; Malinen et al., 2003). Finally, 
real time qPCR is also associated with a high sensitivity due to the significant reduction in the 
production of false positives (99.9%) that can be observed in conventional PCR protocols 
(Mohania et al., 2008; Song et al., 2004).    
 
1.4.2.6 The HITChip   
The human intestinal tract chip (The HITChip) is a powerful phylogenetic microarray, enabling 
high throughput analysis of intestinal microbial communities and capable of targeting over 1000 
different bacterial species found within the human gastrointestinal tract (Rajilić-Stojanović et 
al., 2007). The fundamental principle of phylogenetic arrays relies on the hybridisation of 
isolated microbial DNA to a large set of specific oligonucleotides, immobilised onto a secure 
platform (Mohania et al., 2008). The HITChip is a highly reproducible phylogenetic 
fingerprinting tool that can be used for determining the diversity and relative quantification of 
microbial groups (Rajilić-Stojanović et al., 2009). Moreover, the HITChip is extremely versatile 
and can be utilised in a variety of applications, for example, monitoring the temporal stability of 
the endogenous intestinal microbiota or, simply determining the intestinal microbiota 
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composition (Rajilić-Stojanović et al., 2009). The utilisation of a gastrointestinal specific 
microarray, such as the HITChip, is associated with many benefits, in that it is cost-effective, 
time efficient and provides an alternative to 16S rRNA gene sequencing methods. Nonetheless, 
there are still concerns regarding detection limits and possible hybridisation bias, especially in 
situations where certain bacterial species are capable of hybridising more efficiently than other 
species (Sekirov et al., 2010). The reliability and accuracy of the results generated when using 
the HITChip was recently tested, in an experiment where the stability of the intestinal 
microbiota was analysed in a longitudinal study of five healthy adults, using both PCR-DGGE 
and the HITChip microarray. Data generated, using the HITChip, resulted in a consistent 
clustering of all five donors throughout the study, whereas clustering of only three of the five 
donors was seen when using PCR-DGGE (Rajilić-Stojanović et al., 2009).     
 
1.4.2.7 Metagenomics and High Throughput Sequencing   
Metagenomics is one of the most recent methods to be used in the profiling of microbial 
communities and serves as a powerful alternative to rRNA based sequencing and analysis of 
complex communities (Qin et al., 2010). The current definition of metagenomics is the study of 
a collection of genomes obtained from a complex ecosystem which is capable of providing 
information regarding the phylogenetic and physical properties, as well as potential functions of 
the present microbial communities (Gosalbes et al., 2011; Handelsman, 2004). The principle of 
metagenomics involves extracting and sequencing the total genomic DNA from the microbial 
community (Zoetendal et al., 2008). A metagenomic library can be constructed by cloning the 
DNA fragments into a suitable host such as E. coli, which can then be used for genetic diversity 
analysis of the microbial ecosystem. This is known as sequence-driven analysis. Alternatively, 
the library may be screened for any novel enzymes or functions (function-driven analysis) 
(Zoetendal et al., 2008). The use of metagenomics for either sequence or function-driven 
analysis has recently led to the characterisation of novel genes from uncultured bacterial species 
and comparison of bacterial communities present within different environments. The 
development of other function focused analyses, such as metaproteomics (protein targets), 
metabolomics (metabolite targets) and metatranscriptomics (RNA targets) are being 
implemented more often, in attempting to assess the dynamics of key microbial functions within 
the gastrointestinal tract, as well as determining how these functions affect both the gut 
microbiota and the host (Sekirov et al., 2010).    
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Recent advances in high-throughput DNA sequencing have provided researchers with an 
innovative tool for quickly and affordably obtaining DNA sequences (Jones, 2009). At the end 
of 2008, three different High-throughput sequencing platforms were available commercially: 
the Applied Biosystems SOLiD, Illumina Genome Analyser II/IIx, and the Roche/454 GS FLX 
titanium sequencer (Kircher and Kelso, 2010; Jones, 2009). The Applied Biosystems SOLiD 
and Illumina Genome Analyser systems both use short reads (25-75 bp read length); while the 
Roche/454 GS FLX platform produces average reads of 400 bp (Kircher and Kelso, 2010). An 
advantage of this technique is that it does not require cloning the DNA before sequencing, 
removing one of the main biases in environmental sampling (Kircher and Kelso, 2010). 
Recently, Qin et al., (2010) successfully compiled and described a microbial “gene catalogue” 
of the human intestinal tract, using the Illumina Genome analyzer. The metagenomic approach 
results in the production of large amounts of sequence data (around 3 gigabases (Gb)) which 
require a significant amount of data management and computational analysis (Qin et al., 2010; 
Zoetendal et al., 2008). Such facilities may not currently be available to all research institutes.   
 
Nevertheless, the use of metagenomics, in conjunction with any of the other methods reviewed 
in this thesis, has the potential of providing a detailed analysis of the intestinal microbiome. 
Profiling methods have continued to develop over the last few years, and all of the different 
techniques, discussed in this chapter, have their own unique benefits and drawbacks. The 
particular method used in research will depend upon the questions being addressed. It is 
important therefore, that these methods be utilised in combinations, as well as expanding and 
increasing the number of cultured species from the gastrointestinal tract, enabling more 
phenotypical and biochemical investigations to be conducted under controlled experimental 
settings.   
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1.5  AIMS AND RESEARCH OBJECTIVES OF THIS STUDY 
The primary aim of this project was to determine and identify changes in the composition, 
diversity and abundance of specific members of the gastrointestinal microbiota within HIV-
positive patients. In order to address the above-mentioned aim, and to broaden the understanding 
of how HIV and HAART influence the microbiota, the following research objectives were 
formulated:  
 
Objective 1:  
To establish if the microbial community of HIV-positive donors differed from HIV-negative 
donors in terms of diversity and composition. In order to do this, a baseline comparison (prior to 
HAART initiation) would be undertaken to analyse the microbial condition of the intestinal tract 
in HIV-positive and HIV-negative donors, with respect to total bacteria, as well as the 
Bifidobacterium and Lactobacillus groups using PCR-DGGE.  
 
Objective 2:  
To determine the effect of HIV and HAART on Bifidobacterium and Lactobacillus species in 
HIV-positive donors during a 6 month longitudinal analysis. The Bifidobacterium and 
Lactobacillus communities would be selected because they are well characterised probiotic 
groups that provide a beneficial and protective function to the host. If these groups were reduced 
in HIV-positive patients receiving HAART, then probiotic supplementation with these species 
might be of value.  
 
Objective 3:  
To establish if HIV replication within the gastrointestinal tract and HAART have an effect on 
the abundance of the endogenous microbiota in HIV-positive patients. Real time qPCR would 
be employed to determine the abundance of the total bacterial population, as well as four 
dominant (Bacteroides/Prevotella, Clostridium coccoides, Clostridium leptum, and 
Bifidobacterium) and three sub-dominant (E. coli, Lactobacillus and Enterococcus) 
gastrointestinal bacterial groups, in HIV-positive donors prior to and 6 months after the 
initiation of HAART.  
 
Objective 4:  
To determine the presence of three intestinal pathogens, namely Campylobacter jejuni, 
Salmonella enterica and Clostridium difficile in the faeces of HIV-positive patients not suffering 
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from diarrhoea. A significant alteration to the structure of the endogenous intestinal microbiota 
may result in the loss of the protective barrier function provided by these species, which could 
then lead to an increase in pathogen colonisation.      
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CHAPTER TWO  
Stool sample collection and recruitment of HIV-positive and HIV-negative South African 
donors residing in Cape Town 
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2.1  SUMMARY 
HIV/AIDS is a global epidemic severely affecting the health systems of many countries, 
especially South Africa. HIV-positive patients have a high risk of developing diarrhoea, due 
either to the HIV-infection or the use of antibiotics disrupting the gastrointestinal microbiota. 
This study aimed to establish whether there were changes in the diversity or abundance of 
specific gastrointestinal bacterial groups present in the faeces of HIV-positive patients during 
highly active antiretroviral treatment (HAART). Twelve HIV-positive donors attending Cape 
Town’s Groote Schuur AIDS clinic, as well as 12 age-, race- and gender-matched HIV-
negative donors (females n = 8 and males n = 4) were recruited for this investigation. The 
majority of faecal samples received were from Black, female donors, aged 20-45, and 
represents a demographic group that has been shown to have the highest risk of HIV infection 
within South Africa.    
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2.2  INTRODUCTION 
South Africa has been most heavily affected by the HIV epidemic, having the highest number 
of HIV-positive people of any other country, and an estimated HIV prevalence rate of 
approximately 10.6% (Statistics South Africa, 2011; Long et al., 2010). Despite global trends 
indicating an overall decrease in the number of new HIV infections, the number of people 
living with HIV in South Africa continues to increase steadily. Recent reports have shown 
that the total number of South Africans living with HIV, has increased from 4.21 million in 
2001 to 5.38 million people in 2011, with 316 900 new HIV infections being recorded in 2011 
alone (Statistics South Africa, 2011; UNAIDS, 2010).  
 
Interestingly, the annual number of AIDS-related deaths has begun to show a substantial 
decrease from 2006 to 2011, with approximately 43.6% of all recorded deaths in South Africa 
for 2011 being as a result of AIDS-related illnesses (Statistics South Africa, 2011). This 
decrease is thought to be accredited to the fact that antiretroviral treatment is now being 
initiated earlier in HIV-positive patients, thus successfully reducing the viral load and 
improving the CD4
+
 T cell count. The national HIV/AIDS and sexually transmitted infections 
(STI) strategic plan for South Africa (2007-2011) was implemented by the Department of 
Health (DOH) to increase the number of people receiving ARV medication at public sector 
hospitals across South Africa. The national first-line ARV regime currently administered to 
new HIV-positive patients includes a combination of two nucleotide/nucleoside analogues, 
such as Didanosine (ddi), Lamivudine (3TC), Stavudine (d4T) or Tenofovir (TDF), together 
with a non-nucleoside reverse transcriptase inhibitor such as Efavirenz (EFV) or Nevirapine 
(NVP). At the beginning of 2005, only 101 416 HIV-positive patients were on HAART but, 
by the end of 2010, a total of 1 058 399 HIV-positive patients were receiving HAART 
(Statistics South Africa, 2011; Rehle et al., 2010). However, despite the success and progress 
of this strategic plan, many South African HIV-positive patients still require HAART at 
public sector hospitals.  
 
The use of faecal material to characterise the gastrointestinal microbiota is a useful tool to 
generate knowledge regarding the effect of antibiotics and disease on the gut microbiome. 
Most of the current knowledge regarding the diversity of the human intestinal microbiota is 
as a result of numerous investigations and analysis of faecal material, whereas fewer studies 
identifying the microbiota associated with the mucosal wall have been carried out (Turroni et 
al., 2009; Ahmed et al., 2007; Nielsen et al, 2003). Faecal samples are more readily obtained 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
40 
 
from a donor, but the exact representation of the intestinal microbiota is a contested issue, as 
the microorganisms present within the sample will be mainly composed of those present 
within the lumen of the colon (Isolauri et al., 2004; Zoetendal et al., 2002). The use of biopsy 
samples has begun to generate more interest, due to the fact that specimens can be extracted 
under more controlled conditions and it allows sampling at different locations along the 
gastrointestinal tract (Chandra et al., 2010; Ott et al., 2004). However, despite these 
advantages, retrieval of the biopsy sample requires the donor to undergo an invasive 
procedure, where a small amount of sample is obtained and exposure to oxygen during the 
sampling procedure is high, potentially leading to a remarkable reduction in the number of 
strict anaerobes present (Zoetendal et al., 2002).  
 
On this basis, faecal material was selected as the sampling material in this study, due to the 
fact that numerous studies have conducted similar investigations using faecal material and 
providing a stool sample would be much easier and safer for the HIV-positive donors. In 
order for biopsy samples to be obtained, the donors would have to have undergone an 
invasive endoscopic examination, giving rise to serious ethical concerns, such as the safety 
both of the patient during the procedure and those working with the HIV-infected biopsy 
sample. 
 
Monitoring the diversity and abundance of bacterial species, within the gastrointestinal tracts 
of HIV-positive patients could identify any significant changes in the microbiota that may 
result from HIV replication within the intestinal tract. Establishing if the endogenous 
microbiota is affected and whether, after commencing with HAART, it returns to an HIV-
negative state, may identify an appropriate probiotic strain which could be administered as a 
supportive care to patients receiving HAART. This research study comprised two important 
stages, the first of which was to successfully recruit and acquire faecal samples from HIV-
positive patients prior to and during HAART. Following successful patient recruitment, the 
second stage involved determining the diversity and abundance of several different 
gastrointestinal bacterial groups using specific molecular techniques.   
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2.3  MATERIALS AND METHODS 
2.3.1 Study design, selection criteria of donors and ethical considerations 
This research study was conducted as a collaboration between the Department of Molecular 
and Cell Biology (MCB) and the Groote Schuur AIDS Clinic. HIV-positive patients attending 
this clinic were assessed and recruited by physicians working within the clinic, based on 
specific inclusion and exclusion criteria (Table 2.1). Participation in this study was entirely 
voluntary and patients were free either to refuse participation in this study or withdraw from it 
at any point. All relevant demographic and clinical information for each donor was recorded 
and provided by the clinic.  
 
Table 2.1:  Selection criteria used in the recruitment of HIV-positive and HIV-negative donors 
Inclusion Criteria for 
HIV-positive donors 
Inclusion Criteria for  
HIV-negative donors 
Exclusion Criteria for all 
participants 
Must be HIV-positive, with no 
prior history of HAART. 
Must be HIV-negative  
Donor may be male or female and 
between the ages of 18 and 55. 
Donor may be male or female and 
between the ages of 18 and 55. 
 
Must be TB negative Must be TB negative 
TB positive donors will be 
excluded. 
TB negative participants who 
develop TB during the study 
will also be excluded. 
Must have no intestinal disorders 
or diarrhoea. 
Must have no intestinal disorders 
or diarrhoea. 
Donors who develop diarrhoea 
during the study will be 
excluded. 
Must not be receiving any form 
of chemotherapy, radiation and/or 
probiotics. 
Must not be receiving any form of 
chemotherapy, radiation and/or 
probiotics. 
Exclude if any of these criteria 
change during the study. 
Must not be receiving any 
antibiotics except Bactrim. 
Must not be receiving any 
antibiotics at all. 
Any additional antibiotics 
administered will be recorded. 
Donor remains in individual 
longitudinal study, but is 
excluded from general cohort 
analysis. 
 
Each individual has a unique microbiota in terms of diversity and composition that has been 
developed and influenced over time by a number of different intrinsic and extrinsic factors 
such as: antibiotic treatments, diet, and age. As a result of this, healthy, HIV-negative donors 
were recruited as an age, race and gender-matched control group for the HIV-positive donors. 
All of the HIV-negative donors were recruited through an established community care centre, 
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situated within Cape Town where the donors were aware of their HIV status. Donors were 
recruited through a general advertisement, in conjunction with active recruitment by the 
centre’s staff. Exclusion criteria for the HIV-negative donors included a known history of 
gastrointestinal disorders, or the administration of antibiotics, probiotics or immune-
suppressing medication within the last four months. In terms of the HIV-positive donors, the 
same exclusion criteria were used except that antibiotic usage could not be completely 
excluded, due to the fact that all patients attending the AIDS clinic were receiving Bactrim 
(Trimethoprim-sulfamethoxazole) as supportive therapy (Table 2.4).    
 
HIV-positive patients were clinically assessed by physicians working at the AIDS clinic, and 
donors who met the above selection criteria, and were willing to participate in this study, 
were recruited. Once an adequate sample group had been established, a matched control 
group was recruited for each HIV-positive donor. All donors participating in this study were 
required to complete and sign an informed consent form in their home language (Appendix) 
outlining the objectives of this study. Ethical approval to perform this research study was 
obtained from the University of Cape Town’s Human Ethics Research Committee, reference 
number 077/2008.   
 
2.3.2 Collection and processing of faecal samples 
During the period 2009 to 2011, a total of 12 HIV-positive patients attending the Groote 
Schuur AIDS Clinic and 12 HIV-negative donors were recruited. Each donor was provided 
with a sterile 2L tin, with a secure sealing lid, in which to collect their stool. Faecal samples 
were collected from each HIV-positive donor prior to them initiating their HAART (T0) and 
then at 2 (T1), 6 (T2), 12 (T3) and 24 (T4) weeks following the commencement of HAART. 
HIV-positive donors provided a stool sample on the day of their respective clinic visits and 
these samples were immediately collected and transported back to the laboratory for 
processing. The control HIV-negative group was similarly sampled. A portion of each sample 
was aliquoted into a sterile pathology tube and immediately frozen at -20°C, until required for 
DNA extraction. Processing of the faecal samples was carried out within a Class II biohazard 
safety cabinet (ESCO ® Airstream S-Series).  
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2.4  RESULTS AND DISCUSSION 
2.4.1 Donor demographics and clinical characteristics  
All donors participating in this study were assigned a specific donor ID, namely, P1-P12 
(HIV-positive) or H1-H12 (HIV-negative), thus ensuring that all information received 
remained strictly confidential (Table 2.2). Of the 12 HIV-positive donors initially recruited, 
only eight completed the 6 month longitudinal study (discussed in Table 2.4 and section 
2.4.2), with four of the longitudinal donors providing an additional 12 month faecal sample. A 
single stool sample was provided by all the HIV-negative donors, with the exception of donor 
H3, who also completed the 6-month longitudinal study, so that a comparison between the 
HIV-positive and HIV-negative donors could be established. Full patient data, treatment 
regimens and abbreviations of drug names are shown in Table 2.2.    
 
The administration of HAART is mostly patient specific and influenced by criteria such as 
CD4
+
 T cell count, viral load, as well as the patient’s individual history. All antiretroviral 
regimes were administered according to South Africa’s National public sector HAART 
program. Thirty three percent (4/12) of the recruited HIV-positive donors received standard 
first-line ARV’s (d4T, 3TC and EFV) while another 25% (3/12) received d4T, 3TC and NVP. 
Donors receiving the latter ARV treatment were all Black females, aged 21-38.  
 
2.4.1.1  Gender and population group  
The majority of faecal samples received during this study came from female donors (67%), 
while only 23% of the samples originated from male donors (Figure 2.1A). Most of the 
recruited HIV-positive donors were from the Black African population, accounting for 75% 
of the donors, while the remaining 17% and 8% were represented by the White and Coloured 
populations respectively (Figure 2.1B).  
 
According to Statistics South Africa, the estimated population size of South Africa in 2011 
was 50.59 million people, of which 52% (approximately 26.07 million) was female (Statistics 
South Africa, 2011; UNAIDS, 2010). Population statistics acquired during 2010 showed that, 
53% of the South African HIV-positive population was female, of which 65% were receiving 
HAART, whilst males and children accounted for the remaining 38% and 9% respectively 
(Department of Health, 2010). Statistics South Africa further reported that the Black African 
population constitutes just more than 79.4% of the South African population, while the Asian,  
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Table 2.2: Demographic data of the HIV-positive and HIV-negative donors used in this study   
 
HIV-positive Donors (n = 12) ARV Regime Sampling Period* 
Donor ID Gender Race Age (Yr) d4T 3TC EFV AZT NVP ddi INNs TDF  
P1 Female Black 26 + + +      S 
P2 Female Black 38  +  + +    L 
P3 Female Black 37    +  + +  L 
P4 Female Black 33 + +   +    L 
P5 Male Coloured 43  + +     + L 
P6 Female Black 49 + + +      S 
P7 Female Black 21 + +   +    L 
P8 Male White 50  + +     + L 
P9 Female Black 37 + +   +    S 
P10 Male Black 30 + + +      L 
P11 Male White 43 + + +      L 
P12 Female Black 23   +   +   + S 
HIV-negative Donors (n = 12)      Sampling Period* 
Donor ID Gender Race Age (Yr)          
H1 Male White 52         S 
H2 Female Black 22         S 
H3 Female Black 39         L 
H4 Female Black 24         S 
H5 Female Black 30         S 
H6 Female Black 26         S 
H7 Female Black 50         S 
H8 Male Black 33         S 
H9 Female Black 42         S 
H10 Female Black 44         S 
H11 Male Coloured 43         S 
H12 Male White 33         S 
* [L] Longitudinal samples; [S] Single T0 sample 
* [+] Prescribed ARV administered by physicians at the Groote Schuur AIDS Clinic   
* [d4T] Stavudine; [3TC], Lamivudine; [EFV], Efavirenz; [AZT], Zidovudine; [ddi], Didanosine; [INNs], Aluvia; [NVP], Nevirapine; [TDF], Tenofovir 
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White and Coloured population groups are estimated to represent only 2.6%, 9.1% and 8.9% 
of the total population respectively (Statistics South Africa, 2011). 
 
 
 
 
 
 
 
 
 
 
2.4.1.2 Age 
Population statistical studies have shown that 16.6% of the South African population aged 15 
to 49 years, are HIV-positive (Statistics South Africa, 2011; Rehle et al., 2010). In this study, 
this was reflected by the fact that the majority of the faecal samples were obtained from 
donors in the 30-45 year age group (Figure 2.2 and Table 2.3), with the second largest age 
group providing samples being the 20-29 year group. Interestingly, the latter age group 
consisted solely of black, female donors. 
 
 
 
 
 
 
 
 
 
Figure 2.1: (A) Gender distribution of the HIV-positive and HIV-negative donors recruited for 
this study. (B) Population group distribution of the HIV-positive and HIV-negative 
donors recruited for this study 
Figure 2.2: Age distribution of the HIV-positive (A) and HIV-negative (B) donors recruited for 
this study 
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The mean age of the HIV-positive study group was 36 years, while for the HIV-negative 
group, it was 37 years. When calculating the mean ages based on gender for the HIV-positive 
group (Table 2.3), it was evident that the female donors were nearly 10 years younger (± 33 
years) than the male donors (± 42 years) participating in this study.  
 
Table 2.3: Age and gender comparisons for both donor groups used in this study   
 
 HIV-positive donors HIV-negative donors 
Age Group Female Male Female Male 
20 – 29 3 0 3 0 
30 – 45 4 3 4 3 
46 – 55 1 1 1 1 
Mean age (33) (42) (35) (40) 
 
2.4.1.3 Patient history 
All relevant clinical data and patient history for each of the 12 HIV-positive donors is 
summarised in Table 2.4. The South African Department of Health recommends that the 
administration of ARV medication be initiated in patients based on the clinical stage of the 
HIV-infection (WHO stage 1-4) or in those who have a CD4
+
 T cell count of < 350 cells/µl. 
The CD4
+
 T cell counts of the participating donors were taken at four specific time points, 
namely prior to the initiation of their HAART (T0) and at 12, 24 and 52 weeks after 
commencing with their HAART. In most instances, donors (7/12) initiated ARV treatment at 
CD4
+
 T cell counts lower than 200 cells/µl (median 138 cells/µl), while the remaining 5 
donors were all started on HAART at slightly higher CD4
+
 T cell counts (median 289 
cells/µl) (Table 2.4). Donor P6 in particular, started treatment at a CD4
+
 T cell count of 491 
cells/µl, due to the fact that this donor was diagnosed with severe psoriasis that was thought 
to be HIV-related. Unfortunately, due to poor hospital follow-up, this donor could not be 
contacted and did not return to the clinic. CD4
+
 T cell response within HIV-positive patients 
is extremely variable, and according to physicians at the Groote Schuur AIDS clinic, a CD4
+
 
T cell increase of 50-70 cells/µl over pre-treatment levels is usually expected after one month 
of HAART. Thereafter, an average increase of 70 cells/µl per year is considered to be a good 
indication of increasing CD4
+
 T cells attributable to viral suppression (Dr M Mendelson, 
personal communication). Overall, most of the donors tended to show an increase in their 
CD4
+
 T cell count as the ARV treatment progressed over the 6-months. An exception to this 
trend was donor P2, who initially showed a good rise in CD4
+
 T cell counts 
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Table 2.4: Clinical data and patient history for the 12 HIV-positive donors  
 
Donor 
ID 
CD4
+
 Count 
at T0
§
 
CD4
+
 Count 
at 12 weeks
§
 
CD4
+
 Count 
at 24 weeks
§
 
CD4
+
 Count 
at 1 year
§
 
Viral Load at     
6-months/1 year 
Patient History 
(All patients were receiving Bactrim) 
P1 142 Patient moved to Lesotho in December 2008 No episodes of diarrhoea. 
P2 95 255 304 165 LDL/LDL 
No episodes of diarrhoea.  
Good CD4
+  
rise and viral suppression.  
Patient became pregnant during study. 
P3 90 293 331 
Left clinic in 
August 2009 
LDL 
No episodes of diarrhoea.  
Defaulted treatment after 6 months. 
P4 215 323 305 
Left clinic in 
Dec 2009 
380 
No episodes of diarrhoea. 
Good CD4
+
  rise and viral suppression at 6 months.  
Defaulted treatment after 6 months. 
P5 167 [-] 310 287 LDL/LDL 
No episodes of diarrhoea.  
Good CD4
+
  rise and viral suppression.  
Treatment of recurrent urethritis using multiple antibiotics. 
P6 491 Patient lost to follow up after in hospital ARV initiation 
Severe psoriasis thought to be HIV-related and ARV’s 
started at a higher CD4
+
 T cell count.  
P7 123 213 334 
Transferred 
out of clinic 
LDL 
No episodes of diarrhoea.  
Good CD4
+
  rise and viral suppression.  
Transferred out of clinic after 6 months. 
P8 186 212 281 328 LDL/LDL 
No episodes of diarrhoea.  
Good CD4
+
  rise and viral suppression. 
P9 204 Patient withdrew from the study No episodes of diarrhoea.  
P10 235 578 412 839 LDL/LDL 
No episodes of diarrhoea. 
Good CD4
+ 
 rise and viral suppression. 
P11 163 [-] 270 
No sample 
provided 
LDL 
No episodes of diarrhoea.  
Good viral suppression.  
P12 301 Single sample 
No episodes of diarrhoea.  
New patient to the clinic. HAART prescribed but patient not 
followed up due to termination of pilot study. 
* [LDL] Low detectable levels (< 50 copies/ml) 
* [-] Patient missed appointment and no CD4+ T count was recorded 
§ [CD4+ Cell Count] = cells/µl 
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but, at 52 weeks post-ARV initiation, the CD4
+
 T cell count had dropped considerably to 165 
cells/µl. This reduction was thought to be as a result of her being pregnant and not as a result 
of viral replication (Burns et al., 1996; Biggar et al., 1989; Castilla et al., 1989; Sridma et al., 
1982; Dr M Pandie, personal communication).  
 
Standard HIV/AIDS treatment protocols followed within South African clinics advise that 
Bactrim (Trimethoprim-sulfamethoxazole) be administered to HIV-positive patients, in 
conjunction with HAART, when the CD4
+
 T cell count is below 200 cells/µl. The 
administration of Bactrim is to prevent the development and spread of opportunistic 
infections, such as Pneumocystis pneumonia (PcP). All HIV-positive donors recruited during 
this study received Bactrim prior to HAART on account of their low CD4
+
 T cell counts taken 
at T0 (Table 2.4). Several investigations have looked at the effect of Bactrim on the normal 
intestinal microbiota. Similar results were found in each of these studies, which clearly 
showed that Bactrim was highly effective against Enterobacteriaceae, but caused no 
alterations to the endogenous anaerobic gastrointestinal microbiota (Singer and Nash, 2000; 
Haase et al., 1984; Hargadon et al., 1981; Knothe, 1979).  
 
In conjunction with the CD4
+
 T cell count, each donor’s HIV viral load (plasma HIV-1 RNA 
levels) was recorded after 24 and 52 weeks, to ascertain whether the prescribed ARV regime 
was working (Table 2.4). An infective viral load is approximately 10
4
/10
5
 copies/ml of blood 
and, with the commencement of HAART, it is anticipated that the viral load will be 
suppressed to low detectable levels (LDL), approximately < 50 copies/ml (Department of 
health and human services, 2011; Thompson et al., 2010; Griffith and Mayo, 2006; Chesebro 
and Everett, 1998). All eight donors who participated in the longitudinal study showed good 
viral suppression at both the 24 and 52 week clinic visits. The exception was, however, donor 
P4, who recorded a viral load count of 380 copies/ml and, shortly after this follow-up 
appointment, defaulted on the ARV treatment and subsequent follow-up visits.  
 
In terms of secondary treatment, only donor P5 was receiving multiple antibiotics in order to 
treat a recurrent urethritis infection, as well as a Hepatitis B co-infection (Table 2.4). This 
donor received ciprofloxacin (250 mg), cefixime (400 mg), doxycycline (100 mg) and 
metronidazole (400 mg) administered at the 2, 6, 12 and 24 week clinic visits.  
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Throughout the entire course of this study, none of the 12 participating donors developed 
diarrhoea or any other gastrointestinal complications associated with an HIV infection.  
 
2.4.2 Limitations of recruitment for this study 
As with most clinical based investigations, there were several limitations encountered during 
the course of recruitment of patients for this study. Success of an investigation such as this 
lies in part in the recruitment of donors and the network established between the public sector 
clinic and the recruited donor. A noticeable limitation of this study was its small cohort size 
of 12 HIV-positive donors recruited over an 18 month period. Nonetheless, despite this 
sample size being fairly small, statistical analyses and the drawing of specific conclusions 
could still be carried out successfully (Nachar, 2008). Throughout this project, physicians at 
the Groote Schuur AIDS clinic attempted to recruit a larger sample size of approximately 20 
HIV-positive donors, but the majority of the new patients, declined to participate when 
approached. Reasons cited by these patients were their reluctance to supply a faecal sample 
and having to commit to the longitudinal sampling time constraints. In addition, patient 
transportation continued to be a serious setback, in spite of it being supported financially by 
the study.     
 
The second limiting factor of this study was patient compliance, specifically patient 
adherence to their HAART and committed attendance for the 6-month longitudinal study. 
Unfortunately, some donors missed specific follow-up appointments, stopped attending the 
clinic and, in some instances, donors even defaulted on their treatment after the 6 month 
clinic visit. This meant that extending the longitudinal study to 12 months after ARV 
initiation was not a feasible option for this investigation.  
 
As previously mentioned, patient participation in this study was entirely voluntary and, at any 
point during the study, a donor could withdraw without affecting the administration of their 
HAART. Three of the recruited donors withdrew during the course of the study. One (donor 
P6) was lost as a result of poor hospital follow-up, and another donor (P1) could not 
participate in the longitudinal study because they transferred to another AIDS clinic located 
in a geographical region outside of Cape Town. Donor P9 voluntarily withdrew from the 
study. Patient P12 was only admitted to the study at the end of the pilot study period and, 
therefore, only contributed a sample at T0.    
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2.5  CONCLUSION 
This clinical study is the first investigation to determine the effect of HIV and HAART on the 
actual levels of selected bacterial species in the gastrointestinal tracts of South African, HIV-
positive donors. The first stage of this study involved the recruitment of donors for the HIV-
positive and the control study groups and, despite several limitations encountered during this 
phase of the study, successful HIV-positive and HIV-negative donor recruitment was 
achieved. Even though the cohort size was small, it is an accurate representation of the socio-
demographic profile of the South African population, as well as the HIV-positive population, 
and is amenable to statistical analyses. This sample group also reflects the fact that Black, 
South African women, aged 25-49, have the highest risk of HIV infection than any other 
demographic group within South Africa (Rehle et al., 2010; Rosen et al., 2010). Faecal 
material obtained from both donor groups could now be used for further microbiological and 
molecular investigations.  
 
As discussed in Chapter 1, the human gastrointestinal tract is one of the earliest sites of HIV 
replication and CD4
+
 T cell depletion and is associated with elevated levels of intestinal 
inflammation and possible alterations in the microbial intestinal community. In order to 
determine how HIV replication affects the normal human gastrointestinal microbiome, a 
baseline comparison needs to be established between that of HIV-positive patients, prior to 
HAART initiation (T0) and a normal, healthy, HIV-negative population. To achieve this, the 
diversity of the total bacteria and the two probiotic genera, Bifidobacterium and 
Lactobacillus, was characterised in both study groups as described in Chapter 3.  
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CHAPTER THREE  
PCR-DGGE analysis of total bacteria, Bifidobacterium and Lactobacillus species in South 
African HIV-positive and HIV-negative donors  
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3.1  SUMMARY 
The human gastrointestinal tract houses a complex, commensal microbial community that 
assists in the development and maintenance of the gut associated lymphoid tissue (GALT), 
while simultaneously forming a protective barrier against invading opportunistic pathogens. In 
this study, it is hypothesised that the replication of HIV within the intestinal tract affects the 
endogenous microbiota in such a way that species belonging to genera, such as 
Bifidobacterium and Lactobacillus as well as other possible candidates, are no longer able to 
provide a beneficial and protective function to the host. The diversity of the total microbial 
population as well as the Bifidobacterium and Lactobacillus subpopulations present in the 
faecal material of 12 South African HIV-positive and HIV-negative donors was characterised 
using PCR-DGGE. Analysis of the PCR-DGGE results showed that each donor exhibited a 
unique and host specific profile for all of the investigated bacterial groups. There were no 
statistically significant differences between the diversity of the Bifidobacterium and 
Lactobacillus groups. However, the results showed that the diversity of the total bacterial 
population was significantly lower in the HIV-positive donors (p = 0.009) compared to the 
control HIV-negative group. This finding may possibly be attributed to the replication of HIV 
within the GALT and the associated destruction of the gut mucosa. This is the first study to 
show a noticeable difference in the diversity of the total microbiota within the gastrointestinal 
tracts of South African HIV-positive patients compared to that of their healthy counterparts.   
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3.2  INTRODUCTION 
The endogenous microbiota of the gastrointestinal tract is a large and complex community 
that plays an integral role in intestinal development and maintenance, homeostasis (Marchesi 
and Shanahan, 2007), stimulation of the host’s immune system (Malinen et al., 2005), 
protection against epithelial cell injury (Eckburg et al., 2005), and protection against invading 
pathogens by functioning as a barrier (Marchesi and Shanahan, 2007).  
 
Bifidobacterium and Lactobacillus species belong to the Lactic Acid Bacteria group (LAB) 
and are important constituents of the intestinal microbiota. The genus Lactobacillus, is 
comprised of Gram-positive, rod-shaped, catalase negative, non-sporing, microaerophilic 
species (Felis and Dellaglio, 2007). Although Lactobacillus species are estimated to make up  
less than 1% of the intestinal population, with L. acidophilus, L. gasseri, L. fermentum and L. 
reuteri being the most frequently isolated species in human faeces (Reuter, 2001; Sghir et al., 
2000), these bacteria are actively involved in influencing and maintaining the gastrointestinal 
tract (Felis and Dellaglio, 2007; Rolfe, 2000). Certain Lactobacillus species are capable of 
stimulating macrophages and secreting antimicrobial substances which inhibit the growth and 
attachment of invading pathogens to the intestinal tract (Anuradha and Rajeshwari, 2005; 
Alvarez-Olmos and Oberhelman, 2001). 
 
Bifidobacterium spp. are Gram-positive, non-motile bacteria with a high GC content, and 
represent some of the most common organisms found within the human intestinal tract 
(Turroni et al., 2008; Matsuki et al., 2004, Biavati and Mattarelli, 2001). In addition to 
protecting the host from invading opportunistic pathogens, Bifidobacterium species such as B. 
adolescentis, B. bifidum, B. breve and B. longum also contribute towards the maintenance and 
integrity of the epithelial lining (Felis and Dellaglio, 2007). Bifidobacterium species are 
capable of producing glutamine from NH4
+
 and glutamic acid, which serves as a supplement 
for the intestinal epithelium and maintains the integrity of the mucosal lining (Anuradha and 
Rajeshwari, 2005).  
 
PCR-DGGE (discussed in Chapter 1) has been shown to be a rapid and effective tool in 
studying the diversity of complex microbial populations present within the intestinal tract, and 
in determining the effects that the administration of antimicrobials have on the host’s gut 
microbiota (Turroni et al., 2008; Handschur et al., 2007). The fundamental principle of PCR-
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DGGE relies on the sequence-specific separation of equally sized PCR fragments, generating 
a particular “population profile” for each microbial community (Muyzer et al., 1993).  
 
Investigations into the diversity of the gastrointestinal bacterial community make use of the 
16S rRNA gene which has a high discriminatory index and consists of several distinct 
conserved and variable regions pertaining to a range of phylogenetic levels such as, group, 
genus and species (Mohania et al., 2008; Satokari et al., 2003; Heilig et al., 2002). This 
particular feature has led to the development of group- and species-specific primers that can 
be utilized in the detection and identification of bacteria such as Bifidobacterium and 
Lactobacillus species (Satokari et al., 2003; Heilig et al., 2002). As a result of these differing 
sequences found within the 16S rRNA gene of bacterial species, PCR fragments will possess 
unique and different chemical stability properties causing them to migrate to different 
positions within the denaturing gradient across the gel. However, PCR fragments aligning at 
the same positions do not necessarily prove they are identical or derived from the same 
species, and therefore, sequencing of these fragments or the use of a narrower denaturing 
gradient to further enhance resolution is required (Muyzer et al., 1993). Muyzer et al., (1993) 
showed that PCR-DGGE was sensitive enough to detect a particular bacterial species 
representing only 1% of the total microbial population. 
 
The primary objective of the research presented in this chapter was to examine the microbial 
condition of the gastrointestinal tract in HIV-positive patients, with respect to two well-known 
probiotic groups of bacteria and to the total microbial population. This would assist in 
determining whether the continuous replication of HIV, within the gut, causes a significant 
disruption to the endogenous microbiota and whether probiotic supplementation might help in 
stabilising conditions within the gut. Serious alterations and changes to the distribution of 
intestinal populations, such as the Bifidobacterium and Lactobacillus groups, could result in 
them no longer being able to provide a protective function to the host. Therefore, the major 
representatives of the total microbial population, as well as the Bifidobacterium and 
Lactobacillus groups, present in the faecal material of 12 South African HIV-positive and 
HIV-negative donors were analysed using PCR-DGGE, and the major species represented 
identified phylogenetically.  
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3.3  MATERIALS AND METHODS 
3.3.1 Bacterial strains and plasmids 
All bacterial strains and plasmids used in this section of the study are described in Table 3.1. 
Enterococcus faecalis (Juste-Poinapen, 2007) and all Lactobacillus type strains were cultured 
in de Man, Rogosa, Sharpe (MRS) [Biolab] media, while B. longum and B. adolescentis were 
cultured in Basal Yeast (BYG) medium containing 1% (w/v) glucose, as described by Degnan 
and Macfarlane, (1993). B. fragilis 638R was grown in a supplemented brain heart infusion 
(BHIS) [Difco] medium (Holdeman and Moore, 1972), whilst a Clostridium basal growth 
medium (CBM) was used to culture C. perfringens (O’Brien and Morris, 1971). All reference 
strains, with the exception of E. coli, were grown anaerobically in an anaerobic chamber 
(Forma Scientific Inc, Model 1024) under atmospheric conditions of 85% N2, 10% CO2 and 
5% H2. E. coli was grown aerobically at 37
o
C in Luria Bertani (LB) broth or agar plates 
containing ampicillin (100 µg/ml) when required (Sambrook et al., 1989).   
 
Table 3.1  Bacterial strains and cloning plasmid used in this study 
Bacterial strains and plasmid Relevant characteristics Source or reference
*
 
Bifidobacterium longum NCIMB 702259
T
 Type strain of B. longum NCIMB 
Bifidobacterium adolescentis ATCC 15703
T
 Type strain of B. adolescentis ATCC 
Lactobacillus casei DSM 20011
T
 Type strain of L. casei DSM 
Lactobacillus brevis DSM 20054
T
 Type strain of L. brevis DSM 
Lactobacillus reuteri DSM 20016
 T
 Type strain of L. reuteri DSM 
Lactobacillus gasseri ATCC 33323
T
 Type strain of L. gasseri ATCC 
Lactobacillus fermentum ATCC 9338
T
 Type strain of L. fermentum ATCC 
Bacteroides fragilis 638R Clinical isolate Privitera et al., (1979) 
Escherichia coli DH5α Gram-negative cloning host Hanahan, (1983) 
Enterococcus faecalis (P1.2) MCB laboratory strain MCB  
Clostridium perfringens ATCC 13124
T
 Type strain of C. perfringens ATCC  
Plasmid pTZ57R/T Linearized cloning vector with 
single 3’-ddT overhangs  
Fermentas 
 
*
NCIMB: National Collection of Industrial, Food and Marine Bacteria, United Kingdom, DSM: Deutsche  
  Sammlung von Mikroorganismen, Germany, ATCC: American Type Culture Collection, MCB: Department of  
  Molecular and Cell Biology, University of Cape Town  
 
3.3.2 Genomic DNA extraction 
Total bacterial DNA was extracted from faecal samples collected at T0 (section 2.3.2), using 
the ZR Faecal DNA Kit
TM 
(ZYMO Research) (Yoshikawa et al., 2011). Approximately 200 
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mg of frozen faecal material was added directly to a ZR BashingBead
TM
 lysis tube containing 
750 µl lysis buffer (1.8% Tris; 8% NaCl; 18.6% EDTA and 4 M guanidine thiocyanate [Zymo 
Research MSDS]) and rapidly lysed for 5 minutes at maximum speed in a Mini-Beadbeater
TM
 
(Biospec). Following this, DNA extraction was performed according to the manufacturer’s 
instructions.  
 
DNA extraction from bacterial reference strains was performed using the Genomic DNA 
Purification Kit (Fermentas) for the isolation of nucleic acids from bacterial cultures, as 
described by the manufacturer with a slight modification. Bacterial cells, except B. fragilis 
and E. coli, were initially pre-treated with 200 µl lysis buffer (20 mM Tris-HCl pH 8.5, 2 mM 
EDTA pH 8, 1% (v/v) Triton X-100 and 20 mg/ml lysozyme) for 2 hours at 37
o
C. Following 
this, DNA isolation was completed according to the manufacturer’s instructions. The 
concentration of the extracted DNA was determined spectrophotometrically using a Nanodrop 
(NanoDrop® ND-1000).  
 
3.3.3 PCR-DGGE analysis of selected faecal bacterial populations 
3.3.3.1 PCR amplification  
PCR amplification of the 16S rRNA gene, from faecal genomic DNA, was used for the 
detection of total bacteria as well as Bifidobacterium and Lactobacillus species. Optimal PCR 
products for DGGE analysis were obtained using two rounds of nested PCR. Primers used for 
this section of the work are shown in Table 3.2 and all PCR reactions were performed in a 
GeneAmp® PCR System 9700 (Applied Biosystems).  
 
First round PCR detection of Bifidobacterium species:  
PCR detection of Bifidobacterium species employed primers Bif164F and Bif662R. A PCR 
reaction mixture of 25 µl contained 100 ng of DNA template, 1X PCR reaction buffer, 1.5 
mM MgCl2, 0.5 µM of each primer, 200 µM of each dNTP (Fermentas), Bovine Serum 
Albumin [0.6 µg/µl] (Fermentas) and 0.25 units of Supertherm Taq polymerase (Southern 
Cross Biotechnology). The PCR cycling conditions used were performed according to the 
method described by Satokari et al., (2001) and Kullin, (2010). PCR amplification involved a 
denaturation step at 96
o
C for 5 min, followed by 35 cycles of 96
o
C for 30 sec, 63
o
C for 20 sec 
and 68
o
C for 40 sec, finishing off with a step at 62
o
C for 20 sec and final extension at 68
o
C 
for 7 min. 
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Table 3.2  PCR primers employed in this study 
Primer Primer Sequence (5’-3’) Reference 
Bif164F GGG TGG TAA TGC CGG ATG Kok et al., (1996) 
Bif662R CCA CCG TTA CAC CGG GAA Langendijk et al., (1995) 
Univ341F TCC TAC GGG AGG CAG CAG Muyzer et al., (1993) 
Lab0667R CAC CGC TAC ACA TGG AG Heilig et al., (2002) 
Univ341F-GC CGC CCG CCG CGC GCG GCG GGC GGG GCG 
GGG GCA CGG GGG GTC CTA CGG GAG GCA 
GCA 
Muyzer et al., (1993) 
Univ515R ATC GTA TTA CCG CGG CTG CTG GCA Lane, (1991) 
R2 GGA CTA CCI GGG TAT CTA ATC C Lee et al., (1993) 
M13F CGC CAG GGT TTT CCC AGT CAC GAC  
Yanisch-Perron et al., (1985) 
M13R GAG CGG ATA ACA ATT TCA CAC AGG 
 
First round PCR detection of the Lactobacillus group:  
PCR detection was performed using primers Univ341F and Lab0667R for the Lactobacillus 
group (Lactobacillus, Leuconostoc, Pedicococcus and Weissella genera). Reactions were 
carried out using the following PCR reaction mixture (25 µl): 100 ng of DNA template, 1X 
PCR reaction buffer, 1.5 mM MgCl2, 0.5 µM of each primer, 200 µM of each dNTP 
(Fermentas), Bovine Serum Albumin [0.6 µg/µl] (Fermentas) and 0.25 units of Supertherm 
Taq polymerase (Southern Cross Biotechnology). PCR cycling conditions, previously 
optimized by Magwira, (2008), consisted of an initial step at 96
o
C for 4 min, followed by 30 
cycles of 96
o
C for 40 sec, 55
o
C for 30 sec and 72
o
C for 45 sec, and a final extension step of 5 
min at 72
o
C.  
 
First round PCR detection of total bacteria:  
PCR detection of total bacteria was performed using primers Univ341F and R2 for total 
bacteria. The PCR reaction mixture used comprised (25 µl): 100 ng of DNA template, 1X 
PCR reaction buffer, 1.5 mM MgCl2, 0.5 µM of each primer, 200 µM of each dNTP 
(Fermentas), Bovine Serum Albumin [0.6 µg/µl] (Fermentas) and 0.25 units of Supertherm 
Taq polymerase (Southern Cross Biotechnology). PCR cycling parameters consisted of an 
initial step at 96
o
C for 4 min, followed by 30 cycles of 96
o
C for 40 sec, 53.5
o
C for 30 sec and 
72
o
C for 45 sec, and a final extension step of 5 min at 72
o
C (Magwira, 2008).  
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Second round PCR detection 
For the second round of amplification, to include the GC clamp and to obtain PCR products 
of similar length, 1 µl of the first round PCR product was used as template together with 
primers Univ341F-GC and Univ515R, producing PCR amplicons of approximately 216 bp in 
size. PCR conditions included initial denaturation at 96
o
C for 4 min followed by 30 cycles of 
96
o
C for 40 sec, 55
o
C for 30 sec and 72
o
C for 40 sec with a final extension of 7 min at 72
o
C 
(Magwira, 2008).  
 
The detection of PCR products and their respective molecular sizes was determined using 
agarose gel electrophoresis. Approximately 5 µl of the PCR product was run on a 2% agarose 
(w/v) gel stained with ethidium bromide [10mg/ml] (Promega) and compared to a 100 bp 
molecular weight marker (Fermentas).    
 
3.3.3.2 Denaturing gradient gel electrophoresis (DGGE) 
PCR products generated using primers Univ341F-GC and Univ515R were used for DGGE 
analysis. Polyacrylamide gels consisted of 8% (v/v) polyacrylamide (37.5:1 acrylamide-
bisacrylamide) and 50X TAE buffer (2 M Tris, 1 M Acetic acid, 50 mM EDTA, pH 8). PCR 
products were separated using deionized formamide and urea denaturing gradients of 45-65% 
(total bacteria); 45–55% (Lactobacillus group) and 55-65% (Bifidobacterium) respectively. A 
100% denaturant is defined as a mixture of 7 M urea and 40% (v/v) deionized formamide. 
Electrophoresis was conducted using the DCode
TM
 Universal Mutation Detection System 
(Bio-Rad Inc.) run at a constant voltage and temperature of 62 V and 60
o
C for 17-18 h. 
Enhanced resolution of the DGGE banding pattern was achieved by pre-electrophoresis of the 
gel at 180V for 10 mins. A DGGE reference ladder made up of different bacterial species, 
specific to the group being investigated, was included in each run thereby allowing 
subsequent gel normalisation and inter-gel comparisons. Following electrophoresis, gels were 
stained with ethidium bromide (25 µl in 250 µl 1X TAE buffer [1 µg/µl]) for 15 mins and 
then de-stained in fresh 1X TAE buffer for 30 mins. DGGE banding patterns were visualized 
using the GelDoc XR
+
 imaging system (Bio-Rad Inc.).  
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3.3.4 Statistical analyses of selected DGGE banding patterns 
3.3.4.1 Cluster analysis 
The relationship and similarities between the banding patterns generated by PCR-DGGE 
were analysed using the unweighted-pair group method (UPGMA) to construct dendrograms 
based on the Dice similarity coefficient between samples as previously described by van der 
Gucht et al., (2001). All DGGE banding profiles were digitally analysed in a multistep 
method using the FPQuest
TM
 bioinformatics software version 4.5 (Bio-Rad Inc) (Vitali et al., 
2010). Following gel normalisation, DNA bands present in each lane were automatically 
detected and matched based on their position relative to the standard reference ladder. 
Calculated similarity values were then visually represented in the form of a dendrogram 
(Vitali et al., 2010).  
 
3.3.4.2 Shannon-Wiener diversity index 
The Shannon-Wiener diversity index      was used to determine the diversity of bacterial 
species present within the faecal samples of the two donor groups. The diversity index for 
each gel lane was evaluated using the Quantity One® software version 4.5.2 (Bio-Rad Inc), 
and calculated using the following formula (Gafan et al., 2005):  
 
                
 
   
  
 
where s is the number of bands present in each sample and Pi is the relative intensity of each 
band within the sample. Since the data was not uniformly distributed, a nonparametric 
analysis using the Mann-Whitney U Test (Mann and Whitney, 1947) was performed to 
compare the    values in the HIV-positive and HIV-negative groups and a p value ≤ 0.05 was 
interpreted as being statistically significant. All nonparametric statistical analyses, as well as 
box-and-whisker plots (expressed as medians with quartile ranges [QR]) were performed 
using Stata data analysis and statistical software version 11.1 (StataCorp LP, USA).  
 
3.3.5 Sequence analysis of selected DGGE bands   
3.3.5.1 Excision of DNA fragments and cloning 
DGGE bands were excised as described by Omar and Ampe, (2000). Selected bands were 
excised under UV illumination (360 nm), using sterile surgical blades and re-suspended in 30 
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µl of nuclease-free water for 24 hours at 4
o
C. Samples were centrifuged for 1 min at 
maximum speed, and a 3 µl aliquot was re-amplified using primers Univ341F and Univ515R, 
as described in section 3.3.3.1. The resulting PCR products were purified using the BioSpin 
PCR Purification Kit (BioFlux), as per the manufacturer’s instructions; ligated into the vector 
pTZ57R/T using the InsTAcloneTM PCR Cloning Kit (Fermentas) and transformed into 
competent E. coli DH5α cells. Presence of the insert was confirmed through colony PCR 
(Dafa’alla et al., 2000; Zon et al., 1989) using primers M13F and M13R (Table 3.2). Plasmid 
DNA, containing the insert, was then isolated using the BioSpin Plasmid Extraction Kit 
(BioFlux) and sequenced (Macrogen Inc., Seoul, Korea) using M13F as the sequencing 
primer. Three independent clones were selected for each cloned fragment. Sequences were 
analysed using Chromas version 2.01 (Technelysium Ltd) and DNAMAN version 4.13 
(Lynnon BioSoft), while the similarity of the sequence was compared with those available in 
the Genbank database, using the BLAST algorithm, (Zhang et al., 2000; Altschul et al., 1990) 
and the Ribosomal Database Project (Cole et al., 2009).     
 
3.4  RESULTS AND DISCUSSION 
3.4.1 PCR-DGGE optimisation  
PCR-DGGE has become a valuable tool for monitoring the structure and dynamics of a 
complex microbial population, and has been successfully used in many studies focusing on 
the gastrointestinal microbiota of humans (Ariefdjohan et al., 2010; Wu et al., 2010), farm 
animals (Furet et al., 2009; Petersson et al., 2009) and mice (Bibiloni et al., 2005). To ensure 
that optimal DGGE conditions were used in this study several key components needed to be 
optimised prior to performing the experimental work. These components included: efficient 
genomic DNA extraction; primer selection; PCR conditions; the addition of PCR enhancers 
such as bovine serum albumin (BSA), as well as the denaturing gradient and electrophoresis 
run time to be used.    
 
3.4.1.1 Cell lysis and validation of genomic DNA extraction kit   
An accurate representation of the gastrointestinal microbial community is affected by factors 
such as the quality of the DNA isolated from the sample, as well as incomplete or preferential 
cell lysis. In this study, high quality, inhibitor-free DNA was isolated using the ZR Fecal 
DNA kit. The addition of the bead-beating step ensured that samples underwent efficient and 
rapid cell lysis, while any inhibitors released during the extraction procedure were removed 
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using the specially designed Zymo-Spin
TM
 IV-HRC spin filter, to prevent any interference 
occurring during PCR amplification.  
 
To validate the efficiency of the DNA extraction kit to extract inhibitor-free DNA, and to 
determine the optimum concentration of DNA to be used, PCR was performed on different 
concentrations of DNA (25 ng to 200 ng) using each primer set prior to PCR-DGGE. In most 
cases, PCR inhibition occurred when 150 ng or more of DNA template was used, whilst no 
amplification occurred when 25 ng DNA was used. Maximum PCR amplification was 
however, achieved when a DNA concentration of 100 ng was used, and confirmed that the 
ZR Fecal DNA kit had successfully removed any major inhibitors present within the sample 
(Figure 3.1). This kit was later also used for qPCR analysis (see Chapter 5). Different 
amounts of DNA were evaluated in the qPCR work, and no major inhibitors of the PCR 
reaction were detected. These results confirm the reports by Yoshikawa et al. (2011) that the 
ZR Fecal DNA kit effectively removes PCR inhibitors present in human faecal samples.  
 
      
 
 
 
 
 
 
 
3.4.1.2 PCR Optimisation  
3.4.1.2.1 Primer selection 
The sensitivity and specificity of PCR-DGGE does, in part, also rely on selecting the most 
efficient primer combinations. Primers Univ341F (Muyzer et al., 1993) and R2 (Lee et al. 
1993) are termed universal primers given that they will amplify all predominant bacterial 
species present within the sample.  
Figure 3.1: PCR amplification of serial dilutions of faecal genomic DNA using optimised 
PCR conditions [Univ341F and Lab0667R]. Lane 1: 100 bp molecular weight 
marker (Fermentas); Lane 2:  Negative control (no DNA); Lane 3: 200 ng; Lane 4: 
150 ng; Lane 5: 100 ng; Lane 6: 75 ng; Lane 7: 50 ng and Lane 8: 25 ng.   
  1          2           3          4          5          6          7          8      
500 bp 
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Samples tested using primers Univ341F and R2 all produced a distinct 467 bp DNA fragment 
after the first round of PCR amplification (Figure 3.2A). However, a major limitation of 
using universal primers is that individual shifts within specific smaller bacterial populations 
may not be seen. Thus the development of group-specific primers has meant that bacterial 
Figure 3.2: First and second round PCR detection. (A) Total bacteria employing primers 
Univ341F and R2. (B) Bifidobacterium species employing primers Bif164F and 
Bif662R. (C) Lactobacillus group employing primers Univ341F and Lab0667R. (D) 
Representative gel showing second round PCR detection employing primers 
Univ341F-GC and Univ515R [first round PCR products from panel A were used as 
templates]. Lane 1: 100 bp molecular weight marker (Fermentas); Lane 2: Negative 
control (no DNA); Lanes 3 – 7: HIV-positive donors (P1-P5) and Lanes 8 – 12: HIV-
negative donors (H1-H5). 
467 bp 
210 bp 
 1      2      3     4      5     6      7      8     9     10    11   12     
 1      2      3     4      5     6      7      8     9     10    11   12     
 1      2      3     4      5     6      7      8     9     10    11   12     
 1      2      3     4      5     6      7      8     9     10    11   12     
A 
B 
C 
D 
510 bp 
326 bp 
500 bp 
500 bp 
500 bp 
500 bp 
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species belonging to groups, present in much smaller numbers within the gastrointestinal 
tract, are able to be analysed, better revealing any subtle changes or differences within these 
communities.    
 
In this study, several combinations of published PCR primers were tested (Heilig et al., 2002; 
Kok et al., 1996; Langendijk et al., 1995; Muyzer et al., 1993) and the following primers 
were selected as the most efficient. Group-specific primers Bif164F and Bif662R 
(Bifidobacterium) and Univ341F and Lab0667R (Lactobacillus) were used in the first round 
of PCR producing PCR amplicons of approximately 510 bp and 326 bp respectively (Figure 
3.2B and Figure 3.2C). Lab0667R has been shown to be specific for lactic acid bacteria, and 
has been used for the detection of Lactobacillus species, while also simultaneously 
amplifying members belonging to the phylogenetically related Leuconostoc, Pediococcus and 
Weisella genera (Heilig et al., 2002).  
 
Increased sensitivity and optimal fragment separation were achieved when a nested PCR was 
conducted. An advantage of using the nested PCR approach is that a standard length 16S 
rRNA gene fragment was generated prior to DGGE analysis. Figure 3.2D shows first round 
PCR products (from panel 3.2A) that were amplified using the second round primers. Similar 
results were found after using PCR products shown in Figures 3.2B and 3.2C as templates, 
and all produced equal length product sizes of 210 bp containing the GC-rich clamp essential 
for DGGE analysis. One of the most important functions of the GC clamp is to prevent the 
PCR product from completely dissociating during electrophoresis.  
 
Faint shadow bands, associated with each PCR product, were seen when the universal primer 
sets were used (Figure 3.2A and 3.2D). Numerous attempts were made to eliminate this by 
modifying the PCR conditions, but these particular shadow bands were still evident even 
when relatively low DNA concentrations were used. Shadow bands have been previously 
reported by Qiu et al., (2001) who showed that the production of these PCR artefacts 
increased substantially when the diversity of species present within a sample increased. This 
may be the reason for the bands observed in this study. For the current study, therefore, PCR 
conditions showing the least amount of shadow bands were used (see section 3.3.3).  
 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
64 
 
3.4.1.2.2 PCR Conditions  
Optimisation of PCR cycling conditions was done using previously published methods as a 
basis for Bifidobacterium species (Satokari et al., 2001), as well as the Lactobacillus group 
and total bacteria (Magwira, 2008). To ensure that highly optimised PCR conditions were 
used for each primer set, the MgCl2 concentration, annealing temperature, cycle number, and 
primer concentration were all evaluated and adjusted in various PCR test runs, prior to 
initiating this study. Several MgCl2 titration curves, ranging from 1 mM to 2.5 mM were 
conducted in order to achieve maximum product production, as well as high specificity and 
sensitivity.  
 
The addition of BSA has also been shown to increase PCR product production by stabilising 
the Taq polymerase, in addition to interacting with any remaining inhibitory substances 
present in the sample (Eilert and Foran, 2009; Al-Soud and Rådström, 2000; Nagai et al., 
1998). Two related investigations conducted by Kullin, (2010) and Magwira, (2008) both 
showed that amplification of the 16S rRNA gene from human faecal material was enhanced 
when BSA was added directly to the PCR reaction mix. Therefore, to ascertain whether 
amplification of the 16S rRNA gene from faecal samples used in this study would be 
increased due to the presence of BSA, several PCR reactions were conducted in the presence 
or absence of BSA, and the resulting product examined using gel electrophoresis. A 
noticeable increase in PCR product production was seen for the reactions that had been 
supplemented with BSA (Figure 3.3) and as a result of this, BSA was included in all PCR 
reactions conducted in this study. 
 
 
 
 
 
 
 
 
Figure 3.3: The effect of BSA on PCR product production. Duplicate PCR reactions, 
employing primers Univ341F and Lab0667R, in the presence [+] and absence [-] of 
BSA [0.6 µg/µl]. Lane R: 100 bp molecular weight marker (Fermentas).   
[+] BSA [-] BSA 
 R        P4       P5        P7       P9         P4       P5        P7       P9          
500 bp 
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3.4.1.3 DGGE running conditions 
To achieve the best possible separation of bands, and in so doing make profiling of microbial 
communities easier, optimisation and modification of the denaturing gradient as well as the 
run time had to be performed. For the purpose of this study, a range of gradient 
concentrations were tested to ascertain the best band separation conditions (Temmerman et 
al., 2003a; Satokari et al., 2001). Gradient ranges of 55-65% and 45-55% were identified as 
suitable for the separation of the Bifidobacterium (Figure 3.4A) and Lactobacillus (Figure 
3.4B) populations respectively, while a gradient of 45-65% was used for the analysis of the 
total bacteria profile (Figure 3.5).  
 
Electrophoresis running conditions used for DGGE analysis is another contested issue, with 
some studies preferring a longer time period and low voltage (Boon et al., 2002; Gejman et 
al., 1998) while others have reported that shorter time periods at higher voltages (Sigler et al., 
2004) result in efficient band separation. Optimisation of the electrophoresis run time carried 
out in this study confirmed the findings of Kullin, (2010) and Magwira, (2008) and 
demonstrated that a longer time period (17-18 hours) and a low constant voltage resulted in 
better separation of 16S rRNA fragments amplified from faecal material using the 
Bifidobacterium and Lactobacillus group-specific primers.  
 
PCR products from all bacterial reference strains (Table 3.1) were amplified by means of the 
optimised methods, using either the universal or group-specific primers. Individual PCR 
products were pooled to create three standard DGGE reference ladders representative of 
Bifidobacterium spp. (Figure 3.4A), Lactobacillus spp. (Figure 3.4B) and total bacteria 
(Figure 3.5). 
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Figure 3.4: (A) Bifidobacterium DGGE reference ladder. Separation of PCR products from two 
Bifidobacterium species using a denaturing gradient of 55-65%. Lane 1: Pooled 
reference ladder; Lane 2: B. longum and Lane 3: B. adolescentis. (B) Lactobacillus 
group DGGE reference ladder. Separation of PCR products from four Lactobacillus 
species using a denaturing gradient of 45-55%. Lane 1: Pooled reference ladder; 
Lanes 2: L. casei; 3: L. gasseri; 4: L. brevis and 5: L reuteri.   
Figure 3.5: Total bacteria DGGE reference ladder. Separation of PCR products from nine 
reference strains using a denaturing gradient of 45-65%. Lane 1: Pooled reference 
ladder; Lanes 2: L. reuteri; 3: L. gasseri; 4: L. casei; 5: L. brevis; 6: E. faecalis; 7: E. 
coli; 8: C. perfringens; 9: B. longum and 10: B. fragilis.    
B. fragilis 
L. gasseri 
L. brevis 
E. faecalis 
E. coli 
L. reuteri 
C. perfringens 
B. longum 
L. casei 
B A 
 1          2         3       1     2      3     4     5      
 1      2      3      4      5      6       7     8      9     10      
B. longum 
B. adolescentis 
L. casei 
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L. brevis 
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3.4.2 DGGE profile and cluster analysis of different bacterial groups 
DGGE was used in determining the diversity of the Bifidobacterium and Lactobacillus 
communities, as well as the major gut bacterial species, present in the faeces of HIV-positive 
and HIV-negative donors (Figure 3.6A, Figure 3.7A and Figure 3.8A). When examining the 
banding pattern generated for the Bifidobacterium population (Figure 3.6A), it was evident 
that 2 to 4 dominant bands occurred in most of the gel lanes. This corresponded with similar 
reported PCR-DGGE studies that also focused on Bifidobacterium species within the human 
intestinal tract (Vanhoutte et al., 2004; Nielsen et al., 2003; Satokari et al., 2001). The 
Bifidobacterium population appeared to be quite similar in both the HIV-positive and HIV-
negative donors.  
 
The faecal Lactobacillus population in contrast (making up less than 1% of the total intestinal 
community) showed very different DGGE profiles for each of the donors (Figure 3.7A). The 
banding patterns revealed a minimum of two and a maximum of six detectable bands in all the 
faecal samples screened suggestive of some variation in the diversity of the Lactobacillus 
community within the intestinal tracts of both HIV-positive and HIV-negative donors.  
 
The universal DGGE profiles (Figure 3.8A) were considerably more complex than the 
Bifidobacterium and Lactobacillus profiles. DGGE banding patterns differed to some extent 
between donors both in the number of bands present, as well as the position and intensity of 
these bands within the gel. In most instances, the total bacteria profile was characterised by 
the presence of 8 to 18 different bands across the individual lanes indicating a higher diversity 
when compared to the Bifidobacterium and Lactobacillus groups. However, caution must be 
used when interpreting these results since DGGE provides only an indication of the microbial 
community’s diversity rather than an exact representation (Eichner et al., 1999). The reason 
for this is that when the universal primers are employed to amplify a large mixture of 16S 
rRNA genes within a sample, species present in much lower abundances will not readily 
amplify, and the universal DGGE profile will be skewed to show only the predominant 
species present within that particular community (Muyzer et al., 1993). 
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Figure 3.6: DGGE and cluster analysis of bifidobacterial 16S rRNA genes amplified from 
the faecal material of 12 HIV-positive and 12 HIV-negative donors. (A)  Lane R: 
DGGE reference ladder [(a): B. longum and (b): B. adolescentis]. (B) The 
dendrogram was generated using the Dice Similarity coefficient and clustering 
algorithm UPGMA [(Pink): HIV-positive donor and (Purple): HIV-negative donor]. 
Scale bar indicates similarity (%). 
R      P7   P12   P1   P4    P3   P9   H2   H4   H6   H5  H9  H10   
HIV-positive Donors HIV-negative Donors 
R     P2   P6   P10  P5   P11  P8   H3  H7  H8  H11  H12  H1   
HIV-positive Donors HIV-negative Donors 
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Figure 3.7: DGGE and cluster analysis of the Lactobacillus group 16S rRNA genes amplified 
from the faecal material of 12 HIV-positive and 12 HIV-negative donors. (A)  
Lane R: DGGE reference ladder [(a): L. casei; (b): L. gasseri; (c): L. brevis; (d): L. 
reuteri and (e): L. fermentum]. (B) The dendrogram was generated using the Dice 
Similarity coefficient and clustering algorithm UPGMA [(Pink): HIV-positive donor 
and (Purple): HIV-negative donor]. Scale bar indicates similarity (%). 
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B 
R   P7  P12  P1  P4   P3  P9   H2 H4  H6  H5  H9  H10   
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Figure 3.8: Total bacteria DGGE and cluster analysis of 16S rRNA genes amplified from the 
faecal material of 12 HIV-positive and 12 HIV-negative donors. (A)  Lane R: 
DGGE reference ladder [(a): B. fragilis; (b): L. casei; (c): L. gasseri; (d): L. brevis; 
(e): E. faecalis; (f): E. coli; (g): L. reuteri; (h): C. perfringens and (i): B. longum]. (B) 
The dendrogram was generated using the Dice Similarity coefficient and clustering 
algorithm UPGMA [(Pink): HIV-positive donor and (Purple): HIV-negative donor]. 
Scale bar indicates similarity (%). 
A 
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In both Figures 3.7A and 3.8A, a distinct common background region situated within the 
lower part of the gel was observed. The source of this background may be as a result of 
residual unbound ethidium bromide remaining within the gel after destaining (Vanhoutte et 
al., 2004). Ethidium bromide is capable of binding to both single and double stranded DNA 
(Waring, 1965), and unbound ethidium bromide has also been shown to have significant 
intrinsic fluorescence (Singer et al., 1999). Other nucleic acid gel stains such as SYBR Green 
I or SYBR Gold, produce very little background fluorescence when used in the detection of 
DNA (Vanhoutte et al., 2004). Extending destaining of the gel from 30 mins to 60 mins 
resulted in a reduction in this background region, but with a simultaneous decrease in the 
intensity of the DGGE bands. The background fluorescence was easily differentiated from 
the DGGE bands of interest due to its relatively low intensity and position within the gel, thus 
not influencing the analysis and interpretation of the data. 
 
On the whole, DGGE profiles acquired for all three bacterial groups showed a strong 
tendency towards being host-specific even though some common bands (bands present at the 
same positions) were observed for different donors. This particular observation is consistent 
with what other studies have described (Satokari et al., 2001; Walter et al., 2001; Zoetendal 
et al., 1998). 
 
The relationship of the DGGE banding profile between the HIV-positive and HIV-negative 
donors for the three bacterial groups was analysed and displayed as individual dendrograms 
(Figure 3.6B, Figure 3.7B and Figure 3.8B). The band variation and complex host specificity 
seen for both the Lactobacillus and total bacteria populations meant that no distinct clustering 
of the donors was seen. This general lack of clustering of donors for the Lactobacillus and 
total bacteria populations has also been reported in studies conducted by Maukonen et al., 
(2008) and Vanhoutte et al., (2004). In contrast, the Bifidobacterium population displayed 
strong similarities between the donors, thus enabling the clustering of certain donors. The 
clustering of donors seen for the Bifidobacterium group, however, was not related to the HIV-
status of the donors. 
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3.4.3 Shannon-Wiener diversity index 
The diversity of a specific population was calculated using the Shannon-Wiener diversity 
index, which took into account the species richness (number of bands present) as well as the 
relative intensity of the bands. When the diversity index      was determined for the 
Bifidobacterium population, it initially appeared that the diversity was higher in the HIV-
positive donor group (0.65) than the HIV-negative group (0.37) (Table 3.3). However, when 
the Mann-Whitney U Test was carried out to compare these    values statistically, the result 
showed that this difference was not statistically significant (p = 0.10).  
 
Table 3.3:  Shannon-Wiener diversity indices calculated for the three investigated bacterial groups  
Bacterial Group Donor group Mean      Range of      Statistical Significance 
Bifidobacterium HIV-positive 0.65 0 – 0.93 
p = 0.10 
 HIV-negative 0.37 0 – 1.00 
Lactobacillus HIV-positive 1.06 0.36 – 1.71 
p = 0.49 
 HIV-negative 1.12 0 – 1.73 
Total bacteria HIV-positive 1.80 1.03 – 2.63 
p = 0.009 
 HIV-negative 2.27 1.70 – 2.75 
 
The calculated diversity index      values for the Lactobacillus-group (Table 3.3) showed 
that the HIV-negative group had a slightly higher mean diversity index (1.12) compared to 
the HIV-positive donors (1.06). This difference was also not statistically significant when a 
Mann-Whitney U test was performed (p = 0.49). However, when the total bacteria diversity 
for the two groups was determined (Table 3.3), the results showed that the HIV-positive 
group had a much lower    value (1.80) compared to that of the HIV-negative group (2.27). 
Comparison of these two groups showed that this difference was indeed statistically 
significant (p = 0.009), and that the diversity of the predominant microbiota within the HIV-
positive donor group was reduced. This result could potentially indicate that the overall 
gastrointestinal microbiome of HIV-positive patients has been affected by the presence of the 
virus.   
 
The box-and-whisker plot shown in Figure 3.9 was generated by taking the Shannon-Wiener 
diversity index values for all three groups and comparing them in terms of HIV status and 
gender.  
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Figure 3.9, shows that the overall diversity of total bacteria was higher in the HIV-negative 
donors, and mostly within the female donors with a median value of 2.30 (quartile ranges 
1.70 - 2.75) compared to a median of 2.21 (quartile ranges 1.91 – 2.40) seen in the HIV-
negative males. The diversity of the total bacterial population appeared to be reduced within 
the HIV-positive male donors recording a low median value of 1.55 (quartile ranges 1.19 – 
2.16). However, this particular result should be interpreted cautiously due to the fact that the 
number of male donors participating in this study was extremely small and no statistical 
correlation could be inferred.   
 
3.4.4 Sequence analysis  
DGGE was employed to determine the diversity of selected species in the faecal material 
from both donor groups. The aims of sequencing particular DGGE bands were to evaluate the 
specificity of the group-specific primers, and to determine whether bands co-migrating with 
the standards were the expected species. In addition, bands migrating to other positions, 
within the gel, would also be identified. Bands from both donor groups were excised, cloned 
and sequenced. Selected DGGE bands found in the same position, but located within 
Figure 3.9: Box-and-whisker plot showing the Shannon-Wiener diversity index (  ) from 
the DGGE profiles of 12 HIV-positive and 12 HIV-negative donors.  
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different lanes were also excised to confirm their identity as well as the separation capability 
of DGGE in this study.  
 
Bifidobacterium group: 
Figure 3.10 shows the bands, representing the Bifidobacterium population, which were 
excised and sequenced. Bands 1-7 were confirmed to be Bifidobacterium species thus 
validating the specificity of the genus-specific primers used in the first round of 
amplification. The presence or absence of these bands in all the donors was evaluated (Figure 
3.6 and Table 3.5). Three predominant Bifidobacterium species were identified namely, B. 
longum, B. pseudocatenulatum and B. adolescentis in both the HIV-positive and HIV-
negative donor groups (Table 3.4 and Table 3.5). These three Bifidobacterium species have 
previously been reported to be isolated from human faeces (Hopkins and Macfarlane, 2002). 
 
 
 
 
 
 
 
 
 
 
 
Sequencing of both bands 3 and 4 identified them as B. adolescentis. Satokari et al., (2001) 
showed that B. adolescentis E-981074
T
 (ATCC 15703
T
) can produce two individual 
fragments within a DGGE gel on account of it having several 16S rRNA copies (5 copies) 
with specific sequence differences between these copies. Band 5, at the same position in P5, 
was similarly identified as B. adolescentis. The strong presence of B. adolescentis seen in this 
study, as well as other previously published investigations, shows that this particular species 
Figure 3.10: Selected bifidobacterial DGGE bands excised for sequencing. Bands 1 – 8 were 
excised, cloned and sequenced using the M13F primer. Lane RM:  DGGE reference 
ladder [(a): B. longum and (b): B. adolescentis]. Composite figure generated using 
the FPQuest software.     
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is one of the most dominant and widely distributed Bifidobacterium species found within the 
intestinal tract of adults (Matsuki et al., 2004; Takada et al., 2004). B. longum, B. breve and 
B. bifidum represent the mucosa-adherent members of the Bifidobacterium genus, where 
despite being common faecal isolates, they are also found tightly associated with the human 
intestinal mucosa (Turroni et al., 2009). In this pilot study, B. longum appeared to be more 
predominant in the HIV-positive samples than in the HIV-negative donors (Table 3.5). 
However, DGGE is a qualitative technique and this observation should be followed up by a 
more quantitative approach.  
 
Table 3.4:  Sequence identities of cloned Bifidobacterium DGGE bands 
Donor 
ID 
Excised 
Band  
ID based on 16S rRNA gene sequence 
% Similarity 
of sequence 
Accession 
Number 
P5 5 Bifidobacterium adolescentis ATCC 15703 100 AP009256.1 
P9 6 Bifidobacterium longum subsp. infantis ATCC 15697 99 CP001095.1 
P10 7 Bifidobacterium pseudocatenulatum JCM 1200 100 D86187.1 
P11 3 Bifidobacterium adolescentis ATCC 15703 100 AP009256.1 
P11 4 Bifidobacterium adolescentis ATCC 15703 100 AP009256.1 
     
H9 1 Bifidobacterium longum NCC2705 99 AE014295.3 
H9 2 Bifidobacterium pseudocatenulatum JCM 1200 100 D86187.1 
H10 8 No identifiable sequence obtained - - 
 
A band found directly above the B. longum reference marker (band 8) was also sequenced 
(Figure 3.10). Sequencing of this fragment yielded either a mixed sequence result or an 
unreadable sequence, suggesting that this band was a heteroduplex complex formed during 
PCR (Qiu et al., 2001; Satokari et al., 2001).  
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Table 3.5:  Presence of selected Bifidobacterium DGGE bands in the two donor groups  
Donor ID B. longum B. pseudocatenulatum B. adolescentis Donor ID B. longum B. pseudocatenulatum B. adolescentis 
P1 + - + H1 - - + 
P2 + + + H2 + - + 
P3 + - + H3 - - + 
P4 - - + H4 + + + 
P5 + - + H5 - - + 
P6 - + - H6 + + + 
P7 + + + H7 + + - 
P8 + - + H8 - - + 
P9 + - + H9 + + + 
P10 + + - H10 + + + 
P11 + - + H11 + - + 
P12 + - + H12 - + - 
* [+]: Selected DGGE band is present  
* [-]: Selected DGGE band is absent   
* [P]: HIV-positive donors  
* [H]: HIV-negative donors   
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Lactobacillus group: 
Sequencing of DGGE bands excised from the Lactobacillus group (Figure 3.11) identified 
species that belonged mostly to the Lactobacillus, Streptococcus and Weisella genera (Table 
3.6). In addition, bands 8, 10, 16 and 17, were all found to be closely related to Eubacterium 
biforme, a common constituent of the human gastrointestinal tract. As previously mentioned 
(section 3.4.1.2.1), the selected primer set used in this study was designed to specifically 
amplify species belonging to the Lactobacillus group. However, Heilig et al., (2002) also 
reported the unintended amplification of E. biforme owing to the fact that the 3’ end of the 
Lab0667R primer is complementary to the 16S rRNA sequence of E. biforme and 
Eubacterium cylindroides. Analysis of the frequency of occurrence of the various bands in all 
the donors is complicated by the fact that the primers are not specific for the Lactobacillus 
genus, and bands migrating to the same position are not necessarily the same species (Table 
3.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Selected Lactobacillus group DGGE bands excised for sequencing. Bands 1 – 18 
were excised, cloned and sequenced using the M13F primer.  Lane RM:  DGGE 
reference ladder [(a): L. casei; (b): L. gasseri; (c): L. brevis; (d): L. reuteri and (e): 
L. fermentum]. Composite figure generated using the FPQuest software.     
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Identification of the dominant DGGE bands in both donor groups showed identities most 
similar to L. ruminis, L. reuteri, L. jensenii, L. rossiae and L. crispatus (Table 3.6). 
Furthermore, three of the bands sequenced were identified as Streptococcus thermophilus 
(Bands 2 and 12), a member of the Lactic Acid bacteria group found mainly in yogurt and 
other dairy products (Vodnar et al., 2010) and Weissella confusa (Band 5), a bacterial species 
commonly found in food products and to a lesser extent faecal material (Fusco et al., 2011). 
Both S. thermophilus and W. confusa are associated with beneficial properties such as, 
inducing the production of different cytokines (Aattouri and Lemonnier, 1997) and reducing 
the infectivity and persistence of pathogens such as Helicobacter pylori (Fusco et al., 2011) 
respectively. Only one of the cloned DGGE bands sequenced (Band 6) was identified as an 
uncultured bacterium clone originating from a human colon biopsy sample (Table 3.6). 
 
Table 3.6:  Sequence identities of cloned Lactobacillus group DGGE bands 
Donor 
ID 
Excised 
Band  
ID based on 16S rRNA gene sequence 
% Similarity 
of sequence 
Accession 
Number 
P3 3 Lactobacillus mucosae strain TB-H32 100 AB425938.1 
P3 4 Lactobacillus rossiae strain DSM 15814 99 AB370880.1 
P4 2 Streptococcus thermophilus ND03 99 CP002340.1 
P5 8 Eubacterium biforme strain EBA11-8 99 JF298897.1 
P5 9 Lactobacillus ruminis strain SL1090 100 HQ022863.1 
P6 7 Lactobacillus reuteri SD2112 98 CP002844.1 
P7 1 Lactobacillus johnsonii strain ATCC 33200 100 NR_025273.1 
P8 13 Lactobacillus sakei strain SM7 100 HM568887.1 
P8 14 Lactobacillus jensenii strain KC36b 100 AF243159.1 
P11 10 Eubacterium biforme strain EBA11-8 98 JF298897.1 
P11 11 Lactobacillus ruminis strain JCM 1152 99 AB289286.1 
P11 12 Streptococcus thermophilus ND03 99 CP002340.1 
     
H3 15 Lactobacillus crispatus strain K2-4-3 98 HQ716720.1 
H5 5 Weissella confusa partial 16S rRNA clone 3EV3 99 AM117131.1 
H5 6 ncultured bacterium clone KU74 from human 
colon biopsy 
98 AY916140.1 
H8 16 Eubacterium biforme strain EBA11-8 98 JF298897.1 
H11 17 Eubacterium biforme strain EBA11-8 98 JF298897.1 
H11 18 Lactobacillus ruminis strain SL1090 100 HQ022863.1 
 
The occurrence of bands at the same positions as those shown in Table 3.6 was evaluated in 
all donor samples (Figure 3.7), and the results are shown in Table 3.7. However, due to the 
lack of specificity of the primers, each of these bands would need to be sequenced to confirm 
their identity. An interesting finding was the identification of a characteristically food-
associated Lactobacillus species, namely Lactobacillus sakei (Table 3.6 and 3.7). Several 
studies have suggested that the presence of these food-related species in faecal material 
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demonstrates that certain members of the Lactobacillus population are transient in nature, 
acquired through food eaten by the host, and that only a few Lactobacillus species, such as L. 
ruminis, L. reuteri, L. gasseri and L. salivarius are considered truly endogenous (Reuter, 
2001; Walter et al., 2001; Tannock et al., 2000).   
 
A band representing Lactobacillus mucosae was isolated and sequenced from two of the 
HIV-positive donors (Table 3.6 and 3.7). Bands in the same position were detected in other 
donors from both groups, but these should be independently sequenced to confirm their 
identity. This particular Lactobacillus species is of interest since it has been reported to 
represent approximately 3% of the total lactic acid bacteria population within the colonic 
mucin, and has been more frequently isolated from gastrointestinal biopsies of healthy adult 
donors, where it has been shown to have a tight association with the i testinal epithelium 
(Kinoshita et al., 2006). However, the strong presence of L. mucosae in the faecal material of 
patients who have Short Bowel Syndrome (SBS) has been reported by Joly et al., (2010). 
SBS is a condition, characterised by diarrhoea and malabsorption of vitamins and nutrients 
that can develop in patients suffering from illnesses such as Crohn’s Disease, who have 
undergone a process known as gut re-sectioning. This particular procedure is known to 
severely modify the lumen of the intestinal tract, and Joly et al., (2010) showed that L. 
mucosae was detected only in the samples obtained from the SBS patients and not the healthy 
control group. It would be interesting to explore the specific occurrence of this bacterium in 
both the mucosa and faeces of HIV-positive patients as a future extension of this study. 
 
Overall, the sequencing of DGGE bands in conjunction with the cluster analysis (section 
3.4.2) and the calculated Shannon-Wiener diversity index (section 3.4.3), revealed that the 
diversity of the Lactobacillus population appeared to be fairly similar in both the HIV-
positive and HIV-negative donor groups. 
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Table 3.7:  Presence of selected Lactobacillus DGGE bands in the two donor groups  
Donor  
ID 
L. 
johnsonii 
S. 
thermophilus 
L. 
reuteri 
L. 
rossiae 
W. 
confusa 
L. 
mucosae 
E. 
biforme 
L. 
ruminis 
L. 
sakei 
L. 
jensenii 
L. 
crispatus 
P1 - - - - + - - - - + + 
P2 - - - - + + + + - - - 
P3 - - - + + + - - - - - 
P4 - + + - - - - - - - - 
P5 - - - - - - + + - - + 
P6 - - + - + - + - - + - 
P7 + - - - + - - - - - - 
P8 - - - + - - - - + + - 
P9 + - - - - - - - - + - 
P10 - - - - - - + - - - - 
P11 - + - - - - + + - - - 
P12 - - - - + - - + - - - 
H1 - - - - + - - - - - - 
H2 - - - - - - + - + + - 
H3 - - + - + - + - - - + 
H4 - - - - - - - - - + - 
H5 - - - - + - - - - - - 
H6 - - - - - - - - - - - 
H7 - - - - + - + - - - - 
H8 - - - - + - + - + - - 
H9 - - - - - - - - - - + 
H10 - - - - - - + - - - - 
H11 - - - - + - + + - - - 
H12 - - - - - - - - - - - 
* [+] Selected DGGE band is present; [-] Selected DGGE band is absent   
* [P]: HIV-positive donors; [H]: HIV-negative donors   
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Total bacteria: 
A selection of strong bands, representative of co-migrating bands, was made to get an 
indication of the major species present. A total of 25 different DGGE bands were excised and 
sequenced from the total bacteria gels (Figure 3.12). However, several of the HIV-negative 
and positive donors displayed a region comprised of several bands in close proximity to each 
other, with many of these bands being too close together to be accurately excised. 16S rRNA 
clonal libraries of this region in H2 and H6 were therefore made to identify the species 
present (CL1 and CL2 in Figure 3.12). A similar partial 16S rRNA clonal library was not 
created for any of the HIV-positive donors, but individual bands from these donors, falling 
within the same region, were amongst the 25 bands excised and sequenced (Figure 3.12). A 
total of 96 individual clones from the partial clonal libraries were randomly selected and 
sequenced (Figure 3.13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Selected total bacteria DGGE bands excised for sequencing. Bands 1 – 25 were 
excised, cloned and sequenced using the M13F primer. Lane RM: DGGE reference 
ladder [(a): B. fragilis; (b): L. casei; (c): L. gasseri; (d): L. brevis; (e): E. faecalis; 
(f): E. coli; (g): L. reuteri; (h): C. perfringens and (i): B. longum]. Composite figure 
generated using the FPQuest software. [(CL): Clone library].            
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A number of bands were identified as species belonging mostly to the Bacteroides/Prevotella 
genera, the Clostridium coccoides cluster and the Clostridium leptum group (Table 3.8), 
representing some of the most abundant bacterial groups found within the human intestinal 
tract. Bands 3, 7, 8, 16 and 20 were identified as Prevotella copri, Alistipes shahii, Prevotella 
stercorea, Flavonifractor plautii and Clostridium orbiscindens respectively (Table 3.8).  
 
Sequences derived from unidentified species of the Clostridium genus were also detected for 
a few of the fragments sequenced. Akkermansia mucinphila, (band 6) identified in HIV-
positive donor P4, is a common inhabitant of the human intestinal tract and plays an 
important role in the degradation of mucin (Derrien et al., 2008; Collado et al., 2007; Derrien 
et al., 2004). Bands 23 and 24 present in HIV-positive donor P11 were also excised, cloned 
and sequenced. However, after a number of sequencing attempts, no identifiable sequence 
information could be obtained for these bands (Table 3.8).   
 
Table 3.8:  Sequence identities of cloned total bacteria DGGE bands 
Donor 
ID 
Excised 
Band  
ID based on 16S rRNA gene sequence 
% Similarity 
of sequence 
Accession 
Number 
P1 4 Odoribacter splanchnicus DSM 20712 98 CP002544.1 
P1 5 Faecalibacterium prausnitzii strain ATCC 27768 98 NR_028961.1 
P2 25 Clostridium sp. YIT 12069 gene for 16S rRNA 93 AB491207.1 
P3 9 Clostridium sp. YIT 12069 gene for 16S rRNA 94 AB491207.1 
P3 10 Oscillibacter sp. G2 16S ribosomal RNA gene 96 HM626173.1 
P4 6 Akkermansia muciniphila strain ATCC BAA-835 98 CP001071.1 
P4 7 Alistipes shahii strain EBA11-1 98 JF298871.1 
P4 8 Prevotella stercorea  strain CB35 100 AB244774.1 
P5 21 Ruminococcus sp. ID1  98 AY960569.1 
P5 22 Butyrivibrio crossotus strain DSM2876 100 FR733670.1 
P7 1 Parasutterella excrementihominis strain DSM 21040  97 AB370250.1 
P7 2 Ruminococcus bromii strain ATCC 27255 96 NR_025930.1 
P11 23 No identifiable sequence obtained  - - 
P11 24 No identifiable sequence obtained  - - 
P12 3 Prevotella copri strain CB7 96 AB064923.2 
     
H2 11 Clostridium clostridioforme strain 136069/2010 98 HM008264.1 
H3 15 Uncultured bacterium clone VDRD42cont3 98 JN021854.1 
H3 16 Flavonifractor plautii strain aK2 96 HQ455040.1 
H6 12 Parabacteroides distasonis ATCC 8503  98 CP000140.1 
H6 13 Bacteroides vulgatus ATCC 8482 98 CP000139.1 
H7 17 Clostridium sp. AbxANB1 98 JF813180.1 
H7 18 Succinivibrio dextrinosolvens strain 0554 98 NR_026476.1 
H8 19 Clostridium sp. YIT 12069 gene for 16S rRNA 93 AB491207.1 
H9 14 Eubacterium rectale ATCC 33656 97 CP001107.1 
H11 20 Clostridium orbiscindens strain AIP028.07 97 EU541437.1 
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Upon further examination of the sequencing data (Table 3.8), it was evident that bands 2 and 
5; 7 and 16; and 1 and 25, all ran at the same position in the gel, but had different sequence 
identities. As previously mentioned, this is a frequent problem encountered with the use of 
PCR-DGGE, particularly when using universal primers; PCR fragments aligning at the same 
positions do not necessarily prove they are identical or derived from the same species. 
Depending on the location of sequence differences, it is possible for 16S rRNA gene 
fragments arising from different strains to migrate to the same position on the gel (Vallaeys et 
al., 1997). In order to do an in-depth analysis of the species present, additional DGGE bands 
would have to be excised and sequenced to confirm their identity.     
 
The most commonly identified species from the clonal libraries of the CL1 and CL2 regions 
from HIV-negative donors H2 and H6 are shown in Figure 3.13. The majority of the clones 
sequenced showed a high level of DNA similarity (96-100%) to Bacteroides uniformis, 
Faecalibacterium prausnitzii, Roseburia intestinalis, Clostridium orbiscindens and 
Eubacterium rectale, with Bacteroides spp. making up 43% of the total isolates. The 
following species were found in both the partial clonal libraries and the individual HIV-
positive bands: F. prausnitzii, Alistipes spp. and Clostridium spp. However, the predominant 
occurrence of Bacteroides spp. found in the HIV-negative donors was not evident in the HIV-
positive donors. The following species were not found in the HIV-negative clonal libraries 
but were seen as individual DGGE bands in the HIV-positive patients in the corresponding 
region: Ruminococcus spp., Odoribacter splanchnicus, Akkermansia muciniphila and 
Butyrivibrio crossotus. 
 
Many of the species identified in the partial clonal libraries analysed in this study using PCR-
DGGE and sequencing were also reported by Qin et al., (2010) who used a metagenomic 
approach. This latter technique would also be useful for future, more extensive studies of 
HIV-positive and HIV-negative donors. If a clonal library approach is used, full libraries 
from more of the HIV-negative, as well as the HIV-positive donors should be constructed to 
obtain a more complete data set. 
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3.5  CONCLUSION  
Despite the fact that knowledge regarding the gastrointestinal tract microbiota is continually 
increasing and previously unidentified species are being detected, very little is known about 
the endogenous microbiota within the gastrointestinal tract of HIV-positive patients. The 
main objective of the work presented in this chapter was to determine the diversity of the 
total endogenous microbiota and to evaluate whether there were any noticeable differences 
between the HIV-positive and HIV-negative donor groups with respect to the diversity of 
Lactobacillus and Bifidobacterium spp.   
The results from the DGGE analyses clearly suggested that the HIV-positive donors had a 
significantly lower diversity in the total bacteria present, but there were no significant 
differences with respect to the diversity of the Bifidobacterium and Lactobacillus groups. 
This was an interesting finding since it showed that these latter groups were not disrupted in 
any major way in HIV-positive patients, and that the prescribing of these bacteria (commonly 
found in commercial probiotic preparations) as probiotics would not necessarily aid HIV 
recovery. The findings also pointed the way toward the investigation of other protective gut 
Figure 3.13: Predominant species identified in the partial clonal libraries from the CL1 and 
CL2 regions from donors H2 and H6. Percentage occurrence within 96 clones 
sequenced is shown.           
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species (e.g. Bacteroides). This was done later in this study using qPCR since PCR-DGGE is 
not a quantitative technique (Chapter 5). 
As a scientific approach, the use of DGGE, together with cluster analysis and the Shannon-
Wiener diversity index provided useful data in analysing the relationships and differences 
that exist within complex microbial communities. The DGGE profiles generated showed that 
although some common bands were shared between the two donor groups, a unique microbial 
profile in terms of composition and diversity was displayed for each individual.  
However, the usefulness of the PCR-DGGE technique can be limited by several technical 
factors (see section 3.2), and the results obtained may not necessarily give an accurate 
representation of the diversity of a particular species present within the gastrointestinal tract. 
In this study, several of the main sources of technical bias were eliminated. Careful 
optimisation of the cell lysis procedure was done through the introduction of a bead-beating 
step, and a commercial DNA purification kit was used for extraction of the genomic DNA 
from faecal samples, which has been independently evaluated and shown to be 94% efficient 
in extracting DNA from all faecal bacteria (Yoshikawa et al., 2011). The PCR conditions 
used were also optimised.  
The development of group-specific primers for use in DGGE has led to easier detection and 
identification of bacterial species present in much smaller numbers within the intestinal tract. 
However, as was shown in this and several other studies, published Lactobacillus-specific 
primers are not entirely genus-specific, and primer Lab0067R has been found to amplify up 
not only Lactobacillus species, but species belonging to other phylogenetically related 
genera. The presence of multiple copies of the 16S rRNA gene can also affect the DGGE 
result obtained for a specific population, as was the case in this study for B. adolescentis, 
which produced more than one DGGE band. These sources of error have been considered 
when interpreting the data in the current pilot study. It is clear that alternative approaches 
should be used in future studies to test the validity of the results, and take this research 
forward.  
One such approach would be to use a gene target other than the 16S rRNA gene. Requena et 
al., (2002) and Rantsiou et al., (2004) both showed that alternative gene targets, such as the 
transaldolase gene and the rpoB gene could be successfully used in the PCR-DGGE 
identification of both Bifidobacterium and Lactobacillus species respectively. Alternatively, 
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the use of RNA as opposed to DNA targets, has also been suggested. This has the added 
advantage of increasing the sensitivity and specificity of the reaction, while also providing a 
more accurate representation of the targeted bacterial community (Matsuda et al., 2009).   
Another approach of achieving a more accurate result would be to use a more quantitative 
technique, such as FISH, qPCR, high-throughput sequencing or metagenomics. Over the past 
several years, the use of metagenomics has grown and has been applied to the study of 
microbial populations in different ecosystems, such as the gastrointestinal tract. This has 
resulted in the characterisation and identification of new previously unidentified species. It is 
also becoming an affordable research option, where it was formerly too expensive (Caporaso 
et al., 2011). In the context of the current study reported here, these methods would serve as 
the next step in acquiring a more robust profile of the intestinal microbiota of HIV-positive 
and HIV-negative donors.  
The strong association of specific bacterial species with the intestinal epithelial lining 
suggests a significant interaction between the host and bacteria. As an extension of this 
current research, future studies could compare the composition of bacterial species found 
attached to the lining of the intestinal tract of HIV-positive patients, as a means of 
determining the actual state of the mucosal lining. To conduct such a study, biopsy samples 
would be required. However, the challenges faced in following this course of invasive action 
for this type of project are significant as was previously discussed in Chapter 2.  
The administration of HAART to HIV-positive patients results in significant reductions in the 
viral load, with a simultaneous increase in the individual’s CD4
+
 T cell count. However, a 
question that needs to be addressed is whether the initiation of HAART itself exerts any 
effect on the gut microbiota. The condition of the gastrointestinal microbiota prior to the 
initiation of HAART has been described in Chapter 3. This provides a basis on which the 
diversity and dynamics of the Bifidobacterium and Lactobacillus populations, both important 
probiotic groups, within HIV-positive donors receiving HAART could be determined. This 
qualitative longitudinal investigation monitored the diversity of these two bacterial groups in 
eight HIV-positive donors over a 6-month period using PCR-DGGE analysis. This study is 
described in Chapter 4.   
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CHAPTER FOUR 
PCR-DGGE analysis of Bifidobacterium and Lactobacillus species in South African HIV-
positive donors prior to and during HAART 
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4.1  SUMMARY 
Recent virological investigations have shown that HIV replication and CD4
+
 T cell depletion 
continues to take place within the GALT of HIV-positive patients during HAART. These 
observations suggest that the gastrointestinal tract might remain in a compromised state. It is 
not known whether the endogenous microbiota are disrupted during HAART, and whether 
Bifidobacterium and Lactobacillus species are still present to provide a protective function to 
the host. Therefore, the diversity of the Bifidobacterium and Lactobacillus populations present 
in the faecal material of eight South African HIV-positive donors and one HIV-negative donor 
was characterised, using PCR-DGGE during the first 6 months of HAART. Analysis of the 
PCR-DGGE results revealed that the Bifidobacterium population remained fairly stable within 
individual donors over time with no significant inter-donor variation throughout the 
longitudinal study. There was a strong predominance of B. adolescentis and B. longum 
throughout the course of the study. The Lactobacillus population showed greater variation of 
species within individual donors, as well as between donors, but this was not significantly 
linked to HAART. One of the recruited HIV-positive donors (P5) received multiple antibiotics 
during this study, resulting in a marked reduction in the diversity of the Bifidobacterium and 
Lactobacillus groups present. The fact that no significant changes were observed in these 
bacterial probiotic groups over the 6 month treatment period investigated indicates that neither 
the presence of HIV nor the use of HAART adversely affected their diversity.  
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4.2  INTRODUCTION 
The efficacy of HAART is clinically determined by monitoring two important factors, namely, 
suppression of viral load, and an increase in CD4
+
 T cells in the peripheral blood (Wood et al., 
2005). Even though the gastrointestinal tract is one of the earliest sites of HIV replication, 
knowledge regarding viral suppression, restoration of the mucosal immune system and the 
overall microbial conditions found within the intestinal tract during HAART administration is 
limited.  
 
A longitudinal study conducted by Guadalupe et al., (2003) attempted to determine and 
evaluate the dynamics of viral suppression, CD4
+
 T cell restoration, and regulation of gene 
expression in both blood and biopsy samples obtained from HIV-positive patients who had 
initiated HAART during either a primary (4 weeks after exposure) or chronic infection (8 
months to 1 year after exposure). The results of this particular study provided evidence of 
ongoing viral replication, accompanied by slow and incomplete restoration of CD4
+
 T cells 
within the GALT of HIV-positive patients, possibly contributing to a continual loss of CD4
+
 T 
cells from the mucosal tissue. Immunologic analysis revealed that the majority of repopulating 
CD4
+
 T cells, detected within the gastrointestinal tract, all appeared to express HIV co-
receptors CCR5 and CXCR4, which ultimately could result in them again being targets for 
infection by HIV.  Furthermore, after one year of HAART, restoration of CD4
+
 T cells within 
the GALT remained slow, while eleva ed CD8
+
 T cell levels were recorded suggesting that T-
cell homeostasis had not yet been normalised. Guadalupe et al., (2003) concluded that, even 
after 24 months of HAART, only a minimal CD4
+
 T cell restoration had occurred, and that 
poor CD4
+
 T cell restoration in patients was associated with an increased expression of genes 
responsible for inflammation, cell injury and apoptosis.  
 
Consequently, in light of the above research, the continuous replication of HIV together with 
the delayed restoration of CD4
+
 T cells within the GALT results in conflicting reports between 
conditions in the gastrointestinal tract and the peripheral blood. It has thus been proposed that, 
for treatment purposes, as well as for monitoring the efficiency of HAART, both blood and 
conditions within the gastrointestinal tract need to be monitored, in order to achieve a more 
accurate overview of disease progression and mucosal immune restoration. It was also 
suggested by Guadalupe et al., (2003) that access of HAART to the GALT may not be as 
efficient as in the blood or other lymphoid tissue, which could also be contributing towards the 
incomplete suppression of viral replication during HAART.  
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Extensive temporal based studies have been conducted to determine the effect of external 
factors on the endogenous microbiota of the gut, such as treatment with broad spectrum 
antibiotics (Dethlefsen et al., 2008; De La Cochetière et al., 2005), intestinal disorders (Mättö 
et al., 2005), and nutritional and dietary influences (Spor et al., 2011). Stability of the 
gastrointestinal microbiota has been examined over several weeks, months or even a year by 
means of culture-based techniques (Finegold et al., 1983), PCR-DGGE (Vanhoutte et al., 
2004; Zoetendal et al., 2001; Zoetendal et al., 1998) or FISH (Franks et al., 1998). Temporal 
based studies that have been previously conducted have shown that both the faecal 
Bifidobacterium and Bacteroides populations are relatively stable (Maukonen et al., 2008; 
Vanhoutte et al., 2004), while the Lactobacillus community tends to be more unstable with 
substantial variations (Maukonen et al., 2008; Vanhoutte et al., 2004).  
 
Current research studies strongly point towards a significant delay in the improvement of 
conditions within the gastrointestinal tract, even when HAART has been initiated. This 
particular outcome tends to suggest that the endogenous intestinal microbiota may 
continuously be subjected to disruption, which possibly negatively affects the beneficial 
bacterial groups, resulting in them no longer being able to provide a beneficial function to the 
host.  
 
In Chapter 3 of this study, it was established that, in spite of the chronic and advanced nature 
of the infections in the HIV-positive patients, there was no significant difference in the 
diversity of their Bifidobacterium and Lactobacillus populations as compared to the HIV-
negative control donors prior to the initiation of HAART. There was, however, a statistically 
significant lower diversity of the total bacteria in the HIV-positive donors. The research 
described in this chapter aimed at establishing whether the existing Bifidobacterium and 
Lactobacillus populations in the HIV-positive patients were affected in any way during six 
months of HAART administration. These two groups were targeted (rather than the general 
total bacteria) because of their well-established protective and probiotic potential. It was 
decided that the nature of the observed changes in the total bacterial population would best be 
addressed using qPCR (Chapter 5) in order to specifically investigate the numbers of a larger 
range of specific bacterial groups in the gut microbiota of HIV-positive patients. 
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4.3  MATERIALS AND METHODS 
Faecal samples were provided by 8 HIV-positive donors at specific time points, for the 
duration of the 6 month longitudinal study, resulting in a total of 40 samples being collected. 
Sampling time points for donors (donors P2, P3, P4, P5, P7, P8, P10 and P11) were: prior to 
HAART (T0), and then 2 weeks (T1), 6 weeks (T2), 3 months (T3) and 6 months (T4) after 
HAART initiation. Donor P 11, however, could not be sampled at T3 due to non-attendance at 
the HIV clinic. In some instances, an additional 12 month (T5) faecal sample was provided by 
four of the participating longitudinal donors (P2, P5, P8 and P10). In addition, five faecal 
samples were collected at the same time points from one HIV-negative donor (donor H3) over 
the 6 month longitudinal study. Total bacterial DNA was extracted from all faecal samples 
using the ZR Faecal DNA Kit
TM 
(ZYMO Research), and all materials and methods (PCR-
DGGE, statistical and sequence analyses) employed were identical to those described in 
Chapter 3.   
 
4.4  RESULTS AND DISCUSSION 
4.4.1 Longitudinal DGGE analysis of Bifidobacterium species   
The 6 month longitudinal DGGE profiles of the Bifidobacterium population from 8 HIV-
positive donors (Figure 4.1A – H) and one HIV-negative donor (H3) (Figure 4.1I) were 
included in this longitudinal study, to establish the temporal stability of the Bifidobacterium 
and Lactobacillus populations during HAART.  
 
The Bifidobacterium population detected using primers Bif164F and Bif662R (Chapter 3), 
appeared relatively stable throughout the longitudinal study, indicative of the presence of a 
core, host specific Bifidobacterium community in each of the 8 HIV-positive donors (Figure 
4.1A - H). In most cases (7 out of 8 donors), 2 to 3 dominant DGGE bands were detected and 
identified as B. longum, B. adolescentis and B. pseudocatenulatum (Table 4.1). HIV-positive 
donors P3 (Figure 4.1B), P7 (Figure 4.1E), P8 (Figure 4.1F) and P11 (Figure 4.1H) all 
showed a strong predominance of both B. adolescentis and B. longum throughout the 6 month 
study (Table 4.2). HIV-positive donor P11 missed the 3 month sampling appointment 
(Chapter 2), which resulted in no faecal sample, CD4
+
 T cell count or clinical data being 
collected at this point. HIV-positive donor P10 (Figure 4.1G) was unique when compared to 
the other donors, in that a strong and stable B. pseudocatenulatum population was observed, 
with an absence of B. adolescentis. B. longum and B. adolescentis are both major species  
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Figure 4.1: Longitudinal DGGE profile of 
Bifidobacterium spp. Lane R: DGGE reference ladder 
[(a): B. longum and (b): B. adolescentis]; Lane 2: T0; 
Lane 3: T1; Lane 4: T2; Lane 5: T3; Lane 6: T4 and Lane 
7: T5. Donors (A) P2; (B) P3; (C) P4; (D) P5; (E) P7; (F) 
P8; (G) P10; (H) P11; (I) H3. Circled bands were excised 
for sequencing.  
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associated with the mucosal surfaces of the intestinal tract (Turroni et al., 2009; Kleessen et 
al., 2003). The presence of these two species within the faecal material could be as a result of 
the disruption caused to the gastrointestinal mucosa due to continued HIV replication. 
Bifidobacterium species may be detected more frequently in HIV-positive donors if they are 
unable to adhere to the disrupted gastrointestinal tract, but continue to multiply in the gut 
lumen and are shed in the faeces. This hypothesis would require testing by investigating 
intestinal epithelial biopsy samples from HIV-positive patients for the presence or absence of 
Bifidobacterium species.   
 
Table 4.1:  Sequence identities of cloned Bifidobacterium DGGE bands from longitudinal study 
Donor 
ID 
Excised 
Band  
ID based on 16S rRNA gene sequence 
% Similarity 
of sequence 
Accession 
Number 
P2 2.1 Bifidobacterium longum NCC2705 99 AE014295.3 
P2 2.2 Bifidobacterium adolescentis ATCC 15703 100 AP009256.1 
P3 3.1 Bifidobacterium longum NCC2705 99 AE014295.3 
P3 3.2 Bifidobacterium pseudocatenulatum JCM 1200 100 D86187.1 
P4 4.1 Bifidobacterium longum NCC2705 99 AE014295.3 
P4 4.2 Bifidobacterium adolescentis ATCC 15703 100 AP009256.1 
P4 4.3 Bifidobacterium adolescentis ATCC 15703 100 AP009256.1 
P5 5.1 Bifidobacterium longum NCC2705 99 AE014295.3 
P5 5.2 Bifidobacterium adolescentis ATCC 15703 100 AP009256.1 
P7 7.1 Bifidobacterium longum NCC2705 99 AE014295.3 
P7 7.2 Bifidobacterium adolescentis ATCC 15703 100 AP009256.1 
P7 7.3 Bifidobacterium pseudocatenulatum JCM 1200 100 D86187.1 
P8 8.1 Bifidobacterium longum NCC2705 99 AE014295.3 
P8 8.2 Bifidobacterium longum subsp. infantis ATCC 
15697 
99 CP001095.1 
P8 8.3 Bifidobacterium adolescentis ATCC 15703 100 AP009256.1 
P8 8.4 Bifidobacterium adolescentis ATCC 15703 100 AP009256.1 
P10 10.1 Bifidobacterium longum NCC2705 99 AE014295.3 
P10 10.2 Bifidobacterium pseudocatenulatum JCM 1200 100 D86187.1 
P11 11.1 Bifidobacterium longum NCC2705 99 AE014295.3 
P11 11.2 Bifidobacterium adolescentis ATCC 15703 100 AP009256.1 
P11 11.3 Bifidobacterium adolescentis ATCC 15703 100 AP009256.1 
     
H3 B3.1 Bifidobacterium adolescentis ATCC 15703 100 AP009256.1 
H3 B3.2 Bifidobacterium longum subsp. infantis ATCC 
15697 
99 CP001095.1 
 
HIV-positive donor P2 (Figure 4.1A) showed a stable Bifidobacterium population, with no 
major changes being observed, even though this donor had fallen pregnant between sampling 
time points T4 and T5. The substantial decrease in the CD4
+
 T cell count shown in Figure 
4.2A was thought to be as a result of the pregnancy and not an increase in HIV replication 
within the blood (discussed in Chapter 2).  
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Table 4.2:  Presence of selected Bifidobacterium DGGE bands in donors P2-P11 and H3 throughout the 6 month longitudinal study   
Donor 
ID 
Time 
Point 
B. 
longum 
B. 
pseudocatenulatum 
B. 
adolescentis 
Donor 
ID 
Time 
Point 
B. 
longum 
B. 
pseudocatenulatum 
B. 
adolescentis 
P2 T0 + + + P7 T0 + + + 
 T1 + + +  T1 + + + 
 T2 + + +  T2 + + + 
 T3 - + +  T3 + + + 
 T4 + + +  T4 + + + 
 T5 + + + P8 T0 + - + 
P3 T0 + - +  T1 + + + 
 T1 + + +  T2 + + + 
 T2 + + +  T3 + + + 
 T3 + + +  T4 + + + 
 T4 + - -  T5 + + + 
P4 T0 + + + P10 T0 + + - 
 T1 + + +  T1 + + - 
 T2 + - +  T2 + + - 
 T3 + - +  T3 + + - 
 T4 + - +  T4 + + - 
P5 T0 + - +  T5 - + - 
 T1 + - + P11 T0 + - + 
 T2 + - +  T1 + - + 
 T3 + - +  T2 + - + 
 T4 + - -  T4 + - + 
 T5 + - - H3 T0 - - + 
* [+]: Selected DGGE band is present; [-]: Selected DGGE band is absent   
* [P]: HIV-positive donors; [H]: HIV-negative donors   
 
 T1 + - + 
 T2 - - + 
 T3 + - + 
  T4 + - + 
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The longitudinal DGGE profile obtained for HIV-positive donor P5 (Figure 4.1D) showed a 
reduction in B. adolescentis and a subsequent increase in the abundance of B. longum, 
following HAART initiation and treatment with multiple antibiotics. The multiple antibiotics 
administered to donor P5, consisted of ciprofloxacin (250 mg) at sampling time point T1, 
cefixime (400 mg) and doxycycline (100 mg) at T2 and T3 and cefixime (400 mg), 
doxycycline (100 mg) and metronidazole (400 mg) at T4 (discussed in Chapter 2). Recent 
investigations have shown that, the Bifidobacterium population is generally susceptible to a 
number of antibiotics including cephalosporins, penicillins, macrolides (Mättö et al., 2008), 
and doxycycline (Saarela et al., 2007). However, Moubareck et al., (2005) reported an 
increase in the resistance of B. longum to cefoxitin (a second generation cephalosporin), 
tetracycline and metronidazole. This particular trend of increasing resistance shown in B. 
longum species should be noted, especially in HIV-positive patients where treatment with 
multiple antibiotics is sometimes required.   
 
In a study conducted by Dethlefsen and Relman, (2010), various different measures of 
biological diversity, acquired during a longitudinal investigation, were plotted and compared to 
each other for individual donors. In order to assess whether HAART had any impact on 
microbial diversity over time, the Shannon-Wiener diversity index was determined for each of 
the sampling time points [blue lines], and was plotted together with the CD4
+
 T cell counts [red 
squares] provided by the clinic (Chapter 2) for each of the donors (Figure 4.2A-H). When 
assessing the Shannon-Wiener diversity indices for all eight HIV-positive donors, no distinctive 
common trend was observed that could be attributed to HAART administration. For the most 
part, donors showed some variations in the diversity of the Bifidobacterium group over time, 
but these were specific for each donor and were not statistically significant. HIV-positive donor 
P5 (H’ = 0.72 at T0 relative to H’ = 0 at T5) received multiple antibiotics which eliminated B. 
adolescentis (Figure 4.2D). It is interesting to note that donor P10 (Figure 4.2.G) (H’ = 0.61 at 
T0 relative to H’ = 0 at T5) had less B. adolescentis and B. longum after HAART, with B. 
pseudocatenulatum becoming the dominant species. The exact reasons for this are not known. 
Throughout the 6 month study period, a gradual increase in CD4
+
 T cell numbers, relative to the 
individual starting values, was seen following the initiation of HAART in all of the HIV-
positive donors (Figure 4.2A–H). The only variation in this trend was seen in donor P2, who 
became pregnant at T3, resulting in a decrease in the CD4
+
 T cell numbers. Even so, the CD4
+
 T 
cell level was still higher than before HAART. The increase in CD4
+
 T cell numbers, along 
with a significant reduction in the HIV viral load within the blood, indicates that the ARV  
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Figure 4.2: Shannon-Wiener diversity index of 
Bifidobacterium spp. Donors (A) P2; (B) P3; (C) P4; (D) 
P5; (E) P7; (F) P8; (G) P10; (H) P11; (I) H3. [(Blue line): 
Shannon-Wiener diversity index and (Red blocks): CD4
+
 
T cell count]. 
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regime prescribed for each donor is effective. Nevertheless, it is important to remember that 
this particular result is an indication of conditions within the blood only, and not the 
gastrointestinal tract (Guadalupe et al., 2006).  
 
The Bifidobacterium DGGE profile obtained for the single longitudinal HIV-negative donor H3 
was generally stable, with no significant changes in the diversity occurring during the 6 month 
period (Figure 4.1I). B. adolescentis was detected throughout the 6 months, whilst B. longum 
was only detected at sampling points T1, T3 and T4 (Table 4.1 and 4.2). The absence of B. 
longum could be due to the fact that B. longum is adhering to the healthy, intact gastric mucosa 
of donor H3. He et al., (2001), reported that the adhesion of B. longum within the 
gastrointestinal tract is strain-specific, in that not all B. longum species will adhere strongly to 
the mucosa, and adhesion is also influenced by factors such as substrate availability (mucins or 
fructans). Kleessen et al., (2003) suggested that changes in the mucin composition of the 
gastrointestinal tract, caused by intestinal diseases, could prevent Bifidobacterium species from 
adhering, thereby affecting the composition and diversity of this group. Therefore, in light of 
the fact that the replication of HIV within the gastrointestinal tract creates a compromised 
mucosa, it may be possible that this disruption could be affecting the adherence of 
Bifidobacterium species to the gastrointestinal tract. This would result in species transiting 
through the intestinal tract, and higher numbers being detected within the faecal material of 
HIV-positive donors. However, this conclusion should be viewed with caution due to the fact 
that only one healthy control was available for comparison in this study, and additional healthy, 
HIV-negative controls would be needed to validate this conclusion, together with analysis of 
gut epithelial biopsies.     
 
4.4.2 Longitudinal DGGE analysis of Lactobacillus species     
Figure 4.3(A-H) shows the longitudinal DGGE profiles of the Lactobacillus population during 
6 months of HAART, along with the Shannon-Wiener Diversity Index and CD4
+
 T cell counts 
plots (Figure 4.4A-H). Longitudinal PCR-DGGE analysis of the Lactobacillus population 
revealed a strong host specificity in all 8 HIV-positive donors. All of the eight investigated 
HIV-positive donors exhibited their own distinctive Lactobacillus population with one or two 
species remaining dominant throughout the 6 months (Figure 4.3A-H and Table 4.3). Most of 
these patients showed variation in the Lactobacillus population over time, with P2, P4 and P7 
maintaining a more stable profile (see Figure 4.6A, 4.6C and 4.6E). The temporal changes seen  
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Figure 4.3: Longitudinal DGGE profile of 
Lactobacillus spp.  Lane R: DGGE reference ladder [(a): 
L. casei; (b): L. gasseri; (c): L. brevis; (d): L. reuteri and 
(e): L. fermentum]; Lane 2: T0; Lane 3: T1; Lane 4: T2; 
Lane 5: T3; Lane 6: T4 and Lane 7: T5. Donors (A) P2; 
(B) P3; (C) P4; (D) P5; (E) P7; (F) P8; (G) P10; (H) P11; 
(I) H3. Circled bands were excised for sequencing.   
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for the Lactobacillus group is consistent with the findings from a previous longitudinal PCR-
DGGE study conducted by Vanhoutte et al., (2004) on four healthy volunteers. Employing 
primers Univ341F and Lab0677R, as discussed in Chapter 3, resulted in the identification of 
not only Lactobacillus species, but also S. thermophilus and E. biforme (Table 4.3). Several 
food-associated Lactobacillus species were detected in some donors, and included species such 
as L. sakei, L. delbrueckii subsp. bulgaricus, L. fermentum, and L. brevis.  
 
A relatively diverse but stable DGGE profile was obtained for the Lactobacillus group present 
in HIV-positive donor P2 (Figure 4.3A). Interestingly, donor P2 was the only donor that 
exhibited a strong L. mucosae presence throughout the longitudinal study, including the 12 
month sampling time point, although it was transiently seen in P3 (Table 4.4A). As previously 
mentioned in Chapter 3, L. mucosae has been characterised as a mucosa-associated species, 
frequently identified in biopsy samples obtained from healthy adult volunteers (Joly et al., 
2010). The presence of this bacterium in the faecal samples from two of the HIV-positive 
donors may possibly indicate that conditions within the gastrointestinal tract are in a disrupted 
state. Carroll et al., (2010), conducted a study in which they investigated the luminal and 
mucosal-associated intestinal microbiota in patients with diarrhoea-predominant irritable bowel 
syndrome (D-IBS). Their findings demonstrated a significant increase in the levels of 
Lactobacillus species in faecal samples from D-IBS patients compared to the healthy controls. 
However, in the context of the current study reported in this thesis, the conclusion stated above 
is based on the results for a limited number of HIV-positive donors. Validation of this 
hypothesis would require examination of faecal and biopsy samples from more HIV-positive 
donors. Donor P2 became pregnant during the study, but no significant diversity changes 
between T4 and T5 were observed, indicating that pregnancy did not influence the 
Lactobacillus composition of this patient. 
 
Another interesting result was recorded for the longitudinal DGGE profile of HIV-positive 
donor P3 (Figure 4.3B). This particular donor showed a completely different Lactobacillus 
profile after the initiation of HAART, which seemed to remain stable throughout the remainder 
of the sampling period, accompanied by a fairly consistent increase in CD4
+
 T cells. 
 
The effect of multiple antibiotics, namely, ciprofloxacin, cefixme, doxycycline and 
metronidazole, on the diversity and composition of the Lactobacillus population was evident in 
HIV-positive donor P5 (Figure 4.3D). Common gastrointestinal species L. ruminis and E. 
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biforme were both completely reduced by T2 while, at sampling time points T4 and T5, a 
strong L. reuteri presence was identified and maintained. A study conducted by Temmerman et 
al., (2003b) reported that certain probiotic Lactobacillus strains showed resistance to 
tetracycline (29.5%), chloramphenicol (8.5%) and erythromycin (12%). Interestingly, HIV-
positive donor P5 received 100 mg of doxycycline, a member of the tetracycline antibiotic 
group, from T2 up until T4. Temmerman et al., (2003b) evaluated six L. reuteri strains for their 
susceptibility to tetracycline and all six strains were found to be highly resistant. This particular 
finding might explain the emergence of L. reuteri as the dominant species in P5.    
 
Table 4.3:  Sequence identities of cloned Lactobacillus group DGGE bands from longitudinal study 
Donor 
ID 
Excised 
Band  
ID based on 16S rRNA gene sequence 
% Similarity 
of sequence 
Accession 
Number 
P2 2.1 Lactobacillus ruminis strain SL1090  100 HQ022863.1 
P2 2.2 Lactobacillus mucosae strain CCUG 
43179 
99 NR_024994.1 
P2 2.3 Eubacterium biforme strain EBA11-8 98 JF298897.1 
P3 3.1 Lactobacillus mucosae strain CCUG 
43179 
99 NR_024994.1 
P3 3.2 Lactobacillus rossiae strain DSM 15814 99 AB370880.1 
P3 3.3 Lactobacillus sp. KLDS 1.0716 100 EU600921.1 
P3 3.4 Streptococcus thermophilus ND03 99 CP002340.1 
P4 4.1 Lactobacillus reuteri JCM 1112 96 AP007281.1 
P4 4.2 Streptococcus thermophilus ND03 99 CP002340.1 
P4 4.3 Eubacterium biforme strain EBA11-8 98 JF298897.1 
P5 5.1 Lactobacillus ruminis strain SL1090 100 HQ022863.1 
P5 5.2 Eubacterium biforme strain EBA11-8 99 JF298897.1 
P5 5.3 Lactobacillus reuteri JCM 1112 97 AP007281.1 
P7 7.1 Lactobacillus johnsonii strain ATCC 
33200 
100 NR_025273.1 
P8 8.1 Lactobacillus jensenii strain KC36b 100 AF243159.1 
P8 8.2 Lactobacillus ruminis ATCC 27782 99 CP003032.1 
P8 8.3 Lactobacillus fermentum strain 4353A2 98 HM173677.1 
P8 8.4 Lactobacillus brevis strain k-0004 98 JF520563.1 
P8 8.5 Lactobacillus gallinarum strain ATCC 
33199 
99 NR_042111.1 
P8 8.6 Lactobacillus sakei strain SM7 100 HM568887.1 
P10 10.1 Eubacterium biforme strain EBA11-8 98 JF298897.1 
P10 10.2 Lactobacillus paracasei strain T2-2 100 AB368899.1 
P10 10.3 Lactobacillus delbrueckii subsp. 
bulgaricus ND02 
100 CP002341.1 
P11 11.1 Eubacterium biforme strain EBA11-8 98 JF298897.1 
P11 11.2 Bacterium La3 16S ribosomal RNA gene 99 AY766419.1 
P11 11.3 Lactobacillus ruminis strain SL1090 99 HQ022863.1 
P11 11.4 Lactobacillus paracasei strain p-027 100 JF520605.1 
     
H3 L3.1 Lactobacillus crispatus strain K2-4-3 98 HQ716720.1 
H3 L3.2 Eubacterium biforme strain EBA11-8 98 JF298897.1 
H3 L3.3 Lactobacillus reuteri SD2112 98 CP002844.1 
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Table 4.4A:  Presence of selected Lactobacillus DGGE bands in donors P2-P5 throughout the 6 month longitudinal study   
Donor  
ID 
Time 
Point 
L. 
john. 
S. 
ther. 
L. 
reut. 
L. 
ros. 
L. 
par. 
L. 
muc. 
E. 
bif. 
L. 
rum. 
L. 
sak. 
L. 
jen. 
L. 
cris. 
L. 
ferm. 
L. 
delb. 
L. 
brev. 
L. 
gall.  
P2 T0 - - - - - + + + - - - - - - - 
 T1 - - - - - + + + - - - - - - - 
 T2 - - - - - + + + - - - - - - - 
 T3 - - - - - + + + - - - - - - - 
 T4 - - - - - + + + - - - - - - - 
 T5 - - - - - + + - - - - - - - - 
P3 T0 - - - + - + - - - - - - - - - 
 T1 - + - - - - - - - - - - - - - 
 T2 - + - - - - - - - - - - - - - 
 T3 - + - - - - - - - - - - - - - 
 T4 - + - - - - - - - - - - - - - 
P4 T0 - + + - - - - - - - - - - - - 
 T1 - + + - - - - - - - - - - - - 
 T2 - - - - - - + - - - - - - - - 
 T3 - - - - - - + - - - - - - - - 
 T4 - - - - - - + - - - - - - - - 
P5 T0 - - - - - - + + - - - - - - - 
 T1 - - - - - - + + - - - - - - - 
 T2 - - - - - - + - - - - - - - - 
 T3 - - + - - - - + - - - - - - - 
 T4 - - + - - - - - - - - - - - - 
 T5 - - + - - - - - - - - - - - - 
* [+] Selected DGGE band is present; [-] Selected DGGE band is absent and * [P]: HIV-positive donors; [H]: HIV-negative donors  
 
* Strain Abbreviations: [ L. john]: L. johnsonii;[ S. ther]: Streptococcus thermophilus;[ L. reut]: L. reuteri;[ L. par]: L. paracasei;[ L. muc]: L. mucosae; [E. bif]: E. biforme; [L. rum]: L. ruminis; [L. sak]: L. sakei; 
[L. jen]: L. jensenii; [L. cris]: L. crispatus; [L. ferm]: L. fermentum; [L. delb]: L. delbrueckii; [L. brev]: L. brevis and [L. gall]: L. gallinarum.  
 
 
 
 
 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
102 
 
 
Table 4.4B:  Presence of selected Lactobacillus DGGE bands in donors P7-P11 and H3 throughout the 6 month longitudinal study   
Donor  
ID 
Time 
Point 
L. 
john. 
S. 
ther. 
L. 
reut. 
L. 
ros. 
L. 
par. 
L. 
muc. 
E. 
bif. 
L. 
rum. 
L. 
sak. 
L. 
jen. 
L. 
cris. 
L. 
ferm. 
L. 
delb. 
L. 
brev. 
L. 
gall.  
P7 T0 + - - - - - - - - - - - - - - 
 T1 + - - - - - - - - - - - - - - 
 T2 + - - - - - - - - - - - - - - 
 T3 + - - - - - - - - - - - - - - 
 T4 + - - - - - - - - - - - - - - 
P8 T0 - - - - - - - - + + - - - - - 
 T1 - - - - - - - + + - - - - + + 
 T2 - - - - - - - + - - - + - + + 
 T3 - - - - - - - + - - - + - + + 
 T4 - - - - - - - + + - - - - - - 
 T5 - - - - - - - + + - - - - - - 
P10 T0 - - - - - - + - - - - - - - - 
 T1 - - - - + - + - - - - - - - - 
 T2 - - - - + - + - - - - - - - - 
 T3 - - - - - - + - - - - - + - - 
 T4 - - - - - - - - - - - - - - - 
 T5 - - - - - - + - - - - - - - - 
P11 T0 - - - - - - + + - - - - - - - 
 T1 - - - - - - + + - - - - - - - 
 T2 - - - - - - + + - - - - - - - 
 T4 - - - - + - - - - - - - - - - 
H3 T0 - - + - - - + - - - + - - - - 
 T1 - - + - - - + - - - - - - - - 
 T2 - - + - - - + - - - - - - - - 
 T3 - - + - - - + - - - - - - - - 
 T4 - - - - - - + - - - - - - - - 
* [+] Selected DGGE band is present; [-] Selected DGGE band is absent and * [P]: HIV-positive donors; [H]: HIV-negative donors  
 
* Strain Abbreviations: [ L. john]: L. johnsonii;[ S. ther]: Streptococcus thermophilus;[ L. reut]: L. reuteri;[ L. par]: L. paracasei;[ L. muc]: L. mucosae; [E. bif]: E. biforme; [L. rum]: L. ruminis; [L. sak]: L. sakei; 
[L. jen]: L. jensenii; [L. cris]: L. crispatus; [L. ferm]: L. fermentum; [L. delb]: L. delbrueckii; [L. brev]: L. brevis and [L. gall]: L. gallinarum.  
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Figure 4.4: Shannon-Wiener diversity index of 
Lactobacillus spp. Donors (A) P2; (B) P3; (C) P4; (D) 
P5; (E) P7; (F) P8; (G) P10; (H) P11; (I) H3. [(Blue line): 
Shannon-Wiener diversity index and (Red blocks): CD4
+
 
T cell count]. 
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HIV-positive donor P7 (Figure 4.3E) exhibited a simple Lactobacillus population in 
comparison to the more complex DGGE profiles shown for donors P8 (Figure 4.3F), P10 
(Figure 4.3G) and P11 (Figure 4.3H). When referring to the donor demographic data received 
from the Groote Schuur clinic (Chapter 2), HIV-positive donor P7 was the youngest female 
donor to participate in this study (aged 21), and the only apparent similarity between donors 
P8, P10 and P11, was the fact that they were all males. A noticeable alteration to the 
Lactobacillus population of donor P11 (Figure 4.3H) occurred between sampling time point 
T2 and T4. However, because the T3 sample was not provided, and no clinical data was 
available for donor P11 at T3, no reliable conclusion regarding the cause of this alteration 
could be made.  
 
The Lactobacillus profile for H3 (Figure 4.3I) showed, at T0, a unique and donor specific 
profile, but differed slightly from the profiles seen for the HIV-positive donors in that the 
Lactobacillus group appeared to be less complex with fewer variations being evident over the 
6 month period (Figure 4.4I). Two out of the four bands detected were present throughout the 
6 month period and showed a high level of similarity to L. reuteri (band L3.3) and E. biforme 
(band L3.2) (Table 4.3). The findings reported in this chapter showed that, despite certain 
Lactobacillus strains persisting throughout the longitudinal sampling period, there was some 
variability in the diversity of the Lactobacillus group over the 6 months (Figure 4.4A-H). This 
was, however, not linked to HAART administration.   
 
4.4.3 Longitudinal cluster analysis of Bifidobacterium and Lactobacillus species    
The Bifidobacterium population in all 8 HIV-positive donors (Figure 4.5A and B) tended to 
show a very stable and established community throughout the 6 month longitudinal study. 
This was not affected in a temporal way by the administration of HAART. In contrast, the 
diversity of the Lactobacillus community (Figure 4.6A and B) throughout the 6 months of 
HAART showed some variation, which is an accurate reflection of the fluctuating and 
transient nature of Lactobacillus species within the intestinal tract, of healthy adult subjects 
(Vanhoutte et al., 2004). The variation, however, did not reflect a correlation with the 
administration of HAART. In order for a more objective conclusion regarding stability to be 
made, this study needs to be enlarged further thereby allowing more statistical and cluster 
analyses to be performed, and reducing any experimental scatter or inter-subject variation 
from the analysis.  
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Figure 4.5A: DGGE and cluster analysis of bifidobacterial 16S rRNA genes amplified from 
the faecal material of 4 HIV-positive donors over a 6-12 month longitudinal 
study. The dendrogram was generated using the Dice Similarity coefficient and 
clustering algorithim UPGMA. Donors: (A) P2; (B) P3; (C) P4; (D) P5.   
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Figure 4.5B: DGGE and cluster analysis of bifidobacterial 16S rRNA genes amplified from 
the faecal material of 4 HIV-positive donors over a 6-12 month longitudinal 
study. The dendrogram was generated using the Dice Similarity coefficient and 
clustering algorithim UPGMA. Donors: (E) P7; (F) P8; (G) P10; (H) P11.   
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Figure 4.6A: DGGE and cluster analysis of the Lactobacillus group 16S rRNA genes amplified 
from the faecal material of 4 HIV-positive donors over a 6-12 month longitudinal 
study. The dendrogram was generated using the Dice Similarity coefficient and 
clustering algorithim UPGMA. Donors: (A) P2; (B) P3; (C) P4; (D) P5.   
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Figure 4.6B: DGGE and cluster analysis of the Lactobacillus group 16S rRNA genes amplified 
from the faecal material of 4 HIV-positive donors over a 6-12 month longitudinal 
study. The dendrogram was generated using the Dice Similarity coefficient and 
clustering algorithim UPGMA. Donors: (E) P7; (F) P8; (G) P10; (H) P11. 
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4.5  CONCLUSION 
The overall objective of this chapter was to ascertain whether the diversity of the known 
beneficial bacterial groups, Bifidobacterium and Lactobacillus was affected during 6 months of 
HAART. The findings of this chapter showed that no significant changes occurred in either of 
these populations during HAART, and that any alterations seen were specific for that particular 
donor. In general, however, the Bifidobacterium population tended to be less diverse, but 
temporally more stable than the Lactobacillus population.  
 
A direct comparison between HIV-positive donors receiving the same ARV regime and 
Bifidobacterium and Lactobacillus species present was not conducted. Carrying out this 
particular comparison would have been complicated in that, although several HIV-positive 
donors were on identical ARV treatments, they all had unique and very different characteristics 
including, age, gender, race and previous medical conditions, all of which could play a role in 
influencing the endogenous gastrointestinal microbiota.  
 
The administration of multiple antibiotics over a 22 week period in HIV-positive donor P5, led 
to a reduction in the Lactobacillus population, with a persistence in L. reuteri, which may 
possibly be resistant to these antibiotics. B. longum also appeared to be less affected by the 
antibiotics than B. adolescentis. However, since only one donor received multiple antibiotics, 
general conclusions regarding the responses of these bacteria to antibiotics, in HIV-positive 
donors, requires a more extensive study since the observed responses may be host specific and 
not linked to medication. 
   
Clinical data summarised in Chapter 2 and graphically represented in this chapter, showed a 
general improvement of conditions within the peripheral blood namely, a clinically significant 
reduction in the viral load and an increase in CD4
+
 T cell count, except for donor P2 (who 
became pregnant during the study). All of the HIV-positive donors were classified as having a 
chronic HIV infection when HAART was initiated, which means that, according to the study 
conducted by Guadalupe et al., (2006) a prolonged period of time would need to elapse before 
conditions within the gastrointestinal tract began to improve.   
 
Even though the Bifidobacterium and Lactobacillus population diversity did not seem to be 
affected by the persistence of HIV within the gastrointestinal tract, these conditions or the 
HAART itself could possibly be affecting other dominant intestinal bacterial groups. The 
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results reported in Chapter 3 showed a significant reduction in the total bacterial diversity 
before the initiation of HAART relative to the healthy donors. It would have been interesting to 
also investigate possible changes in the diversity of the total bacteria longitudinally over the 6 
month HAART period. This, however, could not be done in the course of this study due to time 
and equipment constraints, but future work should include this analysis. 
 
As an alternative research strategy (given the available resources), it was decided that the 
abundance and dynamics of other key bacterial groups in the gastrointestinal tract should be 
investigated using qPCR. The groups selected were the four dominant (Bacteroides/Prevotella, 
Clostridium leptum group, Clostridium coccoides cluster and Bifidobacterium) and three sub-
dominant (Lactobacillus, Escherichia coli and Enterococcus) gastrointestinal groups. These 
would be determined in the faecal samples of 12 HIV-positive and 12 HIV-negative donors, 
using qPCR. Samples would be analysed prior to HAART, as well as at 6 months post HAART 
initiation (in the 8 longitudinal patients), in an attempt to establish whether the numbers of 
endogenous microbiota were affected by the conditions found within the intestinal tract during 
HAART. Furthermore, the prevalence of three intestinal pathogens within HIV-positive donors 
would also be evaluated. The findings and conclusions of this work are described and discussed 
in Chapter 5.   
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CHAPTER FIVE 
Quantitative real time PCR analysis of selected gastrointestinal bacterial groups and 
pathogens in South African HIV-positive and HIV-negative donors   
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5.1  SUMMARY 
Real-time PCR has been successfully employed in the quantification of bacterial DNA from 
various sources such as faeces (Malinen et al., 2003; Requena et al., 2002), colonic tissue 
(Fujita et al., 2002) and gastric tissue (He et al., 2002). The final section of this study aimed to 
establish whether there were any significant changes in the abundance of four dominant and 
three sub-dominant gastrointestinal bacterial groups, present in the faeces of HIV-positive 
donors prior to, as well as 6 months after HAART initiation. The dominant groups were 
Bacteroides/Prevotella, Clostridium leptum group, Clostridium coccoides cluster and 
Bifidobacterium and the subdominant were Lactobacillus, Escherichia coli and Enterococcus. 
The findings of this chapter showed that prior to the initiation of HAART, the abundance of the 
C. leptum group was significantly reduced in the HIV-positive donors relative to the HIV-
negative donor group (p = 0.02). The Bacteroides group was also reduced in the HIV-positive 
patients, but this did not attain statistical significance (p = 0.08). There was no significant 
difference between the two donor groups with respect to any of the other groups tested. No 
detectable levels of Enterococcus spp. were found in either the HIV-positive or HIV-negative 
donor groups. After 6 months of HAART, significant reductions in the abundance of the C. 
leptum (p = 0.05) and Bacteroides (p = 0.004) groups as well as the total bacteria (p = 0.03) 
were seen relative to the HIV-negative donor group. This suggests that the microbial 
composition within the HIV-positive gastrointestinal tract was different to the HIV-negative 
state, and that during 6 months of HAART these potentially protective groups decreased 
further. The possible presence of three intestinal pathogens was also determined utilising 
TaqMan probes. No detectable levels of Campylobacter jejuni were found in either of the two 
donor groups, while Clostridium cluster XI species were found in both groups of donors. 
Salmonella species were detected more frequently within the HIV-negative donors (p = 0.02). 
These results showed that qPCR enabled the identification of specific changes in the intestinal 
microbiota, following chronic HIV infection and during a 6 month period during which 
HAART was administered.   
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5.2  INTRODUCTION 
The findings discussed in Chapter 3 and Chapter 4 of this study showed that PCR-DGGE could 
be successfully used in determining the composition and diversity of complex microbial 
communities within the gastrointestinal tract. However, the abundance of strains in these 
bacterial communities could not be accurately measured as DGGE is not a truly quantitative 
technique due to several limitations which were addressed in Chapter 3. Therefore, in order to 
establish any alterations in the abundance of certain species under specific disease conditions, a 
more sensitive, quantitative method, such as real-time PCR, is required (Ahn et al., 2009).  
 
Real-time PCR is an accurate and sensitive technique that has been used in various quantitative 
nucleic acid analyses, such as gene expression and pathogen quantification (Schmittgen et al., 
2008). Current detection methods employed include either SYBR Green I or TaqMan (Kubista 
et al., 2006). SYBR Green I is an asymmetric, cyanine intercalating dye, that has been shown 
to fluoresce 50 to 100 times more brightly when bound to double-stranded DNA, and is the 
most commonly used dye in quantitative PCR (Kubista et al., 2006; Inglis and Kalischuk, 
2004; Malinen et al., 2003). The TaqMan assay, also referred to as the 5’-nuclease PCR assay, 
exploits the 5’ to 3’ exonuclease activity of Taq polymerase and measures the increase in 
fluorescence when a hydrolysis probe, specifically designed to bind inside the amplified region 
is cleaved (Heid et al., 1996). An increase in fluorescence will occur only if the target sequence 
is amplified, thus preventing the detection of non-specific products and increasing the overall 
specificity and sensitivity. TaqMan has been reported to be a hundred times more sensitive than 
conventional PCR (Haarman and Knol, 2005). Unlike the TaqMan assay, SYBR Green has a 
tendency for non-specific binding to any double-stranded nucleic acid or primer dimers, which 
may significantly reduce the specificity of the PCR assay (Inglis and Kalischuk, 2004; Malinen 
et al., 2003). However, SYBR Green is associated with several advantages, including low 
running costs and its suitability for use in most PCR amplification reactions, and thorough 
experimental controls can minimize the formation of primer dimers and non-specific binding 
(Inglis and Kalischuk, 2004; Malinen et al., 2003).  
 
Baseline comparisons established between HIV-positive and HIV-negative donors, in Chapter 
3, showed that the diversity of the total bacterial community had been significantly affected in 
the former group. The development of primers specific for the major and minor bacterial 
groups found in the gut means that an accurate representation of the abundance of these groups 
within the gastrointestinal tract can be determined using qPCR. 
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Several scientific reports have indicated that patients living with a more advanced and 
progressive HIV infection (CD4
+
 < 200 cells/mm
3
), are at higher risk of acquiring and 
developing diarrhoea attributable to a bacterial pathogen (Sanchez et al., 2005; Obi and 
Bessong, 2002; Navin et al., 1999). Enteric pathogens identified as causative agents of bacterial 
diarrhoea in HIV-positive patients, include Clostridium, Campylobacter and Salmonella 
species. These accounted for 53.6%, 13.8% and 7.4% of diarrhoea cases, respectively, reported 
during 1992-2002 (Sanchez et al., 2005). As recorded in Chapter 2, none of the recruited HIV-
positive donors developed diarrhoea during the course of this study. However, the absence of 
diarrhoea within these donors should be interpreted with caution, since potential intestinal 
pathogens may not be completely absent, but could be present in considerably lower numbers, 
suggesting that HIV-positive patients may still be carriers of these pathogens.   
  
The focus of the research reported in this chapter was to evaluate quantitatively whether any 
significant changes in the abundance of four dominant (Bacteroides/Prevotella, Clostridium 
leptum group, Clostridium coccoides cluster and Bifidobacterium) and three sub-dominant 
(Lactobacillus, Escherichia coli and Enterococcus) gastrointestinal groups had occurred. 
SYBR Green was used for the detection of these groups within the faecal material of both HIV-
positive donors (prior to [T0] and 6 months [T4] after HAART initiation), and in the control 
HIV-negative group. Furthermore, the abundance of three bacterial intestinal pathogens, 
namely S. enterica, C. jejuni and C. difficile, within both the HIV-positive and HIV-negative 
donor groups was determined using the TaqMan method.   
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5.3  MATERIALS AND METHODS 
5.3.1 Bacterial strains and plasmids 
Bacterial strains used as positive controls for each of the bacterial groups investigated in this 
chapter, are listed in Table 5.1. All reference strains, with the exception of C. leptum and C. 
coccoides, were cultured as previously described in section 3.3.1. DNA extracted from C. 
leptum DSM 753 and C. coccoides DSM 935, was purchased from the DSM bacterial culture 
collection (Deutsche Sammlung von Mikroorganismen, Germany).     
 
Table 5.1  Bacterial strains and cloning plasmid used in this study 
Bacterial strains and plasmid Characteristics Reference
*
 
Bifidobacterium longum NCIMB 702259
T
 Type strain of B. longum NCIMB 
Lactobacillus gasseri ATCC 33323
T
 Type strain of L. gasseri ATCC 
Bacteroides fragilis 638R Clinical isolate Privitera et al., (1979) 
Escherichia coli DH5α Gram-negative cloning h st Hanahan, (1983) 
Enterococcus faecalis (P1.2) MCB laboratory strain MCB  
Clostridium leptum DSM 753
T
 Type strain of C. leptum DSM 
Clostridium coccoides DSM 935
T
 Type strain of C. coccoides DSM 
pTZ57R/T Linearized cloning vector with 
single 3’-ddT overhangs  
Fermentas 
 
*
NCIMB: National Collection of Industrial, Food and Marine Bacteria, United Kingdom, DSM: Deutsche  
  Sammlung von Mikroorganismen, Germany, ATCC: American Type Culture Collection, MCB: Department of  
  Molecular and Cell Biology, University of Cape Town  
 
The three bacterial pathogens used in this study are described in Table 5.2. Salmonella 
enterica was grown aerobically at 37
o
C in LB broth or agar plates, whilst C. difficile was 
cultured anaerobically in both a supplemented brain heart infusion medium and a Clostridium 
basal growth medium as mentioned in section 3.3.1. A pure, clinical isolate of Campylobacter 
jejuni, grown on Tryptose blood agar under microaerophilic conditions at 33.5
o
C, was 
acquired from the National Health Laboratory Services (NHLS) in Cape Town.   
 
Table 5.2  Bacterial pathogens used in this study 
Bacterial pathogen Characteristics Reference
*
 
Salmonella enterica ATCC 14028
T
 Type strain of S. enterica BD Diagnostics 
Campylobacter jejuni type I Clinical isolate  NHLS 
Clostridium difficile ATCC 9689
T
 Type strain of C. difficile BD Diagnostics 
 
*
BD: Becton, Dickinson and Company, NHLS: National Health Laboratory Services  
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5.3.2 Genomic DNA Extraction  
Total bacterial DNA was extracted from faecal samples collected at T0 and T4, using the ZR 
Faecal DNA Kit
TM 
(ZYMO Research), as previously described in Chapter 3 (section 3.3.2).  
Bacterial gDNA was isolated from the reference strains (Table 5.1) and the three pathogens 
(Table 5.2) using the Genomic DNA Purification Kit (Fermentas) which was also described 
in Chapter 3 (section 3.3.2).  
 
5.3.3 Preparation of plasmid DNA controls 
PCR products generated from the different primer combinations (Tables 5.3 and 5.4) were 
purified, using the BioSpin PCR Purification Kit (BioFlux).  
 
Table 5.3  Target bacterial groups and qPCR primers used in this study 
Target Group 
(amplicon size) 
Primer Sequence (5’-3’) Reference 
Total bacteria 
(123 bp) 
F_Bact 1369 CGG TGA ATA CGT TCC CGG Suzuki et al. 
(2000) R_Prok1492 TAC GGC TAC CTT GTT ACG ACT T 
C. leptum  
(115 bp) 
F_Clept 09 CCT TCC GTG CCG SAG TTA Furet et al., 
(2009) R_Clept 08 GAA TTA AAC CAC ATA CTC CAC TGC TT 
Bifidobacterium 
(137 bp) 
F_Bifid 09c CGG GTG AGT AAT GCG TGA CC Furet et al., 
(2009) R_Bifid 06 TGA TAG GAC GCG ACC CCA 
C. coccoides 
(198 bp) 
F_Ccoc 07 GAC GCC GCG TGA AGG A Furet et al., 
(2009) R_Ccoc 14 AGC CCC AGC CTT TCA CAT C 
Bacteroides 
(130 bp) 
F_Bacter 11 CCT WCG ATG GAT AGG GGT T Furet et al., 
(2009) R_Bacter 08 CAC GCT ACT TGG CTG GTT CAG 
E. coli  
(100 bp) 
E. coli F CAT GCC GCG TGT ATG AAG AA Huijsdens et 
al., (2002) E. coli R CGG GTA ACG TCA ATG AGC AAA 
Lactobacillus 
(352 bp) 
F_Lacto 05 AGC AGT AGG GAA TCT TCC A Furet et al., 
(2009) R_Lacto 04 CGC CAC TGG TGT TCY TCC ATA TA 
E. faecalis  
(143 bp) 
F_Entero CCC TTA TTG TTA GTT GCC ATC ATT Rinttilä et al., 
(2004) R_Entero ACT CGT TGT ACT TCC CAT TGT 
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Table 5.4  Real-time primers and probes employed in this study 
Target Group Primer/Probe Sequence (5’-3’) Reference 
S. enterica 
ttr-6(F) CTC ACC AGG AGA TTA CAA CAT GG 
Malorny et 
al., (2004) 
ttr-4(R) AGC TCA GAC CAA AAG TGA CCA TC 
ttr-5 (P) FAM-CAC CGA CGG CGA GAC CGA CTT T 
C. jejuni 
yphC-F CAT TCT CAA ATA GCA CTT TTG GTT TT 
Iijima et al., 
(2004) 
yphC-R GCC CAG CAA TGC GTT CA 
yphC-P TET-TGG CGC ATG AGG GCT TTA ACG AGC 
Clostridium 
cluster XI        
(C. difficile) 
CXI-F1 ACG CTA CTT GAG GAG GA 
Song et al., 
(2004) 
CXI-R2 GAG CCG TAG CCT TTC ACT 
Probe I FAM-GTG CCA GCA GCC GCG GTA ATA CG 
Probe sequences and names are in bold.  
 
The PCR fragments were ligated into the pTZ57R/T vector (Fermentas), and transformed into 
competent E. coli DH5α cells by means of heat shock (Chapter 3, section 3.3.5.1). The 
presence of the insert was confirmed through PCR amplification, using group or pathogen 
specific primers (Table 5.3 and Table 5.4). Plasmid DNA was extracted using the BioSpin 
Plasmid Extraction Kit (BioFlux) and the concentration determined using the Nanodrop 
(NanoDrop® ND-1000).  
 
5.3.4 Quantitative real-time PCR amplification  
5.3.4.1 SYBR Green Method  
Quantitative PCR detection of the eight selected bacterial groups was carried out in triplicate, 
using optical-quality 96-well PCR plates (0.2 ml volume/well) and sealing film (Lasec SA). 
Assays were performed using the Bio-Rad MyIQ
TM
 Real-Time PCR detection system (Bio-
Rad, Inc) and a reaction mixture (12.5 µl) composed of 1X SensiMix
TM
 SYBR No-ROX 
Master Mix (BioLine), 0.2 µM of each specific primer (Table 5.3) and 1 µl (10 ng) of DNA 
template. Cycling parameters consisted of one cycle at 95
o
C for 10 min, followed by 40 
cycles of 95
o
C for 10 sec, 60
o
C for 15 sec, and 72
o
C for 20 sec.  
 
A detailed melt curve analysis was performed after the last cycle of amplification to confirm 
PCR specificity. The melt curve data was acquired by heating the PCR reaction from 72
o
C to 
95
o
C at a ramp rate of 0.1
o
C/sec. Measurements were then recorded at intervals of 1
o
C. 
Following this, the plasmid copy number/µl was determined by dividing the plasmid DNA 
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concentration with its corresponding plasmid mass, approximately 3.3 x 10
-18 
g (Pèlissier et 
al., 2010). All cloned group and pathogen specific inserts were serially diluted (10-fold 
dilutions) (Table 5.5), and were subsequently used in the optimisation of each qPCR run.  
 
Negative and positive controls, in addition to a standard curve, were included on every plate 
for all qPCR runs. The MyIQ system was calibrated, as prescribed by the manufacturer, with 
the iCycler iQ external well factor solution (Bio-Rad, Inc) which improved the quality of the 
fluorescent data recorded.  
 
5.3.4.2 Taqman (5’- nuclease PCR assay) Method 
Pathogen specific primers and probes used in this study are summarized in Table 5.4. PCR 
amplification and detection of pathogen DNA was performed in a Rotor-Gene
TM
 6000 system 
(Corbett Life Science) with optical-quality PCR tubes (0.1 ml) and caps (Gene target 
solutions). Real-time PCR reactions were performed in triplicate, in a total volume of 12.5 µl, 
which consisted of 1X SensiMix
TM
 II Probe Master Mix (BioLine), 0.4 µM (S. enterica) and 
0.3 µM (C. jejuni and Clostridium cluster XI) of each primer, 0.25 µM (S. enterica and C. 
jejuni) and 0.2 µM (Clostridium cluster XI) of the hydrolysis probe and 1 µl of DNA 
template. All Taqman probes used were labeled with a 5’-reporter dye, either 6-
carboxyfluorescein (FAM) or 6-carboxy-4,7,2',7'-tetrachloro-fluorescein (TET) and the 3’-
quencher dye dimethylaminoazosulfonic acid (DABSYL). The reaction conditions used for 
amplification were 95
o
C for 10 min, followed by 45 cycles of 95
o
C for 15 sec, and 
annealing/elongation for 30 sec at either 61
o
C (S. enterica), 60
o
C (C. jejuni) or 58
o
C 
(Clostridium cluster XI). Product formation was detected by measuring the intensity of the 
reporter dye, which is cleaved off from the probe by the 5’- 3’ exonuclease activity of Taq 
polymerase.   
 
5.3.5 Normalisation of data and statistical analysis  
PCR quantification and melt curve analysis was performed using the iQ5
TM
 Optical System 
software version 2.0 (Bio-Rad, Inc) and the Rotor-Gene 6000 software version 1.7 (Corbett 
Life Sciences). For each of the investigated bacterial groups, the number of 16S rRNA gene 
copies/mg of faecal material was converted into the log of 16S rRNA gene copies/g of faecal 
material.    
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A Mann-Whitney U Test was performed, to compare differences in the abundance of the 
bacterial groups between the HIV-positive and HIV-negative donors, and a p value ≤ 0.05 
was considered to be statistically significant. The qPCR results were also graphically 
represented as box-and-whisker plots, constructed using Stata data analysis and statistical 
software version 11.1 (StataCorp LP, USA) and expressed as median values with quartile 
ranges (QR).  
5.4  RESULTS AND DISCUSSION 
5.4.1 Optimisation of the SYBR Green I-based real-time PCR assays 
All qPCR optimisation experiments were performed according to the relevant internationally 
recognized MIQE Guidelines: Minimum Information for Publication of Quantitative Real-
Time PCR Experiments (Bustin et al., 2009). All qPCR assays performed in this study, were 
run in triplicate, together with two independent negative qPCR controls on each PCR plate. In 
addition, genomic DNA was also extracted twice from individual faecal samples. 
 
5.4.1.1 qPCR primer selection  
Previously published primers, described in Table 5.3, were used in the detection of eight 
specific gastrointestinal bacterial groups. The specificity of each primer set was validated by 
means of conventional PCR, using genomic DNA isolated from the bacterial reference strains 
summarised in Table 5.1. Each individual primer set was also tested against all eight 
representative species from each bacterial group to confirm specificity. When the total 
bacterial primer set (F_Bact 1369 and R_Prok 1492) was evaluated, a PCR product of 
approximately 123 bp was produced in all eight species (Figure 5.1A). The remaining 
bacterial group qPCR primer sets were highly specific for each group and produced a positive 
result for only the corresponding target species, with no cross reactions or non-specific 
binding occurred with any of the other target groups (Figure 5.1B – H).  
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Figure 5.1: Specificity of the qPCR primers employed in the SYBR Green Method. (A) Total 
bacteria [F_Bact 1369 and R_Prok 1492]; (B) C. leptum group [F_Clept 09 and 
R_Clept 08]; (C) Bifidobacterium group [F_Bifid 09c and R_Bifid 06]; (D) C. 
coccoides group [F_Ccoc 07 and R_Ccoc 14]; (E) Bacteroides group [F_Bacter 11 
and R_Bacter 08]; (F) E. coli [E. coli F and E. coli R]; (G) Lactobacillus group 
[F_Lacto 05 and R_Lacto 04] and (H) Enterococcus group [F_Entero and R_Entero]. 
Lane 1: 100 bp molecular weight marker (Fermentas); Lane 2: Negative control (no 
DNA); Lane 3: C. leptum; Lane 4: B. longum; Lane 5: C. coccoides; Lane 6: B. 
fragilis; Lane 7: E. coli; Lane 8: L. gasseri and Lane 9: E. faecalis. Arrows indicate 
sizes of PCR products in bp.  
A B C 
 1     2    3    4    5    6    7     8    9  1     2    3    4    5    6    7     8    9  1     2    3    4    5    6    7     8    9 
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 1     2    3    4    5    6    7     8    9   1     2    3    4    5     6     7    8     9  1     2    3    4    5    6     7     8     9 
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 1     2    3    4    5     6    7     8    9   1     2    3    4   5     6     7    8     9 
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In the study published by Furet et al., (2009), a final primer concentration of 0.2 μM was used 
for all of the evaluated primer sets. To some extent lower qPCR primer concentrations (0.2-
0.4 μM) are usually favoured when employing SYBR Green I in an attempt to reduce non-
specific amplification (Sigma Aldrich, 2008). Therefore, the optimal qPCR primer 
concentration for this study was determined by testing each primer set, using qPCR, at the 
following concentrations: 0.1 μM, 0.2 μM, 0.3 μM, and 0.4 μM. Optimal qPCR conditions 
were achieved when a primer concentration of 0.2 μM was used.  
 
To determine the purity of the extracted gDNA, as well as the concentration which would 
result in the greatest amount of amplification, a standard DNA dilution series was established 
using varying amounts of gDNA (1 ng/µl to 100 ng/µl). A ten-fold increase in DNA should 
lead to a decrease in the threshold cycle (Ct) value by approximately 3.32, provided the PCR 
efficiency is acceptable. Relatively high concentrations of DNA could result in the inhibition 
of the qPCR reaction, whereas too little DNA may be undetectable (Edwards, 2004). To 
determine the reproducibility of the qPCR assays, two separate DNA extracts (derived from 
the same faecal sample) were evaluated under optimised conditions. Briefly, 10 ng of each 
gDNA extract was run in triplicate, under the same reaction conditions, with strongly 
reproducible results being achieved for both samples.    
 
5.4.1.2 qPCR reaction conditions    
PCR cycling conditions, previously optimised by Furet et al., (2009), were also evaluated for 
use in the current study. A very important variable in ensuring that optimal conditions and 
acceptable qPCR efficie cies are achieved is the annealing temperature. Prior to the initiation 
of qPCR, the annealing temperature for all eight primer sets were tested and evaluated. After 
performing numerous qPCR runs at four different annealing temperatures (58
 o
C, 59
 o
C, 60
 
o
C, 61
 o
C), the optimum annealing temperature, for all eight primer sets, was determined to be 
60
o
C. This result was in agreement with the conditions recorded and employed by Furet et 
al., (2009). Another key variable in the optimisation of qPCR is the magnesium chloride 
(MgCl2) concentration. High MgCl2 concentrations may result in low product formation and 
a significant increase in the production of non-specific PCR products, such as primer dimers 
(Edwards, 2004). Several MgCl2 titration curves, ranging from 1 mM to 5 mM were 
conducted, and the optimal MgCl2 concentration determined for this research study was 3 
mM.  
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5.4.1.3 qPCR validation: specificity, sensitivity and efficiency (using SYBR Green)  
The presence of primer dimers or non-specific amplification can affect the overall PCR 
reaction efficiency and limit the detection range (Bustin et al., 2009). Therefore, performing a 
melt curve analysis is necessary when using SYBR Green I, on account of its relatively high 
affinity for non-specific binding. As the temperature is increased during the melt curve 
analysis, double stranded DNA begins to denature, causing SYBR Green I to dissociate from 
this complex and results in a decrease in the fluorescence. Non-specific PCR products or 
primer dimers formed during PCR, have different melting properties compared to the product 
of interest (primer dimers usually melt at lower temperatures than specific PCR products), 
and would therefore been seen as additional peaks (van der Velden et al., 2003). The melt 
curve analyses carried out in this study were observed from 72
o
C to 95
o
C. A single product 
was obtained for all of the primer sets (Figure 5.2). Furthermore, when analysing each of 
these products using agarose gel electrophoresis and ethidium bromide staining, the gels also 
confirmed that no non-specific products were produced at 72
o
C.  
 
The reaction efficiency, sensitivity and detection limits of the SYBR Green qPCR assays were 
determined, by creating 10-fold serial dilutions of the plasmids containing each of the cloned 
bacterial group inserts (Table 5.5). Standard curves were generated by plotting the value of 
the threshold cycle (Ct) against the log copy number of the corresponding known standard 
(Figure 5.3A - C), with standard curve correlation coefficient values (R
2
) ranging between 
0.994 and 1.000 being recorded.  
 
Table 5.5  Standard curve ranges used for each target group  
Target Group 
Standard curve 
range (copies/µl) 
Target Group 
Standard curve 
range (copies/µl) 
Total bacteria  3.03x10
3
 – 3.03x108 S. enterica 2.08x103 – 2.08x109 
C. leptum  3.04x10
3
 – 3.04x108 C. jejuni 3.07x104 – 3.04x109 
Bifidobacterium 3.02x10
3
 – 3.02x108 Clostridium cluster XI 3.02x104 – 3.02x109 
C. coccoides 2.96x10
3
 – 2.96x108   
Bacteroides 3.03x10
3
 – 3.03x108   
E. coli 3.06x10
3
 – 3.06x108   
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Figure 5.2: Melt curve analysis of bacterial group specific PCR products. (A): Total bacteria 
[F_Bact 1369 and R_Prok 1492]; (B): C. leptum [F_Clept 09 and R_Clept 08]; (C): 
Bifidobacterium [F_Bifid 09c and R_Bifid 06]; (D): C. coccoides [F_Ccoc 07 and 
R_Ccoc 14]; (E): Bacteroides [F_Bacter 11 and R_Bacter 08]; (F):  E. coli [E. coli F 
and E. coli R]; (G): Lactobacillus [F_Lacto 05 and R_Lacto 04] and (H): 
Enterococcus [F_Entero and R_Entero]. Specific primers used are shown in the 
square brackets and in Table 5.3. [Experiments A-H were performed in triplicate].   
E 
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H D 
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Overall, both the primer sensitivity and reaction efficiencies were good, in that a template 
range of between 10
3 
to 10
8
 copies was easily detected using SYBR Green I, and the lowest 
and highest efficiencies, calculated using the formula E = [10
(-1/slope)
 – 1] (Penders et al., 
2005), were 86% and 107.7% respectively (Figure 5.3A – C). A slope between -3.9 and -3.0 
(80-110% efficiency) is considered, in the literature, to be acceptable (Stapleton et al., 2009; 
Sigma Aldrich, 2008). Numerous attempts were made to try to bring the PCR efficiencies 
recorded in this study closer to 100%. However, changing the annealing temperature and 
primer concentrations did not improve the efficiencies shown in Figure 5.3 significantly.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3A: Standard curves of bacterial group specific PCR products generated using the 
SYBR Green method. (A): Total bacteria [F_Bact 1369 and R_Prok 1492] and (B): 
C. leptum [F_Clept 09 and R_Clept 08]. Specific primers used are shown in the 
square brackets and summarized in Table 5.3. [All standard curve dilutions were 
assayed in triplicate for each experiment].    
R
2
 = 0.999 
E= 107.7%      
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Figure 5.3B: Standard curves of bacterial group specific PCR products generated using the 
SYBR Green method. (C): Bifidobacterium [F_Bifid 09c and R_Bifid 06]; (D): C. 
coccoides [F_Ccoc 07 and R_Ccoc 14]; (E): Bacteroides [F_Bacter 11 and R_Bacter 
08]. Specific primers used are shown in the square brackets and summarized in Table 
5.3. [All standard curve dilutions were assayed in triplicate for each experiment].   
R
2
 = 0.999 
E= 94%      
R
2
 = 1.000 
E= 92%         
R
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 = 0.999 
E= 92%          
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Figure 5.3C: Standard curves of bacterial group specific PCR products generated using the 
SYBR Green method. (F):  E. coli [E. coli F and E. coli R]; (G): Lactobacillus 
[F_Lacto 05 and R_Lacto 04] and (H): Enterococcus [F_Entero and R_Entero]. 
Specific primers used are shown in the square brackets and summarized in Table 5.3. 
[All standard curve dilutions were assayed in triplicate for each experiment].   
F 
R
2
 = 0.999 
E= 92%         
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 = 0.994 
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5.4.2 Sensitivity of the qPCR primers and probes used for the bacterial pathogens 
The DNA target region for each pathogen was cloned into pTZ57R/T and the presence of the 
insert was validated, using the pathogen specific primers. Three clones, randomly selected, all 
had the correct insert present in each case (Figure 5.4). The sensitivity of the TaqMan primer 
and probe combinations, as well as the reaction efficiencies were both determined in the same 
manner as the bacterial group primers discussed above. The detection limits for all three 
primer and probe sets were approximately 10
3
 to 10
9
 copies, with reaction efficiencies of 
96%, 104% and 96% obtained for S. enterica, C. jejuni and C. difficile respectively.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Specificity (1) and detection range (2) of the qPCR primers employed for the 
TaqMan Method. Lane 1: 100 bp molecular weight marker (Fermentas); Lane 2: 
Negative control (no DNA); Lanes 3-5: Clones 1, 2, 3 and Lane 6: Positive control 
(gDNA). (A): S. enterica; (B): C. jejuni and (C): C. difficile. [All standard curve 
dilutions were assayed in triplicate].   
A 
B 
C 
 1        2       3       4       5      6     
 1       2       3       4        5       6     
 1       2       3       4        5       6     
 R2 = 0.994     
 R2 = 0.999     
 R2 = 0.998     
1 2 
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5.4.3 Quantitative analysis of gastrointestinal bacterial groups in faecal samples   
SYBR Green qPCR was performed, to quantify and determine the abundance of eight 
specific dominant and sub-dominant gastrointestinal bacterial groups in the faecal samples of 
HIV-positive donors (prior to HAART) and HIV-negative donors. The results obtained for 
each bacterial group are presented in Tables 5.6 and 5.7, and are also graphically represented 
as box-and-whisker plots (Figure 5.5).    
 
5.4.3.1 Occurrence of major and minor groups in the HIV-negative donors 
The numbers of bacteria detected by qPCR in the healthy control group in this study are 
shown in Table 5.6, and the values were compared to other similar qPCR studies on healthy 
individuals reported in the literature. Published, peer-reviewed literature reflects a wide range 
of variation in the levels of bacterial numbers in healthy individuals detected using qPCR 
methods. A comparison of our data with four such articles (Table 5.6) showed that the values 
obtained for the C. leptum, C. coccoides, Bacteroides/Prevotella, and Lactobacillus groups 
were all within the range previously reported by other researchers using similar methods and 
primers (Larsen et al., 2010; Furet et al., 2009; Zhang et al., 2009; Bartosch et al., 2004). 
However, the estimation of the total bacterial numbers in this study appears to be towards the 
maximum levels reported in these published studies. This may be linked to the qPCR 
efficiency of 107% detected in the construction of the standard curve although this was still 
within the published recommended efficiency range (Stapleton et al., 2009). This higher 
estimation could result, perhaps, in a slight overestimation of the total numbers of bacteria 
(Figure 5.3A). Since the median values for all the other groups tested were very close to the 
published values, a calculation of the percentage representation of these groups, relative to 
the higher total bacterial value, would lead to the impression that the groups were under-
represented. All attempts to improve the optimisation of the qPCR conditions as described 
earlier, did not change these values.  
 
However, for the purposes of this study, the aim was to draw a direct comparison between the 
healthy and HIV-positive cohorts. The qPCR experiments for both groups were done within 
the study under identical conditions, and with the appropriate number of biological and 
technical replicates. The data is, therefore, sufficiently reliable to be used for a direct 
comparison between the bacterial numbers in the two donor groups.  
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Table 5.6  Comparison between the qPCR data from this study (healthy volunteers) with four 
                  published studies 
Target Group 
This Study Larsen et al., (2010) Zhang et 
al., (2009) 
Furet et 
al., (2009) 
Bartosch et 
al., (2004) 
Median
†
 Range
†
 Median
†
 Range
†
 Range
†
 Median
†
 Median
†
 
Total bacteria 11.86 10.3 – 13.1 10.5 10.0 – 11.3 10.2 - 11 11.5 12.0 
C. leptum 9.73 8.4 – 10.8 9 7.5 – 10.5  10.8 10.3 
C. coccoides 8.52 7.7 – 10.4 9.9 6.5 – 10.5  10.3  
Bacteroides/Prevotella 9.34 8.0 – 10.5 9.6 6.5 - 11  10 10.5 
Lactobacillus group 7.01 5.5 – 8.8 6.4 3.5 – 8.5  7.6  
 
† 
Values expressed as Log10 bacteria per g stool  
 
5.4.3.2 Comparison of HIV-positive (T0) with HIV-negative donors 
The numbers of bacteria detected by qPCR in the healthy control group and the HIV-positive 
cohort are shown in Table 5.7. The abundance of the total bacteria was slightly lower in the 
HIV-positive donors, before the commencement of HAART, than in the control HIV-negative 
donors, but this was not statistically significant (p = 0.15). The most statistically significant 
difference between the HIV-positive and HIV-negative donors, at this time point, was seen for 
the C. leptum group (p = 0.02), in that the number of 16S rRNA gene copies detected for this 
group was greatly reduced within the HIV-positive donors. There was a relatively lower 
abundance of the Bacteroides group within the HIV-positive donors, but this was not 
statistically significant (p = 0.08). Species belonging to the Enterococcus group were not 
detected in either of the donor groups as, in most instances; the results that were recorded 
were below the minimum detection limit of the qPCR reaction. 
 
The box-and-whisker plots shown in Figure 5.5 were generated for all seven bacterial groups 
comparing them in terms of HIV status. The quartile ranges (QR) of each box extend from the 
lower 25
th
 percentile to the higher 75
th
 percentile along with the median (50
th
 percentile). The 
highest and lowest values recorded for each group are shown by the whiskers extending above 
and below each box. Statistical comparison between the numbers of the groups using this 
analysis confirmed the significant reduction of the C. leptum group in the HIV-positive 
cohort, as well as the trend towards a reduction in Bacteroides (although this was not 
significant) (Figure 5.5A [a]). 
    
It is of interest that Larsen et al., (2010) and Manichanh et al., (2006) both found significant 
reductions to the C. leptum and C. coccoides populations using qPCR, in donors suffering 
from diabetes or Crohn’s disease respectively. The Bacteroides, C. leptum and C. coccoides  
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Table 5.7  Real-time PCR quantification of eight dominant, sub-dominant and three pathogenic gastrointestinal bacterial groups in the faecal samples of  
                 HIV-negative donors and HIV-positive donors at (T0) and (T4) 
 
Bacterial Group 
HIV-Negative (n=12) HIV-Positive T0 (n=12) HIV-Positive T4 (n=8) Significance 
Mean Min Max Mean Min Max Mean Min Max HIV-Negative  
vs.  
HIV-positive (T0) 
HIV-positive (T0) 
vs.  
HIV-positive (T4)
a
 
HIV-Negative  
vs.  
HIV-positive (T4) 
Total Bacteria 11.82 10.31 13.05 11.21 9.57 12.54 10.70 9.41 12.68 p = 0.15 p = 0.60    p = 0.03
*
 
C. leptum 9.73 8.44 10.79 8.97 7.63 10.26 8.77 7.46 10.65  p = 0.02
*
  p = 0.83    p = 0.05
*
 
Bifidobacterium 7.88 5.92 10.86 8.35 6.97 10.19 8.10 6.42 10.04 p = 0.23 p = 0.75 p = 0.49 
C. coccoides 8.52 7.67 10.43 7.87 5.64 9.38 8.24 6.94 9.44 p = 0.42 p = 0.14 p = 0.82 
Bacteroides 9.34 8.03 10.50 8.52 6.65 10.57 7.94 6.87 9.77  p = 0.08  p = 0.29    p = 0.004
*
 
E. coli 6.80 4.79 8.63 6.98 5.28 8.48 6.98 5.61 8.32 p = 0.67 p = 0.83 p = 0.76 
Lactobacillus 7.01 5.52 8.81 7.00 4.83 9.42 7.16 5.03 9.72 p = 0.82 p = 0.67 p = 0.88 
Enterococcus > LOD   > LOD   > LOD      
S. enterica 5.45 4.13 6.14 5.04 4.52 5.57    p = 0.02
*
   
Clostridum cluster XI  5.92 4.11 7.51 6.19 4.70 7.75    p = 0.43   
C. jejuni NDL   NDL         
Results are expressed as log gene copies/g of stool. Min: minimum; Max: maximum  
> LOD: lower than minimum level of detection 
NDL: No detectable levels  
* Indicates a significant difference between HIV-Positive and HIV-Negative samples (p ≤ 0.05) 
a
 Only the 8 longitudinal HIV-positive donors were compared at T0 and T4  
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groups are the most predominant populations found within the human intestinal tract 
(Eckburg et al., 2005; Sghir et al., 2000), and are considered to be important components of 
the intestinal microbiota (Lay et al., 2005; Duncan et al., 2002). Some species belonging to 
the C. leptum and C. coccoides groups are capable of producing butyrate, which is the 
preferred energy source within the colonic mucosa (Roediger, 1980) and has been shown to 
play a key role in reinforcing the colonic defence barrier, by increasing the production of 
mucins and antimicrobial peptides and reducing intestinal epithelial permeability (Van 
Immerseel et al., 2010). Members of the Bacteroides group also play an important role within 
the gastrointestinal tract, such as being able to utilise a wide variety of carbon sources 
(Macfarlane and Gibson, 1991). Any form of disruption or reduction in the number of 
butyrate producing and Bacteroides species could negatively affect these essential functions 
and networks established between the host’s epithelial cells and the endogenous intestinal 
microbiota (Manichanh et al., 2006). 
 
With regard to Enterococcus, Bartosch et al., (2004); Vanhoutte et al., (2004) and Marteau et 
al., (2001) also reported extremely low detection levels and abundance of the Enterococcus 
community in human faeces. The administration of Bactrim as a prophylactic treatment to 
HIV-positive patients in this study (discussed in Chapter 2), is associated with a reduction in 
both Enterobacteriaceae and Enterococcus species (Knothe, 1979). An important point to 
bear in mind is, however, that at T0, the recruited HIV-positive donors had only just started 
treatment with Bactrim and any major changes to the abundance of both E. coli and 
Enterococcus species was ther fore not expected at this stage.  
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Figure 5.5: Box-and-whisker plots of bacterial groups quantified using qPCR. Bacterial 
groups were quantified using SYBR Green in (A) HIV-positive donors (HAART-
naïve); (B) HIV-positive donors 6 months after initiating HAART and in (C) HIV-
negative donors. Results are expressed as log 16S rRNA gene copies/g of stool while 
the black and orange dots indicate observations considered to be outliers.  
* Significant differences between:  
[a]: HIV-positive (T0) vs. HIV-negative (C. leptum, p = 0.02);  
[b]: HIV-positive (T4) vs. HIV-negative (Bacteroides, p = 0.004);  
[c]: HIV-positive (T4) vs. HIV-negative (C. leptum, p = 0.05) and  
[d]: HIV-positive (T4) vs. HIV-negative (Total bacteria, p = 0.03) 
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5.4.3.3 Longitudinal evaluation of bacterial numbers in HIV-positive donors, 6 months after  
           HAART initiation 
 
The influence of HAART administration on the abundance of the seven selected major or 
minor bacterial groups over a 6 month period was measured using qPCR. The numbers of the 
bacteria in HIV-positive donors prior to HAART (T0) were compared to those present in the 
same donors at 6 months after HAART initiation (T4), and the results of this comparison are 
summarised in Table 5.7 and Figure 5.5A and B. After 6 months of HAART no significant 
changes in abundance of any of the seven investigated bacterial groups were seen.  
 
The difference in the abundance of the E. coli group over 6 months was not significant (Table 
5.7). Due to the fact that the HIV-positive donors had been continuously administered 
Bactrim over the 6 month period, a marked difference between the T0 and T4 time intervals 
was expected. However, several investigations have shown that the resistance of E. coli 
species, in HIV-positive patients, towards Bactrim has increased significantly, with reports of 
24% (Murray et al., 1982), 76% (Martin et al., 1999) and 85% (Hamel et al., 2008) resistance. 
As a consequence, the persistence of this bacterium may be attributable to an increase in the 
resistance of E. coli to Bactrim, following 6 months of continuous administration. Manichanh 
et al., (2006) found that, in donor’s with Crohn’s disease, an increase in the number of Gram-
negative bacteria colonising the intestinal tract occurred, which they attributed to a reduction 
in the Firmicutes within the gastrointestinal tract.    
   
There were, however, significant changes seen in the abundance of each of the investigated 
bacterial groups when the HIV-positive donors at T4 (6 months of HAART) were compared 
to the control HIV-negative donors (Table 5.7 and Figure 5.5B and C). This comparison 
showed significant reductions in the total bacteria (p = 0.03), as well as the dominant C. 
leptum (p = 0.05) and Bacteroides (p = 0.004) groups. This result suggests that alterations in 
certain important members of the HIV-positive microbiome exist, relative to the control 
group, even when patients have received HAART and show signs of clinical improvement. 
There was, however, no significant change in the abundance of the Bifidobacterium and 
Lactobacillus populations, once again suggesting that these probiotic strains are not affected 
by the disease or the administration of HAART. This is in contrast to the results reported by 
Gori et al., (2008), who found that the relative proportions of both the Bifidobacterium and 
Lactobacillus populations in Italian, HIV-positive, HAART-naïve patients with average CD4
+
 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
134 
 
T cell counts of 520 cells/mm
3
 and plasma HIV RNA levels of 28 393 copies/ml were 
reduced to approximately 2.5% and 0.02% of the total bacterial population respectively. This 
study, however, used FISH analysis, and so cannot be directly compared to the data reported 
here. 
 
5.4.4 Quantitative analysis of potential intestinal pathogens in faecal samples   
The abundance of three intestinal pathogens within the faecal samples of the recruited HIV 
negative and HIV-positive donors was also determined. These particular pathogens were 
selected since they had been previously detected in the faeces of HIV positive patients with 
diarrhoea (Obi et al., 2007; Sanchez et al., 2005). Previously designed oligonucleotide primer 
pairs and hydrolysis probes specific for S. enterica (Malorny et al., 2004), C. jejuni (Iijima et 
al., 2004) and Clostridium cluster XI (C. difficile) (Song et al., 2004) were used. The 
detection levels for each of the three pathogenic bacteria are shown in Table 5.7.  
 
S. enterica was detected significantly more frequently within the HIV-negative donor group 
(p = 0.02) (Table 5.7), while no differences between the two donor groups were seen for the 
Clostridium cluster XI. Furthermore, no detectable levels of C. jejuni were found in either the 
HIV-positive or HIV-negative donors. The prevalence of enteric bacterial pathogens in the 
stool samples of South African HIV-positive and HIV-negative donors was determined, using 
standard culture techniques, in a study conducted by Obi et al., (2007). The findings of that 
particular investigation showed that the most frequently isolated pathogens amongst HIV-
positive donors experiencing diarrhoea were E. coli (21.5%) and Campylobacter (20.5%) 
species, while E. coli was also significantly more common amongst HIV-positive donors 
without diarrhoea. In the light of these findings, the absence of C. jejuni in all HIV-positive 
donors recruited for the current study was not surprising given that all of these donors had no 
clinical signs or symptoms of diarrhoea. HIV-positive donors presenting with diarrhoea, were 
excluded from participating in this study (discussed in Chapter 2), thereby ensuring that the 
baseline comparisons obtained were not affected by secondary factors such as antibiotic 
treatment for diarrhoea.  
 
Even though the detection of S. enterica and species belonging to the Clostridium cluster XI 
was successful, several limitations encountered during this study need to addressed in future 
work. The first limitation of this study was the poor primer specificity of CXI-F1 and CXI-R2 
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used for the detection of C. difficile. Although the primers used were originally reported to 
detect C. difficile (Song et al., 2004), they are also capable of detecting other Clostridium 
species belonging to the Clostridium cluster XI. Clostridium cluster XI is a taxonomically 
heterogeneous group including species such as C. difficile, Clostridium lituseburense and 
Clostridium bifermentans, which are all endogenous to the intestinal tract (Collins et al., 
1994). The low primer specificity shown by this primer set, taken together with the fact that 
C. difficile has approximately 10 to 12 rrn copies, suggests possibly that the result reflected in 
Table 5.7 may not be an exact reflection of the abundance of C. difficile. Thus, to achieve a 
more accurate reflection, the above limitation needs to be addressed by selecting a more 
suitable primer and probe set that is specific for C. difficile and does not target the 16S rRNA 
gene. Recently, Luna et al., (2011) successfully detected toxigenic C. difficile strains, in 
human faecal samples, using TaqMan qPCR that targeted the toxin genes tcdA and tcdB.  
 
The second limitation of this study was attempting to determine the number of detectable 
pathogens present in the stool sample by means of copy number. A problem associated with 
the use of copy number in the detection of pathogens is that it does not give an indication of 
an infective dose or what the minimum level of detection is for that specific pathogen. In most 
instances, studies utilising TaqMan qPCR for the detection of pathogens determine the 
probability of detecting the pathogen in the presence of background microbiota by generating 
a standard curve based on CFU/ml. To establish this, a stool sample is spiked with a known 
concentration of the specific pathogen, following which, DNA is then extracted from the 
spiked sample and used for qPCR. The detection probability of the specific pathogen at a 
certain concentration can, therefore, be determined. An attempt was made in this study to 
determine the minimum level of detection for all three of the investigated pathogens. 
However, due to several culture and growth technicalities encountered, the minimum 
detectable level of C. jejuni could not be determined. Nevertheless, the minimum detectable 
levels of S. enterica and C. difficile were concluded to be around 10
3
 CFU/ml and 10
4
 
CFU/ml respectively (data not shown). These detection limits were in accordance with two 
previously published studies by Malorny et al., (2004) and Rinttilä et al., (2004).     
 
The selected target region used for the detection of Salmonella species was the ttrRSBCA 
locus, located on the Salmonella Pathogenicity Island 2, which is critical for the proliferation 
of S. enterica (Hensel, 2000) while also playing an important role in tetrathionate respiration 
and intestinal colonisation (Rohmer et al., 2011). The composition of the endogenous 
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gastrointestinal microbiota has been shown to influence enteric pathogen colonisation. 
Sekirov et al., (2008) and Lupp et al., (2007) both showed that colonisation by S. enterica 
serovar typhimurium increased when the overall Firmicutes to Bacteroides ratio had been 
significantly altered, as a result of antibiotic treatment. Although the results obtained for this 
study are preliminary, (due to the limitations identified above), the detection of significantly 
less S. enterica in the HIV-positive donors could be due to Bactrim administration. Hamel et 
al., (2008) found that monitoring the number of E. coli species resistant to Bactrim was 
necessary, as it served as a marker for possible resistance amongst other Enterobacteria 
species such as Salmonella and Shigella. An increase in the number of resistant E. coli 
species, together with efficient horizontal gene transfer between E. coli and Enterobacteria 
species such as Salmonella, could result in an increase in the resistance of Enterobacteria, not 
only to Bactrim, but to other antibiotics such as ampicillin, cefazolin and gentamicin, which 
has been shown by Sibanda et al., (2011) and Martin et al., (1999). The possible development 
of multiple drug resistance, especially within the context of this study, is of concern, in that 
one of the recruited donors was receiving a multiple antibiotic treatment plan, in addition to 
Bactrim and HAART (Chapter 2).  
 
Real-time PCR employing TaqMan probes, is a useful method in determining the presence of 
pathogens present in very low numbers. In order to achieve an accurate result, appropriate 
gene targets and standard curves are important. Future work should, therefore, involve 
accurately determining the number of enteric bacterial pathogens present within HIV-positive 
donors, using more specific primers for C. difficile together with a more robust standard 
curve. Furthermore, in light of the results recorded by Obi et al., (2007), future qPCR 
investigations should consider determining the presence of additional pathogens such as E. 
coli, Shigella and Aeromonas hydrophila within South African, HIV-positive donors who 
have not been excluded due to diarrhoea. 
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5.5  CONCLUSION 
The results generated in this chapter clearly show that both the SYBR Green and TaqMan 
assays could be successfully used in the quantification of bacterial groups, as well as intestinal 
pathogens, and provide a representation of the differences in abundance of specific intestinal 
groups. The results reported in this chapter indicate that prior to the initiation of HAART, the 
abundance of the C. leptum group was significantly reduced in the HIV-positive donors, when 
compared with the HIV-negative control group (p = 0.02). There were, however, no significant 
differences in the abundance of the C. coccoides (p = 0.42), Lactobacillus (p = 0.91), E. coli (p 
= 0.49) and Bifidobacterium (p = 0.27) groups in either donor group. 
 
After 6 months of HAART, a statistically significant reduction in the abundance of certain 
bacterial groups, relative to the control HIV-negative group, was observed. This may possibly be 
an indicator of poor viral suppression and inefficient CD4
+
 T cell replenishment within the 
gastrointestinal tract. Future investigations, in particular, for the longitudinal study, should 
attempt to recruit a larger donor group in conjunction with xtending the sampling period to 24 
months after HAART initiation. A smaller sample size is affected by host specificity, while a 
larger donor group would ensure that any individual host variations affecting the outcome of the 
results generated and conclusions drawn in this section would be eliminated. The study 
published by Guadalupe et al., (2006) showed that, even after 24 months of HAART, HIV-
positive patients experienced a minimal increase in CD4
+
 T cell levels and viral suppression 
within the gastrointestinal tract. Therefore, as an extension of this current study, future studies 
could determine whether the abundance of the dominant groups, which were further reduced 
after 6 months HAART in this study, is affected further after 24 months of HAART. 
Furthermore, establishing closer sampling time intervals may assist in identifying significant 
differences as well as drawing specific conclusions.  
 
As discussed in Chapter 4, Guadalupe et al., (2006) showed that inefficient viral suppression 
and delayed restoration of CD4
+
 T cells within the GALT occurred, despite a subsequent 
decrease in the viral load and increase of CD4
+
 T cells in the blood of HIV-positive donors, 
one year after initiating HAART. In addition, genes associated with inflammation, apoptosis 
and immune response were significantly upregulated, while a decrease in the expression of 
genes involved in regulating the epithelial barrier, mucosal repair and regeneration as well as 
lipid metabolism and nutrient absorption, was reported (Sankaran et al., 2005; Guadalupe et 
al., 2003). Continued intestinal inflammation and disruption to the mucosal lining could 
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continue to affect the dominant bacterial groups within the gastrointestinal tract, despite the 
fact that patients were being administered HAART and showed indications of improved blood 
CD4
+
 T cell levels and reduced viral load. In light of the above, it may be a worthwhile option 
to investigate specific immunological markers such as mucosal T lymphocytes, cytokine 
levels, and peripheral blood mononuclear cells (PBMC) in both faecal and mucosal biopsy 
samples, while, at the same time, sampling the faecal material.   
 
A drawback of using quantitative real-time PCR is selecting an appropriate gene target and, 
despite the obvious limitations associated with using the 16S rRNA gene, numerous qPCR based 
studies have conducted successful investigations with primers designed to target the 16S rRNA 
gene (Gueimonde et al., 2010; Furet et al., 2009; Rinttilä et al., 2004; Huijsdens et al., 2002). 
Nevertheless, certain studies have opted to focus rather on a single bacterial species from a 
particular group, thereby eliminating any under or overestimation that may be caused as a result 
of the number of rrn copies. However, since the genome size and copy number of rrn operons is 
limited for the vast majority of species, it can therefore b  concluded that in most instances, 
when using qPCR targeting the 16S rRNA gene, only general estimations and conclusions 
regarding the population can be made (Vaughan et al., 2000; Farrelly et al., 1995). The detection 
of absolute numbers of total bacteria might be improved by employing other previously 
published primers (Larsen et al., 2010).  
 
TaqMan qPCR showed that the inclusion of hydrolysis probes increases the overall specificity 
and sensitivity of the reaction, which is necessary when detecting specific species such as enteric 
pathogens, present in relatively low numbers. This study also showed that previously published 
TaqMan probes successfully detected two intestinal pathogens present in subclinical levels 
within HIV-positive donors. Unfortunately, specific conclusions regarding the abundance of C. 
difficile within the donor groups could not be made, due to the fact that the primer set used for 
the detection of C. difficile was not specific. More specific primers are now available and should 
be used in future studies (Matsuda et al., 2012; Luna et al., 2011).  
 
The noticeable reduction of Salmonella within the HIV-positive donors, together with the 
relatively stable abundance of E. coli species, 6 months after HAART, suggests a possible 
increase in the resistance of E. coli to Bactrim. While outside the scope of this study, it would be 
interesting to determine and monitor whether E. coli, in addition to Salmonella, found within the 
recruited HIV-positive donors, showed increased resistance to Bactrim and antibiotics such as 
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ampicillin and gentamicin, which could possibly indicate the transferral of resistance from E. 
coli.   
 
Finally, the significant reduction in the abundance of total bacteria, C. leptum and Bacteroides 
groups in the HIV-positive cohort after 6 months of HAART, suggests that probiotic 
supplementation with specific bacteria from within these groups may be a therapeutic direction 
to be explored in assisting in normalising the gut microbiota. Species belonging to these 
dominant bacterial groups could be considered as possible probiotic candidates, as increasing 
the abundance of these groups within the intestinal tract, may counteract and reduce the 
disruption and inflammation caused by the replication of HIV. For example, Faecalibacterium 
prausnitzii, a member of the C. leptum group, is estimated to make up approximately 10% of 
the human faecal bacteria (Ramirez-Farias et al., 2009; Eckburg et al., 2005) and has been 
shown to be significantly reduced in the gastrointestinal tracts of IBD patients (Van Immerseel 
et al., 2010). The probiotic potential of F. prausnitzii has been previously suggested and 
investigated, as a result of its known anti-inflammatory properties for use in patients suffering 
from Crohn’s disease or IBD (Sokol et al., 2008). However, species belonging to the C. leptum 
group within the gastrointestinal tract are phylogenetically diverse and it has not yet been 
determined which of these species are reduced in the HIV-positive patients evaluated in this 
study. Therefore, changes to the diversity and abundance of F. prausnitzii should be monitored, 
in the HIV-positive donors, using both PCR-DGGE and qPCR, prior to HAART and 24 months 
after HAART initiation, in order to determine whether the administration of F. prausnitzii 
might be beneficial in patients if they showed significantly reduced levels.  
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CHAPTER SIX 
General Conclusions 
 
The endogenous microbiota of the gastrointestinal tract is a large and complex community 
that plays an essential role in the maintenance and regular function of the intestinal tract 
(Ponnusamy et al., 2011), development of the host immune system (Kassinen et al., 2007) and 
various other functions involved in human health, such as complex food digestion and the 
production of essential vitamins (Ponnusamy et al., 2011). The structure of the 
gastrointestinal microbiota of humans has been extensively studied and characterised, using 
both culture-dependent and culture-independent methods, including PCR-DGGE (Muyzer et 
al., 1993), TGGE (Zoetendal et al., 1998), FISH (Franks et al., 1998) and more recently, the 
HITChip (Rajilić-Stojanović et al., 2010) and metagenomics (Qin et al., 2010). Characterising 
the endogenous microbial diversity allows the identification of species that can be classified 
as belonging to the normal microbiota and, in turn, provides a better understanding of changes 
and imbalances in either the diversity or composition brought about by various diseases. At 
the start of this project, very little scientific data and information was available regarding the 
effect of HIV on the intestinal tract and the associated endogenous microbiota. This study 
utilised some of the abovementioned molecular techniques to analyse aspects of the 
microbiota found within HIV-positive and HIV-negative donors. This research project is the 
first investigation to determine the effect of HIV and HAART on selected bacterial species in 
the gastrointestinal tracts of South African, HIV-positive donors. The results generated have 
increased the understanding of how HIV may affect specific groups within the endogenous 
microbiota. 
 
The first objective of this project was to establish if the microbial community of HIV-positive 
donors differed from HIV-negative donors in terms of diversity and composition. Donor 
recruitment and sample collection were successfully conducted for both donor groups, 
providing an accurate representation of the socio-demographic profile of the South African 
population, as well as the HIV-positive population. Establishing a baseline comparison 
between the 12 HIV-positive and 12 HIV-negative donors revealed a significant reduction in 
the diversity of the total bacterial population present in HIV-positive donors. PCR-DGGE 
analysis of the Bifidobacterium and Lactobacillus groups showed that the diversity of the 
Bifidobacterium population was higher in the HIV-positive donors than the control group, but 
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that this difference was not statistically significant. However, a study of a larger cohort would 
be needed to confirm the validity of this observation. The detection of bacterial species 
normally closely associated with the intestinal epithelial lining (such as L. mucosae), might 
point towards a disrupted mucosal lining caused by the replication of HIV. To verify whether 
the mucosal lining of HIV-positive donors is compromised, future investigations should 
attempt to compare the diversity and abundance of selected bacterial groups in both faecal and 
biopsy samples. Unfortunately, this particular aspect of work will only be able to be 
conducted following ethical approval and the implementation of specific safety criteria, both 
within the laboratory and in the clinic setting.    
 
The second objective of this project was to determine the effect of HIV and HAART on 
Bifidobacterium and Lactobacillus species in HIV-positive donors during a 6 month 
longitudinal analysis. Data generated in this study, using PCR-DGGE, showed that the 
Lactobacillus population was temporally more unstable than the Bifidobacterium population 
in both donor groups. After 6 months of HAART, no significant changes in either the 
Bifidobacterium or Lactobacillus populations were seen. However, due to the continuous, 
disrupted state of the gastrointestinal tract during HAART, as reported by Guadalupe et al., 
(2003), the results generated also emphasised the importance of investigating the composition 
of and changes in other bacterial groups of the endogenous microbiota. The comparative 
DGGE study should, therefore, be expanded to include a longitudinal diversity analysis of the 
total bacterial population as well as other specific bacterial groups of interest.    
 
The third objective of the study was to establish if HIV replication, within the gastrointestinal 
tract, and HAART have an effect on the abundance of the endogenous microbiota in HIV-
positive patients. A quantitative analysis using qPCR was undertaken in order to obtain an 
overview of the abundance of selected bacterial groups. The key observation made, following 
analysis of the qPCR data, was that the abundance of the total bacteria as well as two 
dominant bacterial groups, C. leptum and Bacteroides was significantly reduced in the HIV-
positive donors after 6 months of HAART relative to the HIV-negative donor group. Bacterial 
species belonging to the C. leptum group are actively involved in the production of butyric 
acid, which serves as an essential energy source for the colonic mucosa (Lara-Villoslada et 
al., 2006; Roediger, 1980), as well as enhancing the integrity of the epithelial barrier (Van 
Immerseel et al., 2010) and modulating the intestinal immune system (Lara-Villoslada et al., 
2006). A major disruption to this group, as seen in the HIV-positive donors, could potentially 
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result in the establishment of an imbalanced microbiota composition. Consequently, all 
beneficial and vital functions performed by this group may be reduced or no longer provided. 
It was interesting to note that there were no significant changes in the abundance of the 
Bifidobacterium and Lactobacillus species throughout the study period. This indicates that 
these commonly used probiotic candidates would not necessarily improve the microbial 
composition within the gastrointestinal tract of HIV-positive patients, and that the lack of 
other key bacteria might point towards identifying more appropriate probiotics. Targeted 
probiotic supplementation with such bacteria might assist in restoring the beneficial functions 
and integrity of the gastrointestinal tract.      
 
A review of the relevant literature reveals that several research studies have been conducted, 
employing similar qualitative and quantitative molecular techniques, to provide further 
insights into the structure and exact role of the endogenous microbiota in human health and 
diseases, such as Crohn’s disease, IBS and diabetes. A summary, representing a few of these 
studies, together with the results generated, is briefly discuss d below.  
 
Taken together, it is clear that the results obtained in these studies depend to a large degree on 
the method used. An example of this was clearly seen in the studies of Sghir et al., (2000) and 
Franks et al., (1998) who both characterised similar bacterial groups within healthy adult 
donors, but utilized dot blot hybridization and FISH respectively. The use of two different 
methods produced varying results when comparing the groups with each other, with results 
ranging from 0.7 to 3% having been recorded for the Bifidobacterium population. The studies 
conducted by Kerckhoffs et al., (2009) and Manichanh et al., (2006), both showed a reduction 
in the abundance of C. leptum, C. coccoides and Bifidobacterium, when analysing the 
microbial conditions present during IBS and Crohn’s disease respectively. A similar trend was 
shown by Bartosch et al., (2004), who also reported significant reductions in the total 
bacteria, as well as the Bacteroides and C. leptum groups, when using qPCR to investigate the 
effect that aging and a weakened immune system have on the endogenous microbiota. 
Although not technically a “disease condition”, the process of aging has been shown to 
seriously affect the composition of the endogenous microbiota (Biagi et al., 2010). Type 2 
diabetes was also associated with considerable changes in the composition of the intestinal 
microbiota (Larsen et al., 2010). The abundance of the Firmicutes was significantly lower in 
the diabetic patients relative to the non-diabetic group. Conversely, the Bacteroidetes and 
Proteobacteria were present in a much higher abundance. The abundance of F. prausnitzii, a 
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member of the C. leptum group, was also found to be significantly reduced in the 
gastrointestinal tracts of IBD and Crohn’s patients as well as the elderly (Van Immerseel et 
al., 2010). The probiotic potential of F. prausnitzii has been previously suggested and widely 
investigated, for use in patients suffering from Crohn’s disease or IBD, due to its known anti-
inflammatory properties (Sokol et al., 2008). In light of this, future studies focusing on the 
microbiota of HIV-positive patients should evaluate the levels of F. prausnitzii with a view to 
determining whether increasing the abundance of this species within the intestinal tract of 
HIV-positive patients, may counteract and reduce the disruption and inflammation caused by 
the replication of HIV.  
 
The fourth objective of this project was to detect any pathogen activity within the HIV-
positive donors, due to the fact that the microbial composition has been altered and may no 
longer be functioning as a protective barrier. Preliminary analysis indicated that the TaqMan 
probes successfully detected the presence of Salmonella species in both groups of donors, but 
at a higher level in the HIV-negative cohort. It would appear, however, that the levels were 
not high enough to cause diarrhoea in either group. A future aspect of this work would be to 
investigate the presence and activity of other bacterial pathogens in HIV-positive patients 
with diarrhoea symptoms and in those without diarrhoea. Secondly, it is imperative that the 
increasing resistance of the intestinal microbiota, as well as intestinal pathogens, towards 
antibiotics such as Bactrim, doxycycline, ampicillin and gentamicin, within HIV-positive 
donors, be carefully monitored, especially in view of the fact that doctors working at local 
South African provincial clinics will continue to administer these antibiotics for treatment 
purposes.   
 
The findings reported in this thesis show that differences do indeed exist in the microbiota of 
HIV-positive and HIV-negative donors and, in most cases, the disrupted microbial conditions 
found within the gastrointestinal tract did not improve, even after 6 months of HAART. It is 
important to remember that this particular project was the starting point of a projected larger 
investigation. The results obtained thus far have identified the need for additional 
investigative studies into the intestinal microbiota of HIV-positive patients. Notwithstanding  
certain shortcomings identified in this project, the data generated can be used as a foundation 
upon which future characterisation studies can build. The combination of PCR-DGGE and 
qPCR produced reliable and accurate comparative results within the study regarding the 
relative  composition of the microbiota of South African HIV-positive donors as compared to 
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HIV-negative individuals. However, in order to verify our findings and acquire a more robust 
and in depth analysis of the intestinal microbiota, it would be valuable to complement these 
two methods with other profiling techniques such as the HITChip and high throughput 
sequencing. This research project could also be further expanded to include samples collected 
from HIV-positive donors residing outside of the Western Cape, such as the remaining eight 
South African provincial provinces or internationally. The main motivation for this would be 
to determine if diet and lifestyle, which are both known to influence the structure and 
diversity of the gastrointestinal microbiota, will affect the differences identified in 12 HIV-
positive donors from a single study site in the Western Cape. Additionally, it may also be 
worthwhile extending the longitudinal study to cover a longer time period, for example 2 to 3 
years after HAART initiation, along with shorter, more consistent sampling points.   
 
The final and most important aim of this project was to identify any significant changes in the 
intestinal microbiota profile that could necessitate the administration of probiotics. The results 
showing the lack of improvement in the abundance of specific dominant bacterial groups after 
6 months of HAART, suggest that probiotic supplementation may well assist in normalising 
the intestinal microbiota and could possibly re-establish a healthy gastrointestinal balance. 
However, before proceeding with any form of probiotic supplementation, prior investigations 
into the diversity and abundance of several probiotic candidates, for example F. prausnitzii, 
need to be conducted prior to HAART and during HAART. Furthermore, a particular stage at 
which the probiotic can be safely administered, as well as the mode of delivery to be used, 
needs to be identified. Upon successful establishment of these criteria, controlled clinical 
trials involving HIV-positive volunteers could be initiated.  
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Figure 5.1: Specificity of the qPCR primers employed in the SYBR Green 
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R_Ccoc 14]; (E) Bacteroides group [F_Bacter 11 and R_Bacter 08]; 
(F) E. coli [E. coli F and E. coli R]; (G) Lactobacillus group [F_Lacto 
05 and R_Lacto 04] and (H) Enterococcus group [F_Entero and 
R_Entero]. Lane 1: 100 bp molecular weight marker (Fermentas); Lane 
2: Negative control (no DNA); Lane 3: C. leptum; Lane 4: B. longum; 
Lane 5: C. coccoides; Lane 6: B. fragilis; Lane 7: E. coli; Lane 8: L. 
gasseri and Lane 9: E. faecalis.  
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[F_Clept 09 and R_Clept 08]; (C): Bifidobacterium [F_Bifid 09c and 
R_Bifid 06]; (D): C. coccoides [F_Ccoc 07 and R_Ccoc 14]; (E): 
Bacteroides [F_Bacter 11 and R_Bacter 08]; (F):  E. coli [E. coli F and 
E. coli R]; (G): Lactobacillus [F_Lacto 05 and R_Lacto 04] and (H): 
Enterococcus [F_Entero and R_Entero]. Specific primers used are 
shown in the square brackets and summarized in Table 5.3. 
[Experiments A-H were performed in triplicate] 
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Figure 5.3A: Standard curves of bacterial group specific PCR products 
generated using the SYBR Green method. (A): Total bacteria 
[F_Bact 1369 and R_Prok 1492] and (B): C. leptum [F_Clept 09 and 
R_Clept 08]. Specific primers used are shown in the square brackets 
and summarized in Table 5.3. [All standard curve dilutions were 
assayed in triplicate for each experiment] 
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Figure 5.3B:  Standard curves of bacterial group specific PCR products 
generated using the SYBR Green method. (C): Bifidobacterium 
[F_Bifid 09c and R_Bifid 06]; (D): C. coccoides [F_Ccoc 07 and 
R_Ccoc 14] and (E): Bacteroides [F_Bacter 11 and R_Bacter 08]. 
Specific primers used are shown in the square brackets and 
summarized in Table 5.3. [All standard curve dilutions were assayed in 
triplicate for each experiment] 
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Figure 5.3C:  Standard curves of bacterial group specific PCR products 
generated using the SYBR Green method. (F):  E. coli [E. coli F and 
E. coli R]; (G): Lactobacillus [F_Lacto 05 and R_Lacto 04] and (H): 
Enterococcus [F_Entero and R_Entero]. Specific primers used are 
shown in the square brackets and summarized in Table 5.3. [All 
standard curve dilutions were assayed in triplicate for each experiment] 
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Figure 5.4: Specificity (1) and detection range (2) of the qPCR primers 
employed for the TaqMan Method. Lane 1: 100 bp molecular weight 
marker (Fermentas); Lane 2: Negative control (no DNA); Lanes 3-5: 
Clones 1, 2, 3 and Lane 6: Positive control (gDNA). (A): S. enterica; 
(B): C. jejuni and (C): C. difficile. [All standard curve dilutions were 
assayed in triplicate] 
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Figure 5.5: Box-and-whisker plots of bacterial groups quantified using qPCR. 
Bacterial groups were quantified using SYBR Green in (A) HIV-
positive donors (HAART-naïve); (B) HIV-positive donors 6 months 
after initiating HAART and in (C) HIV-negative donors. Results are 
expressed as log 16S rRNA gene copies/g of stool while the black and 
orange dots indicate observations considered to be outliers 
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Patient Information Sbeet: 
Investigation of qualitative and quantitative changes in selected gut microbiota of HI V positive 
patients during HAART treatment. 
. 
Investigators: A. ProfVR Abratt I, A. ProfS] Reid l , Dr M Mendelson\ Dr M. Pandie2, 
Dr M. Handschur l 
I Department of Molecular and Cell Biology, University of Cape Town; 2 Department of Medicine, 
University of Cape Town 
What are we trying to do? 
• We are researchers from Groote Schuur Hospital and the University of Cape Town. We are 
interested in finding out ways of helping people suffering from HIV by protecting them from 
developing the unpleasant and painful symptoms of diarrhoea ("runny tummy"). 
• In order to do this, we need to understand what bacteria (germs) in the body cause these symptoms 
and what good bacteria might help to prevent the bad bacteria from making people sick. 
• We know that these good bacteria are important for our health, and we think that people who are 
suffering from HIV and AIDS may have lost their good bacteria because of the HIV infection and 
treatment with antibiotics. We think that during antiretroviral treatment, the good bacteria may 
once again begin to grow as the virus is killed, and that these bacteria can help a person recover. 
• We would, therefore, like to look more closely at the bacteria in your gut before and during your 
antiretroviral treatment to see if the good bacteria begin growing again. 
• The only way we can do this is to find them in your stool sample. his may seem unpleasant, but 
it is a very helpful way to see what is going on in your gut. 
• The results will help US find out which good bacteria are missing from people who have AIDS. In 
future, these good bacteria might be given in food supplements to people who have AIDS to help 
them recover faster during their antiretroviral treatment. 
What will you be asked to do? 
• Your doctor will tell you about the study and ask you if you would like to take part. 
• If you agree to this, you will be asked some general questions about your age and medical history. 
• You will be given a large, very clean tin container in which to collect your stool on the day of 
your clinic visit. This container is big enough to sit on and can be tightly sealed so there will be no 
mess or bad smell. 
• You will also be given an attractive cooler bag in which to transport your tin so it is kept private. 
Are there any risks involved for you if you take part in the study? 
• Y au Will not be asked to change your treatment in any way. 
• There are no risks involved. 
• There will be a minimum of discomfort by having to use the tin to collect your stool. 
• All the stool samples will be destroyed after we have finished studying them. 
• No-one will know your results or your personal information. Your name will not be given to 
anyone. The results of the study will be made available to the scientific community but no names 
will be linked to any of the results. 
• You can change your mind about taking part in the study at any time without giving a reason and 
this will not affect the quality of your HAART treatment in any way. You are not obliged to take 
part in the study. . 
What will you get if you take part? 
• There is no payment or reward for taking part in the study but you will be given R20 to help you 
with transport when you bring your sample to the clinic 
• You will be helping us understand why AIDS sufferers get such severe "runny tummies". We 
hope that what we learn will help in the treatment of this condition. 
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Patient Consent Sheet 
Do you agree to participate in tbis trial? 
Please ask any questions you bave about the study. 
Your contact person for tbis study is Dr Marc Mendelson: Tel 0214066079. 
__________ ____ _____ CName in block capitals) have carefully read and 
understood the Patient Information Sheet and Informed Consent or have had these read and explained to 
me. All my questions about the study have been answered to my complete satisfaction. I understand that I 
can keep copies of these documents. I was given enough time to decide about taking part in the study. 
By signing the Informed Consent Sheet, I declare that I take part in this study of my own free will and 
without being persuaded or pressurised by another person. I understand that I can withdraw from the 
study at any time without giving a reason. 
I document my informed consent by signing my name below: 
Participant Signature Date Place 
_ _ _ ___________ _ CName of researcher or hislher delegate) have fully informed 
the above person of the procedures, aims and risks oflhe study and answered all questions truthfully. 
Researcher/delegate Signature Date Place 
